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Oral administration of therapeutic peptides could benefit millions of chronically ill people world-
wide, through easier and less stigmatized therapy, and likely improve the long-term effects of
currently widespread disease mismanagement. However, oral peptide delivery is a formidable
task due to the harsh and selective gastrointestinal system, and development has lacked far behind
injection therapy.
Peptide acylation is a powerful tool to alter the pharmacokinetics, biophysical properties and
chemical stability of injectable peptide drugs, primarily used to prolong blood circulation, but
it is not widely studied in an oral context. As acylation furthermore increases interactions with
the lipid membranes of mammalian cells, it offers several potential benefits for oral delivery of
therapeutic peptides, and we hypothesize that tailoring the acylation may be used to optimize
intestinal translocation.
This work aims to characterize acylated analogues of two therapeutic peptides by systemati-
cally increasing acyl chain length in order to elucidate its influence on membrane interaction and
intestinal cell translocation in vitro. The studied peptides are the 33 amino acid Glucagon-like
peptide-2 (GLP-2) , which promotes intestinal growth and is used to treat bowel disorders such as
inflammatory bowel diseases and short bowel syndrome, and the 32 amino acid salmon calcitonin
(sCT), which lowers blood calcium and is employed in the treatment of post-menopausal osteo-
porosis and hypercalcemia. The two peptides are similar in size and structure, but oppositely
charged at physiological pH. Both peptides were acylated with linear acyl chains of systematically
increasing length, where sCT was furthermore acylated at two different positions on the peptide
backbone.
For GLP-2, we found that increasing acyl chain length caused increased self-association and
binding to lipid and cell membranes, whereas translocation across intestinal cells displayed a non-
linear dependence on chain length. Short and medium chains improved translocation compared
to the native peptide, whereas long chain acylation displayed no improvement in translocation.
This indicates an initial translocation benefit for shorter chains through increased interaction
with the cell membrane, which reverts to a hindrance for long chains, i.e. the analogues get
stuck in the cell membrane. Co-administration of a paracellular absorption enhancer was found to
increase translocation similarly for each analoguewhile retaining acyl chain length dependence. A
transcellular enhancer displayed increased synergy with the long chain acylation, consistent with
increased membrane fluidization ’liberating’ bound peptide, although medium chain acylation
remained optimal overall. The results indicate that rational acylation of GLP-2 can increase its in
vitro intestinal absorption, alone or in combination with permeation enhancers, and are consistent
with the initial project hypothesis.
For sCT, an unpredicted effect of acylation largely superseded the anticipated membrane
interactions; i.e. acylated sCT acted as its own in vitro intestinal permeation enhancer. Acylated
analogues permeabilized lipid membranes, causing drastically increased peptide permeability
through reversible cell effect similar to transcellular permeation enhancers. The effect likely stems
from a synergy between the positive peptide charge and membrane-active acyl moiety, supported
by its pH-dependency, whereby the effect increased with decreasing pH and concomitant charge
increase. The extent of permeation enhancing effect was highly dependent on acylation chain
length and position, with highest peptide permeability for short chain N-terminal acylation or
6medium/long chain Lys18 acylation, whereas permeability and cell membrane binding appeared
correlated only for some analogues. However, prolonged heating and/or solution storage of
certain acylated sCT analogues caused aggregation in physiological buffer solutions, potentially
forming fibril-like structures. Lys18 acylation appeared superior to N-terminal acylation, most
clearly exemplified by the short chain analogues, however, no systematic dependence on acylation
chain length was apparent. All analogues could be monomerized by addition of cyclodextrin,
however, their separate permeability enhancing effects were reduced in the mixtures, and the
additive was not investigated further. Thus, acylation of sCT for oral delivery purposes may not
be indiscriminately applicable, and requires rational choices of acylation details and/or additives.
Further investigations of themost cell-permeable sCT analogues unveiled quite distinct perme-
ation enhancer effects, ranging fromhighmembrane binding / high permeability and non-specific
enhancing effect on model compounds, to very low membrane binding / high permeability and
very limited unspecific permeation enhancer effects, i.e. selective and efficient translocation.
Peptide receptor potency was retained for GLP-2 analogues following acylation, whereas sCT
analogues displayed substantially reduced potency, depending on acylation position and length.
Overall, rational acylation of the studied peptides can increase in vitro intestinal permeability,
modestly for GLP-2 and drastically for sCT, andmight benefit oral delivery. GLP-2 results provide
a well-founded predictive power for future peptide analogues, whereas sCT results hold great
promise for future analogues, albeit with a larger uncertainty in predictions.
7Resumé
At kunne administrere terapeutiske peptider oralt ville gavne millioner af kronisk syge menne-
sker verden over, igennem lettere ogmidre stigmatiserende behandling, og forbedre forebyggelsen
af komplikationer og følgesygdomme som følge af utilstrækkelig sygdomsregulering. Men oral
peptid-behandling er en udfordring på grund af det skrappe og selektive tarmsystem, og udvik-
lingen har haltet langt efter præperater til injektion.
Acylering af peptider er et kraftfuldt værktøj til at ændre farmakokinetik, biofysiske egenska-
ber og kemisk stabilitet af injicerede terapeutiske peptider. Det bliver primært brugt til at forlænge
cirkulationstiden i blodet, men er ikke så velundersøgt i orale sammenhænge. Idet acylering yder-
mere øger interaktionen med mammale cellers lipidmembraner, kan det give adskillige fordele
for oral administrering af terapeutiske peptider, og vi foreslår at skræddersyede acyleringer kan
bruges til at optimere absorption i tarmsystemet.
Dette projekt har til formål at karakterisere acylerede analoger af to terapeutiske peptider, ved
systematisk at forøge acylkædelængden og undersøge effekten på binding til lipidmembraner og
translokation igennem tarmceller in vitro. Det første peptid er det 33 aminosyre lange Glucagon-
like peptide-2 (GLP-2), som fremmer tarmvækst og kan bruges til at behandle tarmlidelser såsom
inflammatoriske tarmsygdomme og patienter med for kort tarm. Det andet peptid er det 32
aminosyre lange lakse calcitonin (sCT), som sænker calcium-niveauet i blodet og kan bruges til
at behandle post-menopausal osteoporose og hypercalcæmi. De to peptider er sammenlignelige
i størrelse og struktur, men har modsat ladning ved fysiologisk pH. Begge peptider blev acyleret
med lineære acylkæder med systematisk stigende længde, hvor sCT desuden blev acyleret i to
forskellige positioner på peptidet.
For GLP-2 fandt vi at stigende acylkædelængde forårsagede stigende selv-associering og bin-
ding til lipid- og cellemembraner, medens absorption igennem tarmceller afhang ikke-lineært
af acyleringslængde. Korte og mellemlange acylkæder forbedrede translokationen sammenlignet
med det native peptid, hvorimod langkædet acylering ikke gav nogen forbedring. Dette indi-
kerer en indledningsvis translokationsfordel for kortere kæder grundet forøget interaktion med
cellemembranen, som udvikler sig til en hindring for længere kæder idet peptidet sidder fast
i cellemembranen. Inklusion af en paracellulær absorptionsenhancer forøgede translokationen
sammenligneligt for hver analog, dvs. afhængigheden af acyleringslængde blev bibeholdt. En
transcellulær absorptionsenhancer udviste synergi med langkædet acylering, konsistent med at
membran-fluidisering kan ’befrie’ membranbunden peptid, omend medium kædelængde for-
blev optimal overordnet set. Resultaterne illustrerer at rationel acylering af GLP-2 kan forøge
tarmabsorption in vitro, alene eller i kombination med absorptionsenhancere, og er i tråd med
projekthypotesen.
For sCT fandt vi en uventet effekt af acylering som til dels fortrængte de forventede mem-
braninteraktioner, idet acyleret sCT opførte sig som en in vitro absorptionsenhancer. Acylerede
analoger permeabiliserede lipidmembraner, og forårsagede drastisk forøget peptid-permeabilitet
igennem reversible effekter på cellelaget i stil med transcellulære absorptionsenhancere. Effekten
skyldes sandsynligvis en synergi mellem den positive peptidladning og membran-aktive acylkæ-
de, hvilket understøttes af pH-afhængigheden, hvorved effekten voksede ved faldende pH og
ledsagende ladningsforøgelse.Omfanget af enhancer-effektenvar særdeles afhængig af acylerings-
kædelængde og -position, med størst peptid-permeabilitet for kort-kædet N-terminal acylering
8eller medium/langkædet Lys18 acylering, men hvor membranbinding og permeabilitet kun var
korreleret for nogle analoger. Længerevarende opvarmning eller håndtering i opløsning af nogle
sCT analoger medførte aggregering i fysiologiske bufferopløsninger, potentielt i fibril-lignende
strukturer. Lys18-acylering fremstod bedre end N-terminal acylering, mest tydeligt eksemplifice-
ret for de kort-kædede analoger, men ingen systematisk afhængighed af acylkædelængden var
tydelig. Alle analoger kunne monomeriseres ved tilsætning af cyclodextrin, men deres seperate
absorptionsenhancer-effekter blev reduceret i blandingerne, og kombinationen blev ikke yderli-
gere undersøgt. Altså er acylering af sCT til oral administration ikke nødvendigvis uvilkårligt
anvendeligt, og kræver rationelle valg af acyleringsdetaljer og/eller tilsætningsstoffer.
Yderligere undersøgelser af de mest celle-permeable sCT analoger afslørede meget forskellig-
artede absorptionsenhancer-effekter, rangerende fra høj membranbinding / høj permeabilitet og
uspecifik enhancer-effekt på modelstoffer til meget lav membranbinding / høj permeabilitet og
lav uspecifik enhancer-effekt, altså selektiv og effektiv peptidtranslokation.
Peptidets receptor-aktivering var intakt efter acylering for GLP-2 analoger, hvorimod sCT
analoger udviste mærkbart reduceret potens, afhængig af acyleringslængde og -position.
Overordnet set kan rationel acylering af de undersøgte peptider forøge in vitro tarmabsorption,
moderat for GLP-2 og drastisk for sCT, og kan muligvis give en fordel i oral administration. GLP-
2 resultaterne giver et velfunderet forudsigelsesgrundlag for fremtidige analoger, medens sCT
resultaterne virker lovende for fremtidige analoger, omend forbundet med en større usikkerhed.
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Chapter 1
Introduction
1.1 Why study oral peptide delivery?
Millions of peopleworldwide suffer from severe chronic diseases that require frequent administra-
tion of biomacromolecules, which for the vastmajority involves injections. Although development
of the treatment in itself is profound and life-changing, injecting oneself is a both physical and
mental barrier, not least for themany chronically ill children. In fact, writing ’ill’ hints at one of the
problems, i.e. the stigma associated with injections, which mars the otherwise normal lives these
modern medications have allowed patient to live. Sadly, this is one of the causes for otherwise
treatable diseases being mismanaged. Swallowing a tablet is for many people much less invasive,
but entry through the oral route is a formidable task for therapeutic peptides, due to the harsh
and selective gastrointestinal system.
1.2 Thesis scope
So what does oral peptide delivery have to do with lipid membranes and acylation?
This work focuses on how therapeutic peptides cross the intestinal barrier to enter circulation,
particularly how modifying them with a fatty acid chain affects this crossing. Peptide acylation
is a powerful tool to alter the pharmacokinetics, biophysical properties and chemical stability of
injectable peptide drugs, primarily used to prolong blood circulation, but is not widely studied
in an oral context. The hydrophobic character of the acyl chain motivated a focus on interactions
with the lipid membranes surrounding intestinal cells, where both cell models and artificial lipid
membranes are employed as sketched in fig. 1.1. Cell models are most biologically relevant and
are well correlated with in vivo results, whereas artificial membranes allow more well-controlled
and quantitative studies, and the project attempts to bridge the gap between these two disciplines.
Conducting the project in an interface between several scientific disciplines gives rise to both
possibilities and challenges, and the aim is a high level of consistency in experimental procedures
(e.g. peptide concentrations and solutionbuffers)wheneverpossible. This encompassespreferably
using themethods and techniques that work in the chosen experimental conditions, as opposed to
changing experimental conditions to fit each technique, even if it signifies discontinuing otherwise
well-used characterization methods.
The project follows a circular setup, to accommodate synthesis and characterization of several
families of acylated peptides, depending on the obtained result. Furthermore, investigations of
two different peptides with similar acylations are incorporated, in order to separate the effects of
acylation and backbone.
Understanding the effects of acylation may allow future rational design of orally delivered
peptide drugs.
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Figure 1.1: Study objective cartoon. A very popular scientific sketch to introduce how the
membrane interaction and in vitro permeability of acylated peptides are investigated using an
intestinal cell model and model lipid membranes.
1.3 This thesis at a glance
The thesis consists of one introductory chapter, two published papers, one manuscript in prepara-
tion, a section with additional results, a collaboration project, and a final concluding chapter. The
introductory chapter, Chapter 2, introduces the core concepts of the project and briefly reviews
the state of the quite diverse research fields. More specific literature reviews are included in the
papers and manuscripts. Chapter 2 also contains a more elaborate discussion of the thesis scope
than provided above. Chapter 3 concerns the first peptide GLP-2, and contains the first pub-
lished paper along with some additional comments. It was written for a quite broad, open-access
journal, and features fairly comprehensive introductions to several of the core techniques used
in this thesis, therefore a separate section describing these techniques is not included. Chapter
4 concerns the second peptide sCT, and contains a published paper, a manuscript, and a section
with additional results which will later be collected in a manuscript. Chapter 5 briefly decribes
a collaboration project aiming at developing a microfluidic setup for in vitro studies like those
employed in this project, where the resulting manuscript in preparation is appended in appendix
C. The final concluding chapter, Chapter 6.1, summarizes the findings of the thesis and briefly
discusses future directions of research.
1.4 Publications
Research papers
1. S. Trier, L. Linderoth, S. Bjerregaard, T.L. Andresen andU.L. Rahbek. Acylation of Glucagon-
like peptide-2: interaction with lipid membranes and in vitro intestinal permeability. PLOS
ONE 9 (2014) e109939.
2. S. Trier, L. Linderoth, S. Bjerregaard, H.M. Strauss , U.L. Rahbek, T.L. Andresen. Acylation of
salmon calcitonin modulates in vitro intestinal peptide flux throughmembrane permeability
enhancement. Eur J Pharm Biopharm. 2015;96: 329–37.
3. S. Trier, L. Linderoth, S. Bjerregaard, H.M. Strauss, T.L. Andresen and U.L. Rahbek. Acy-
lated salmon calcitonin and dimethyl-β-cyclodextrin – self-association and in vitro intestinal
permeability. Manuscript under preparation; to be submitted.
4. H-Y. Tan, S. Trier, M. Dufva, J.P. Kutter and T.L. Andresen. A multi-chamber microchip
platform for studying drug transport across tissue barriers. Manuscript under preparation; to
be submitted.
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Conference contributions
S. Trier, L. Linderoth, S. Bjerregaard, H.M. Strauss, T.L. Andresen and U.L. Rahbek. Acylation of
Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability.
Poster presented at Liposome Research Days 2014, August 2014, Copenhagen.
Miscellaneous
A Danish popular scientific article was awarded 2nd prize in the Industrial PhD and Post Doc
association 2014 communication competition, awarded by the Danish minister of research, and
published at the popular scientific site Videnskab.dk.
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Chapter 2
Background
2.1 Therapeutic peptides
Peptide therapeutics have assumedan increasingly important rolewithindiseasemanagement, e.g.
diabetes, oncology, metabolic, cardiovascular and infectious diseases, and constitute a substantial
fraction of recent FDA approved drugs [3, 31]. Although macromolecular drugs (≥ 1000 g/mol)
are generally highly selective and efficacious, e.g. production, stability/solubility and delivery
route is farmore challenging than small molecules, and development has lacked behind. Themost
well known use of a therapeutic peptide is probably type 1 diabetes, where insufficient insulin
production in patients is compensated by external administration of the peptide. Although this
thesis focuses on other peptides, insulin deserves mentioning as it has been pivotal in driving
peptide technology forward, due to the wide (and fast increasing) spread of diabetes.
Initially, insulin injection therapy was based on native insulin of animal origin, i.e. the peptide
was purified from animal tissue. Gene technology enabled recombinant production of human
insulin, which vastly improved large-scale manufacturing and availability, and further allowed
modifications of the native peptide. Modern insulin analogues feature amino acid substitutions,
truncation and/or attachment of non-peptide moieties, thereby improving production, storage
stability, physico-chemical properties and physiological stability. In contrast to small molecules,
where synthetic large-scale production was feasible early on, peptide synthesis is often too low-
throughput and costly for drug production, although relevant for research purposes (see section
2.2).
The two therapeutic peptides studied in this thesis, GLP-2 and sCT, will be introduced in
section 2.5.
As a brief note on terminology, the words peptide and protein are not always clearly defined,
and often appear to overlap. In some texts the distinction is made at 50 amino acids in length,
whereas others note that proteins are more structured. Here, therapeutic peptides signify small
proteins (30-50 aa) with specific biological function and solution structure.
2.2 Peptide synthesis and characteristics
Single amino acids are readily available, but combining them into peptides through the amide
bonds is tricky for large peptides, due to the many possible combinations of reactive groups,
increasing with increasing peptide length. Peptides are synthesized by coupling the carboxyl
group or C-terminus of one amino acid to the amino group or N-terminus of another. To avoid
unintended reactions with ’the other’ carboxyl / amine group or side chain functional groups,
so-called protecting groups are usually necessary, where two different types can be used (orthog-
onal protecting groups, e.g. acid labile and base labile). The standard method is Solid Phase
Peptide Synthesis (SPPS), where peptide chains are built from the C-terminal end on functional-
ized resin beads, through repeated cycles of N-terminal deprotection-wash-coupling-wash. The
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’immobilization’ of peptides allows easy filtration, where liquid-phase reagents and by-products
of synthesis are flushed away. The finished peptide can be cleaved from the bead, followed by
side chain deprotection and purification on preperative HPLC. The repeated coupling steps can
be automated, where coupling yields are optimized by adding amino acids in major excess in
optimized coupling reagents, and speed can be increased by heating, e.g. microwave-assisted
SPPS, allowing synthesis of peptides up to around 100 aa. However, certain amino acids and
combinations of neighboring amino acids are more troublesome, e.g. due to steric considerations
increasing racemization, which can sometimes be alleviated by using di- or tri-amino acid build-
ing blocks, by reducing temperature or optimizing coupling reagents, or in severe cases require
alteration of the peptide sequence. [85]
The amino acid sequence constitute the peptide primary structure, whereas the secondary/ter-
tiary/quaternary structure is dynamic and depends on the peptide surroundings. Intra- or inter-
peptide disulfide bonds form between two cysteines and intra-peptide hydrogen bonding deter-
mines organization into α-helix or β-sheet motifs. Electrostatic or hydrophobic interactions can
cause peptide self-association into oligomers, which is highly dependent on solvent, peptide con-
centration, pH, temperature and ions. Most peptides exert their biological function as monomers,
and either the secondary structure is required for function or it changes upon interaction with the
target receptor or membrane. [34, 85]
2.3 Peptide acylation
Physiological peptide levels change slowly in response to tightly controlled feed-back loops, and a
sudden increase in peptide concentration upon external administration can be inefficient or even
harmful, particularly for insulin. The blood circulation time of peptides can be prolonged by
modification with a fatty acid, motivated by a naturally occurring post-translational modification
and fatty acid’s affinity to long-circulating albumin. The resulting acylated (or lipidated) peptide
can piggy-back on serum albumin, which is present in large amounts in the blood, thus preventing
clearance and prolonging the circulation time [39, 54]. Acylated insulin can further be tailored
to yield highly prolonged release following subcutaneous injection, through slowly dissolving
multihexamers [45, 89].
The acylation technology (sketched in fig. 2.1) has expanded from insulin to other peptides,
including several marketed drugs [51, 58, 96, 105]. It has further been shown to improve peptide
enzymatic stability, likely due to reduced affinity for the highly specific enzymes [26, 35, 105].
Acylation often affects peptide solubility and self-association behavior, which in turn can alter
secondary structure and solution stability (the latter in both directions) [12, 78, 97].
Figure 2.1: Acylation example. Carboxylic acids (e.g. hexadecaonic/palmitic acid as shown in
grey) can be attached to peptides at the −amino group of lysine (blue) or peptide N-terminal,
possibly through a linker or spacer to increase flexibility (e.g. β−alanine as shown in green).
Alteration of therapeutic peptides generally carries the risk of reducing potency, so the acyl
chain placement must be tailored to the peptide, e.g. by considering the structure-function
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relationship of the peptide, i.e. which parts of the pepide are crucial for receptor binding and
activation [35, 59, 88, 106]. A different approach to avoid impaired function is the prodrug strategy,
where the acylation is reversibly attached, and is slowly cleaved off in a biological environment
[20, 105].
As a brief note regarding the large-scale production of acylated peptides, the peptide backbone
(precurser) can be produced recombinantly, and later modified synthetically with the acyl chain.
[37, 85]
2.4 Oral delivery of peptides
Attempting to deliver peptides orally entails circumventing a well-functioning digestive system,
which is intended to digest peptides and proteins from our food, and only allow entry of the
harmless and useful building blocks. This thesis merely aims to investigate a small part of this
formidable problem, but we will briefly describe some of the major challenges and possible
solutions.
(It should be noted that oral peptide delivery is a very active research field, and a plethora of
excellent reviews and book chapters describe it in far greater detail than attempted here [15, 19,
64, 80].)
Macromolecules may be protected through the esophagus and stomach by enteric coating of
the dosage forms, and released as pH increases in the small intestine (i.e. the duodenum, jejunum
and ileum), a technology which has been applied successfully to some peptides. [1, 14, 17, 70]
The small intestine constitutes a highly metabolic environment, featuring numerous intestinal
enzymes [17], but peptides may be protected by adding enzyme inhibitors to formulations [86, 95,
99, 100] or possibly through acylation as described in the previous section.
The mucosal lining of the intestine is tightly sealed to avoid unspecific absorption, and passive
permeation of large, hydrophillic peptide drugs is limited [19, 48, 69]. This challenge is the focus
of the thesis, and will be discussed further in the next section. For completeness sake it should
be mentioned that after absorption, peptides are challenged by first-pass metabolism in the liver
and clearance from the blood stream (depending on where in the body they exert their function)
[33]. Incidently, hepatic entry is similar to endogenous insulin, and may thus be beneficial for this
peptide, compared to the high systemic levels ensuing from subcutaneous injections. [107]
2.4.1 Intestinal absorption of peptides and in vitro models
Firstly, a brief note on the words absorption and permeation, which are used as synonyms here,
but in some texts are used to distinguish between active and passive translocation across the cell
layer. This work focuses on passive translocation, and features no attempts at shuttling peptides
across via intestinal transporters [40]. Conversely, peptide transport most often describes passive
permeation, which may be slightly misleading for newcomers to the field.
The passive translocation routes through the epithelial cell monolayer of the intestine are
sketched in fig. 2.2. The transcellular route is efficient for small, hydrophobic molecules, whereas
the larger hydrophilic peptides are generally believed to enter primarily through the paracellular
route (albeit very inefficiently). [15, 19]
Intestinal absorption is often assessed in vitro by measuring drug translocation across mono-
layers of the human colon cancer cell line (caco-2). Although the cell line stems from the colon, it
appears closer to the small intestine in regard to tightness and protein expression and is a good
predictor of oral bioavailability [9, 42]. The experimental caco-2 setup is described in detail in
[42], and as applied in this work in paper 1 (e.g. fig. 6). As a brief practical note, caco-2 cell
lines change over time (e.g. with increasing passage number), and differ widely between different
research labs [40]. One should be cautious in comparing literature values for e.g. permeability,
and in our investigations (performed in the same lab, but over the course of several years) we used
various internal standards to bridge permeability values. It should further be noted that caco-2
cell monolayers are a very simple model of the intestinal barrier, devoid of mucus-production,
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Figure 2.2: Intestinal translocation. Schematic illustration of passive permeation pathways
through epithelial cells, from the apical side (corresponding to luminal or inner side in the
intestine) to the basolateral side (corresponding to the serosal side, connecting to the circulatory
system). The transcellular route entails crossing the outer cellular membrane twice and diffusing
through the cytosol, whereas the paracellular route requires crossing the tight junction protein
complex (green) sealing the cell boundaries. Inspired by fig. 3.1 in [17].
spatial effects, lymphoid tissue, and possibly several barrier/carrier proteins [40]. The relevance
of mucus in peptide absorption is debated [15, 74, 76, 80], and more complex systems have been
developed with mucus-producing HT29-MTX-E12 goblet cells alone [32, 71], cocultured with
caco-2 cells in various ratios [61, 102], or even as triple cocultures [7]. Interestingly, the appended
collaboration manuscript concerning caco-2 cells in a microfluidic setup feature some indications
of caco-2 mucus-production, possibly due to the shear forces exerted on the cells (also previously
observed for a similar microfluidic setup [49]). The complexity and biological similarity can be
increased further in the ex vivo Ussing chamber model, where cell monolayers are substituted by
rat intestinal tissue [24, 76], but this method is labor-intensive and requires continuous supply of
rat intestines (which obviously involves sacrificing the animals).
Both in vitro and ex vivomodels lack many natural variations in GI tract conditions, influenced
e.g. by food andwater consumption, which can affect peptide solubility and stability. Severalmore
complex buffers have been used to mitigate this, e.g. fasted/fed state simulated intestinal fluid
(FaSSIF/FeSSIF), which include bile salts and phospholipids [50], but such increased complexity
may interfere with the delicate peptide-membrane interactions studied in this project.
Increasing peptide permeation The most prominent strategy to increase peptide absorption
across the intestine is the co-addition of absorption enhancers that reduce the intestinal tightness.
Absorption enhancers are a diverse class of compounds, that function either through a detergent-
like unspecific destabilization of the cell membrane(s) or more specific interaction with surface
proteins, inducing cellular mechanisms that effectuate an opening of the paracellular space be-
tween the cells (i.e. at the tight junction proteins) [11, 60, 101]. Often, the mechanism of action
is not entirely clear, and may be a mix of both pathways. Some enhancers were initially used to
increase the drug solubility, but were later found to have an independent effect on the epithelium
[29, 43, 64].
The cellular effects of absorption enhancers can be quite profound, and most are cytotoxic
at high concentrations. The concentration dependent cytotoxicity differs widely for different
enhancers, and the concentration window for function without toxicity is often quite narrow [11,
101]. However, mucosal cells in vivo may be more resilient as they are replenished quite rapidly,
and oral dosing with absorption enhancers is safe and efficacious in many instances [64].
The gut is a crowded place, and unintended absorption of harmful compounds due to unspe-
cific reduction of epithelial tightness must be avoided. In many cases permeation enhancers can
be optimized regarding specificity for their peptide payload, and quickly reversible effects.[15].
Other approaches include advanced delivery systems, e.g. mucoadhesive chitosan devices [36,
72, 91], nanoparticles [2, 29, 81, 84, 93], liposomes [29, 87] or combinations thereof [62, 66]. Alter-
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Table 2.1: Peptide characteristics
Name Size (aa) Weight (g/mol) PI Sequence
GLP-2 33 3766 4 HADGSFSDEMNTILDNLAARDFINWLIQTKITD
sCT 32 3455 10.5 CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-NH2
Details: sCT contains a disulfide bridge at aa 1-7.
natively, the peptide itself can be modified with complex moieties, e.g. a cell-penetrating peptide
motif [31] or vitamin B12 conjugation to attempt transporter-mediated active translocation [4]. The
risk of reduced peptide potency following these modifications may be alleviated by the prodrug
approach, whereby the added moiety is cleaved off after absorption [15].
2.4.2 Acylation and oral delivery
The majority of reports regarding acylated peptides have focused on subcutaneous injection,
whereas the potential for oral administration remains an emerging field. Acylation has been
shown to increase intestinal permeability and/or oral bioavailability of a few peptide drugs [21,
94, 96, 106], but mechanistic insights and optimization is sparse. In vivo experiments in live
animals are limited, whereas experiments with cells and model lipid membrane allow more
expansive investigations (although model systems are never as powerful as in vivo tests, which
should always be kept in mind).
2.4.3 Acylation and interaction with lipid membranes
Intestinal absorption may benefit from the peptide (or parts of it) to be sufficiently hydrophobic
to allow partitioning into lipid bilayers, but not to get stuck there. The hydrophobicity was
traditionally measured as the octanol/water partitioning coefficient [82], but model lipid bilayers
closer mimic the cell membranes, and can provide more detailed information concerning peptide
membrane interactions [13, 52, 82]. Model lipidmembranes come inmany forms, where spherical,
nano-sized bilayer liposomes are versatile tools to study interaction with peptides in solution, e.g.
through fluorescence spectroscopy. If the peptide contains a tryptophan, which fluorescence
depends on the polarity of the micro-environment, peptide membrane interaction (and peptide
self-association) can be measured label-free [56]. Alternatively, the peptide can be modified with
a fluorescent moiety, although this may affect the peptide properties. If the peptide perturbs the
membrane upon insertion, it may be investigated by encapsulating a water-soluble fluorophore in
the liposome (although this was not part of the original study objective, we will see its relevance
in chapter 4).
Liposome partitioning studies are quite well-established for membrane-active peptides, such
as antimicrobial peptides [57], where acylation has been shown to alter peptide interaction with
lipid membranes more profoundly than expected from the increased hydrophobicity [30, 41].
Even small changes in acylation chain length was shown to affect membrane partitioning and
thereby antimicrobial efficacy [30, 41], however such mechanistic studies remain rare in an oral
delivery context, particularly in combination with in vitro investigations.
2.5 Peptides studied in this thesis
The two peptides (see table 2.1) are chosen partially as model peptides to study the impact of
acylation on oral delivery potential, but also due to their biological activity and relevance as oral
drug candidates.
GLP-2 and sCT are similar in size, whereas they are oppositely charged at physiological
pH. GLP-2 is mainly unstructured in solution, where the native peptide is not expected to be
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membrane active and spontaneously insert into lipid membranes, although these properties are
not well established [25]. sCT contains a disulfide bridge (aa 1-7) and reportedly some alpha helix
secondary structure in solution [6], and there are reports of membrane insertion, possibly as an
amphipathic alpha helix [27, 65, 67, 68]. An amphipathic structure is partially consistent with
parts of the peptide sequence’s alternating hydrophobic and hydrophilic residues, illustrated e.g.
by Kyte-Doolittle plots [55] (see fig. A.1 in appendix A).
GLP-2 is secreted in the intestine upon nutrient ingestion, and most importantly promotes
intestinal growth and function [28, 73, 92]. It has (quite recently) been used to treat bowel disorders
(e.g. Crohn’s disease and short bowel syndrome) where it is administered as subcutaneous
injections of the native peptide, possibly with minor amino acid substitutions [44, 95]. The plasma
half-life of GLP-2 in humans is limited to a few minutes [38] due to renal clearance and enzymatic
cleavage at the N-terminus (aa 1-2) by dipeptidyl peptidase-4 (DPP-IV) [38, 90], substantially
decreasing the receptor potency [38]. A GLP-2 analogue with an A2G amino acid substitution,
which is more stable towards DPP-IV is currently in clinical trials [44], but to the best of our
knowledge, no previous attempts at developing oral GLP-2 have been reported. However, as
GLP-2 elicits its function in the intestine, the oral entry route may be beneficial, and could in fact
circumvent some of the usual complications in oral delivery.
Calcitonin is secreted in the thyroid in response to excess calcium in serum, and functions to
reduce bone breakdown [22]. Human calcitonin is physically and chemically unstable in solution
[10], so therapeutic use is based on salmon calcitonin (sCT), which is efficiently recognized by
the human calcitonin receptor and circulates longer [23, 77]. sCT has long been used to treat
osteoporosis and hypercalcemia, with parenteral or intranasal administration [79]. However, oral
administration of sCT is extensively studied and tablet formulation development is far advanced,
where the majority of reports employ native sCT in combination with oral permeation enhancers,
carrier molecules or enzyme inhibitors [2, 8, 14, 16, 46, 47, 77].
Motivation for peptide modifications Reports of GLP-2 modifications are sparse, but acylation
at aa 17 was previously reported in [78], along with interchanging of Lys/Arg (i.e. natural
Lys30 changed to Arg, Leu17 changed to Lys and acylated, resulting in no net charge change),
which motivated the GLP-2 analogues in this project. A D3E mutation was introduced to avoid
racemization at the aa 2-3 Ala-Asp sequence.
The potency of sCT is highly dependent on the C-terminus [79], whereas the role of the N-
terminal cysteine bridge and the central a-helix motif is somewhat unclear [6]. 2K PEGylation
at Lys18 of sCT [103] or dual acylation with long chains at the sulfide bridge in a reversible
or permanent manner was well tolerated regarding potency [20, 21, 96]. To accomodate Trp-
fluorescence studies for sCT analogues as performed for GLP-2 analogues (employing its native
Trp), a Y22W mutation was initially introduced in the sCT backbone.
In the present work, both peptides were acylated with linear acyl chains, either short (c8, i.e.
using octanoic acid), medium (c12) or long (c16). The acylation was placed at aa 17 in GLP-2,
and at aa 18 or the N-terminus in sCT. These systematic analogue series allow investigations into
the effects of the acyl chain length, backbone charge and acylation placement, on the peptide-
membrane interaction and in vitro intestinal permeability. Such results may enable elucidating
potential general trends of peptide acylations on membrane translocation properties.
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Chapter 3
Results for GLP-2
3.1 Paper 1
The following section contains paper 1, as typeset by the journal, as well as the supplementary
information available online.
Summary The paper investigates a systematic series of acylated GLP-2 analogues, with c8, c12
or c16 acyl chains at the artificial Lys17.
The results demonstrate that increasing acyl chain length causes increased self-association and
binding to lipid and cell membranes, whereas translocation across intestinal cells displays a non-
linear dependence on chain length. Short and medium chains improve translocation compared
to the native peptide, whereas long chain acylation display no improvement in translocation.
This indicates an initial translocation benefit for shorter chains through increased interaction with
the cell membrane, which reverts to a hindrance for long chains, i.e. the analogues get stuck
in the cell membrane. This interpretation is supported by the effects of co-administered para-
and transcellular enhancers, which increases translocation irrespective of acyl chain length for the
former, whereas the latter display increased synergy with the long chain acylation, however, with
the c12-acylation remaining optimal. Thus, rational acylation of GLP-2 can increase its intestinal
absorption, alone or in combination with permeation enhancers, and the absolute quantification
of liposome binding (partitioning coefficient 1300 M−1 for c12-GLP-2) may be used to predict the
optimal acylation chain length for other acylation types or peptides.
Acylation of Glucagon-Like Peptide-2: Interaction with
Lipid Membranes and In Vitro Intestinal Permeability
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Abstract
Background: Acylation of peptide drugs with fatty acid chains has proven beneficial for prolonging systemic circulation as
well as increasing enzymatic stability without disrupting biological potency. Acylation has furthermore been shown to
increase interactions with the lipid membranes of mammalian cells. The extent to which such interactions hinder or benefit
delivery of acylated peptide drugs across cellular barriers such as the intestinal epithelia is currently unknown. The present
study investigates the effect of acylating peptide drugs from a drug delivery perspective.
Purpose: We hypothesize that the membrane interaction is an important parameter for intestinal translocation, which may
be used to optimize the acylation chain length for intestinal permeation. This work aims to characterize acylated analogues
of the intestinotrophic Glucagon-like peptide-2 by systematically increasing acyl chain length, in order to elucidate its
influence on membrane interaction and intestinal cell translocation in vitro.
Results: Peptide self-association and binding to both model lipid and cell membranes was found to increase gradually with
acyl chain length, whereas translocation across Caco-2 cells depended non-linearly on chain length. Short and medium acyl
chains increased translocation compared to the native peptide, but long chain acylation displayed no improvement in
translocation. Co-administration of a paracellular absorption enhancer was found to increase translocation irrespective of
acyl chain length, whereas a transcellular enhancer displayed increased synergy with the long chain acylation.
Conclusions: These results show that membrane interactions play a prominent role during intestinal translocation of an
acylated peptide. Acylation benefits permeation for shorter and medium chains due to increased membrane interactions,
however, for longer chains insertion in the membrane becomes dominant and hinders translocation, i.e. the peptides get
‘stuck’ in the cell membrane. Applying a transcellular absorption enhancer increases the dynamics of membrane insertion
and detachment by fluidizing the membrane, thus facilitating its effects primarily on membrane associated peptides.
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Introduction
Acylation of peptides with fatty acids is a naturally occurring
post-translational modification, which has inspired alteration of
therapeutic peptides for drug delivery. Acylation prolongs the
systemic circulation half-life of otherwise rapidly cleared peptide
drugs, through increased enzymatic stability [1–3] and binding to -
and piggy-backing on - serum albumin [4]. An additional effect of
acylation is increased peptide self-association and aggregation,
which has been employed to ensure prolonged release of peptide
drugs following subcutaneous injection [5]. Acylation can be
performed without disrupting the peptide’s biological potency [6],
and has been employed for a multitude of therapeutic peptides
[2,4,7,8], including several marketed drugs (e.g. insulin and
Glucagon-like peptide-1).
The increased enzymatic stability of acylated peptides is
particularly beneficial for oral administration, due to the highly
metabolic environment in the stomach and intestine [9]. Another
requirement for oral drug delivery is adequate absorption through
the intestinal epithelial barrier, which is a major challenge for
large, hydrophillic peptide drugs [10]. A widely used method for
predicting oral absorption in vivo is in vitro quantification of
translocation across monolayers of the human colon cancer cell
line (Caco-2), which has been shown to correlate well with oral
bioavailability [11,12]. Acylation has previously been shown to
increase intestinal permeability of peptide drugs [6,7,13], but
detailed investigations of systematic acyl variations are lacking,
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which would benefit rational new designs of peptide drugs. The in
vitro intestinal translocation studies can be further supplemented
by measurements of peptide binding to model lipid membranes
[14–16] in order to investigate the influence of membrane binding
of acylated peptides on cellular membrane translocation.
Glucagon-like peptide-2 (GLP-2) is a 33 amino acid peptide,
which is secreted from the human intestine following nutrient
intake [17,18]. Therapeutically, GLP-2 stimulates intestinal
growth and is employed in the treatment of inflammatory bowel
diseases (e.g. Crohn’s disease) and short bowel syndrome (e.g.
following intestinal surgery) [19,20]. The plasma half-life of GLP-2
in humans is limited to a few minutes [21] due to extensive renal
clearance and rapid enzymatic degradation by dipeptidyl pepti-
dase-4 [21,22]. Furthermore, GLP-2 is presently administered as
subcutaneous injections, which compromises patient comfort and
compliance, in particular for chronic diseases like Crohn’s. It
would be highly beneficial to enable oral administration, and the
combined effects of prolonged circulation time, improved enzy-
matic stability and intestinal permeability may render acylated
GLP-2 a suitable candidate for oral drug delivery. Currently,
however, there are no reports on the intestinal permeability or oral
drug delivery potential of acylated GLP-2.
In the present study we synthesized and characterized acylated
analogues of GLP-2, with systematically increasing acyl chain
length, in order to investigate the effect of the acyl chain on
membrane interaction and in vitro intestinal permeability. This
was achieved by combining investigations of the interaction with
lipid membranes and translocation across an intestinal cell model,
as outlined in fig. 1.
We hypothesize that the acylation chain length can be
optimized for translocation across the intestinal barrier, i.e. a
moderate interaction with the lipid cell membrane is beneficial for
translocation, whereas a stronger interaction may impair translo-
cation. Acylation is expected to confer membrane affinity to GLP-
2, as the native peptide is not membrane active. In this regard,
GLP-2 was employed as a model peptide, however, the results may
be applicable for development of a rational acylation strategy for
other peptide drugs.
Absorption enhancers are often employed to increase oral
peptide absorption, which makes it interesting to investigate how
these affect the translocation of acylated peptides [23]. In the
present study we included two enhancers with different enhancing
mechanism, in order to investigate the effect of the enhancing
mechanism. Ethylene glycol-bis(b-aminoethyl ether)-N, N, N, N-
tetraacetic acid (EGTA) is a paracellular enhancer which increases
transport between the cells by opening of the tight junctions [24],
and sodium dodecyl sulfate (SDS) is a transcellular enhancer which
increases transport through the cells at low concentrations,
predominantly by fluidizing the cell membrane [25].
We hypothesize that the effect of paracellular enhancers will not
be influenced by acylation, whereas the effect of transcellular
enhancers that directly interact with the cell membrane may
depend on the peptide-membrane interaction, through altered
membrane affinity and/or dynamics of membrane insertion.
Materials and Methods
Materials
Resin and natural amino acids were purchased at Novabiochem
(Germany). c8, c12 and c16 carboxylic acids, Fmoc-beta-Alanine
and native GLP-2 were provided by Novo Nordisk A/S.
Palmitoyloleoylglycerophosphocholine (POPC) was purchased
from Avanti Polar Lipids (USA). HEPES, Ovalbumin (OVA,
from chicken egg white) and other standard chemicals were
purchased from Sigma-Aldrich (Denmark). DMEM medium, l-
glutamine and penicillin/streptomycin was purchased from Lonza
(Switzerland). HBSS buffer, fetal bovine serum (FBS), nonessential
amino acid and other standard cell culture products were
purchased from Gibco (Denmark). Radioactively labeled
[3H]mannitol, scintillation fluid (Microscint-40), luciferase sub-
strate (SteadyLite) and 96-well plates for luciferase assay
(CulturPlate, black) were purchased from PerkinElmer (USA). 12
well Transwell plates for Caco-2 cell monolayers (polycarbonate,
12 mm, pore size 0.4 mM) were purchased from Corning Costar
Corp. (USA). GLP-2R BHK cells were provided by Novo Nordisk
(the cloning was previously described by Thulesen et al. [26] and
Sams et al. [27]) and Caco-2 cells (HTB-37) were purchased from
ATCC.
Peptide synthesis
The peptides were synthesized by automated Fmoc based SPPS,
using a preloaded Fmoc-Asp(OtBu)-Wang polystyrene LL resin in
0.25 mmol scale on a CEM Liberty microwave peptide synthesizer
(CEM Corporation, NC) using standard protocols, with a modified
coupling temperature of 500C [28]. Fmoc deprotection was
carried out in 5% piperidine and 0.05 M HOBt in NMP.
The acylation was conjugated to the lysine side chain by
incorporation of lysine as Lys(Mtt), which allowed chemical
modification using the standard coupling procedures stated above,
following Mtt removal. The Mtt group was removed by washing
the resin with DCM and suspending the resin in neat (undiluted)
hexafluoroisopropanol for 20 minutes followed by washing with
DCM and NMP. After synthesis the resin was washed with DCM,
and the peptide was cleaved from the resin by a 3 hour treatment
Figure 1. Schematic illustration of the study objective. The membrane interaction and in vitro permeability of acylated GLP-2 is investigated
using an intestinal cell model and model lipid membranes.
doi:10.1371/journal.pone.0109939.g001
Acylated GLP-2 and Intestinal Permeability
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e109939
with TFA=TIPS=H2O (95/2.5/2.5) followed by precipitation
with diethylether. The peptide was dissolved in a suitable solvent
(e.g. 1:1 MeCN : H2O) and purified by preparative HPLC on an
XBridge c18 column (Waters), using a gradient from 10%MeCN/
Buffer (10 mM TRIS and 15 mM (NH4)2SO4, pH 7.3) to 50%
MeCN over 40 min, flow rate 60 mL/min. The fractions were
analysed by a combination of UPLC and LCMS methods, and the
appropriate fractions were pooled and transferred to TFA salt for
lyophilization, using a gradient from 10% MeCN/0.1% TFA/
MQ to 60% MeCN. The peptides were finally quantified using a
chemiluminescent nitrogen detector, as previously described by
Fujinari et al. [29].
The isoelectric point of GLP-2 is approximately 4, with a
theoretical charge of -4 at neutral pH, and the analogues are
expected to be very similar.
Liposome preparation and characterization
POPC lipid films were prepared by evaporation from chlor-
oform:methanol (9:1 v/v) using a gentle nitrogen flow. The
residual organic solvent was evaporated in vacuum overnight and
the lipid films were rehydrated to 25 mM in HEPES buffer
(10 mM HEPES, 150 mM NaCl, pH 7.4) at room temperature
with frequent vigorous agitation for 1 hour. The multilamellar
lipid suspensions were subjected to 10 cycles of freeze-thawing
(isopropanol/dry-ice and 400C water bath) and extruded to
100 nm liposomes by passing it 21 times through a 100 nm
polycarbonate filter in a manual extruder (Avanti Polar Lipids).
[30]
The liposome hydrodynamic size after extrusion was measured
in a ZetaPALS Zeta Potential Analyzer (Brookhaven Instruments
Corporation), after dilution to 50 mM in sterile filtered HEPES
buffer. In all experiments the liposome diameter was 130+5 nm
with PDI 0.1.
The lipid concentration in liposome suspensions after extrusion
was determined by phosphorous analysis, as previously described
by Rouser et al. [31]. Briefly, the phospholipid sample was
degraded with heat and perchloric acid, reacted with ammonium
molybdate and reduced by ascorbic acid. Absorbance of the
resulting molybdenum oxides (molybdenum blue) was measured at
812 nm, and lipid sample concentration was determined from a
phosphate standard row. All samples were measured in triplicates.
A typical final concentration after extrusion at 25 mM was
22:5+0:1 mM.
Tryptophan fluorescence measurements
Peptide self-association. Fluorescence measurements were
carried out using an OLIS SLM8000 fluorescence spectrometer
equipped with excitation and emission monochromators and
polarizers. Tryptophan was excited at 280 nm and emission scans
were aquired from 300 to 400 nm with 2 nm step size, 2 s
integration time and slit widths 16 nm. Quartz cuvettes with an
excitation pathway of 10 mm and an emission pathway of 4 mm
were used with 1 mL sample volume. Peptide samples in the
concentration range 0.5–100 mM were prepared directly in the
cuvette from 100 mM stock solutions in sterile filtered HEPES
buffer. Temperature was maintained at 370C via an external water
bath, and the solutions were mixed by magnet stirring in the
cuvette.
The recorded spectra were fitted to obtain the peak position and
intensity, as described by Burstein et al. [32], using an iterative
least-squares fit (built-in in Gnuplot). Self-association of the
peptides causes a blue-shift and increase in tryptophan maximum
fluorescence, due to increased hydrophobicity near the tryptophan
residue, and the blue-shift is used as an indicator of self-
association.
Liposome partitioning. Fluorescence measurements were
conducted similarly to self-association experiments, with integra-
tion time 4 s, slit widths 8 nm (excitation) and 16 nm (emission)
and polarizers set to 900 (excitation) and 00 (emission).
The peptide solution was prepared directly in the cuvette and
was subsequently titrated with a 20 mM liposome suspension. The
peptide was used at a concentration (2 mM) below its self-
association concentration, to avoid any signal from self-association.
The fluorescence was initially measured as full wavelength scans
(300–400 nm), where the wavelength yielding the largest change
with liposome addition was identified (344 nm). Subsequently, the
fluorescence was measured as time-scans at 344 nm, and the
fluorescence after each liposome addition measured for 5 minutes
(increased and stabilized rapidly) and averaged over the last 3
minutes. It was verified that the fluorescence did not change
substantially after the 5 minute measurement (up to 1.5 h).
Liposome partitioning model
The membrane partitioning model is described in detail by
Etzerodt et al. [33]. Briefly, the tryptophan fluorescence after the
i’th addition of liposome (Fi) depends on the lipid concentration
after the i’th addition (Clip,i) and the partition coefficient (K )
through:
Fi~F0z(Finf{F0):
K :Clip,i
CwzK :Clip,i
ð1Þ
where F0 is the initial fluorescence of peptide alone, Cw is the
concentration of water (55 M) and Finf is the fluorescence at ‘full’
partitioning, i.e. after infinite liposome addition, which is a fitted
value.
eq. 1 is reorganized to yield
Fi{F0
Finf{F0
~
K :Clip,i
CwzK:Clip,i
ð2Þ
which is equal to the concentration of peptide bound in the
membrane CM divided by the total concentration of peptide Ctot,
i.e. the fraction of peptide that is membrane-bound. eq. 2 was used
for plotting (the left hand side) and fitting (the right hand side),
where the fit was an iterative least-squares fit with respect to K and
Finf (Gnuplot).
The partition coefficient K can be converted to the standard
Gibbs free energy of partitioning (DG0) through:
DG0~{R:T : ln(K) ð3Þ
where R is the gas constant (8.314 J/(K mol)) and T is the
temperature (310 K). For simplicity, the absolute value of DG0 is
displayed in graphs.
The partition coefficient K is unitless, but can be converted to
the more commonly used molar partition coefficient (in units
M{1) through dividing by the molarity of water (55 M).
Addition of liposomes to the peptide solution causes scattering
of excitation and emission light, which yields artifacts in the
experimental data that are accounted for by Ladokhin et al. [34].
To minimize these effects the fluorescence was measured using
cross-polarized light settings, where the excitation light was
horizontally polarized and the emission was measured vertically
polarized. This ensures that only the emitted light is measured, as
scattering does not alter the polarization, whereas fluorescence
Acylated GLP-2 and Intestinal Permeability
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randomizes the polarization. However, scattering still causes a
decrease in measured fluorescence, which is corrected for by a
correction factor H, measured by titrating the non-partitioning
probe L-Trp with liposomes:
H~
FL{Trp,i
FL{Trp,0
ð4Þ
where FL{Trp,i is the fluorescence of L-Trp after the i’th addition
of liposome and FL{Trp,0 is the initial fluorescence before liposome
addition.
H was fitted to a polynomial, which was used to correct the
measured peptide fluorescence during titration with liposomes.
All fluorescence measurements were normalized for peptide
concentration, including the slight concentration decrease during
titration.
Interaction with cells
Luciferase assay. A BHK cell line (GLP-2R BHK) was
previously modified to stably express the human GLP-2 receptor,
which controls the expression of firefly luciferase [26,27].
GLP-2R cells were cultured in DMEM with 10% FCS, 100 U
penicillin, 100 mg/mL streptomycin, 1 mM Na-Pyruvate, 250 nM
methotrexate, 1 mg/ml geneticin and 0.4 mg/ml hygromycin.
The assay was performed in DMEM without phenol red,
containing 10 mM HEPES, 1% glutamax and 1 mg/ml OVA.
For experiments, cells were seeded in 96-well plates at
20.000 cells/well (100 mL=well) and incubated overnight. The
medium was removed and the cells were washed once and
replenished with 50 mL=well assay medium. The test solution
(containing peptide) was diluted in HBSS buffer (containing
10 mM HEPES and 1 mg/ml OVA, pH 7.4) and 50 mL=well was
added to the cells. The cells were incubated for 3 h (at 370C and
5% CO2) and the test compound was removed. 100 mL=well
HBSS buffer was added along with 100 mL=well luciferase
substrate, the plate was sealed and incubated at room temperature
for 30 minutes. The luminescence (Relative Luminescence Units,
RLU ) was measured in a topcounter (Packard Topcount) and
depends on the peptide concentration as:
RLU~Az
B{A
1z10((logEC50{x)
:C)
ð5Þ
where x is log(concentration) of the peptide in M, and A, B, C and
EC50 are fitting parameters [35].
The peptide test solutions were diluted to fall within the
dynamic range of the assay (approximately 1–100 pM), and on
each plate with test solutions a peptide standard row was included,
which was fitted according to eq. 5 (using GraphPad Prism).
Caco-2 cells. Caco-2 cells (passage 40–65) were cultured
routinely [11] in DMEM with 10% (v/v) FBS, 1% (v/v)
nonessential amino acids, 100 U penicillin, 0.1 mg/mL strepto-
mycin and 2 mM L-glutamine. The Caco-2 cells were seeded at a
density of 1:105 cells/well on 12 well Transwells plates and grown
for 14–16 days in DMEM with media change every second day.
The cell layer was confirmed to consist of a single monolayer of
cells by fixing and staining the cell layer, and visualizing by
fluorescence microscopy.
Before transport experiments, DMEM medium was changed to
HBSS buffer (containing 10 mM HEPES and 0.1% (w/v) OVA;
0.4 mL apical side and 1 mL basolateral) and left to equilibrate for
60 minutes. Buffer was replaced apically by 0.4 mL test solution at
time zero, and the plates were incubated at 370C and 5% CO2
with gentle shaking. Test solutions contained 100 mM peptide and
0.8 mCi=mL [3H]mannitol (a permeability marker). Basolateral
samples of 200 mL were taken every 15 minutes for 1 hour, and
replaced by buffer. The apical test solution and basolateral
samples were diluted and analyzed for peptide content with the
luciferase assay and for [3H]mannitol content in a scintillation
counter (Packard TopCount), after mixing 1:1 with scintillation
fluid.
The integrity of cell monolayers before, during, and after
experiments was verified by measuring the the translocation of
radioactively labelled mannitol and the transepithelial electrical
resistance (TEER), using a Milicell ERS-2 epithelial volt-ohm
meter (Millipore, USA) [11]. Mannitol translocation and TEER
values were not affected by addition of peptide or analogues
compared to buffer.
After experiments, the cells were washed twice with buffer and
replenished with medium for 24 hour recovery, or washed thrice
with ice cold buffer and frozen at {800C for cell binding and
uptake analysis.
For cell binding and uptake studies, all preparations were
carried out on ice, and all the buffers were ice cold. The filters
were cut out of the inserts and placed in 12 well plates with the cell
layer facing up. 250 mL of buffer was added and the cells were
scraped off carefully with a cell scraper. The scraping was
repeated, and the cell suspensions were pooled and centrifuged
(13.000 rpm, 20 min, 40C). The supernatant was analyzed for
peptide content (cell uptake), and the pellet was resuspended in
buffer and vortexed thoroughly. The membrane-bound peptide
was recovered from the cell debris by addition of ethanol, followed
by thorough vortexing and centrifugation (13.000 rpm, 20 min,
40C). The supernatant solvent was evaporated under nitrogen-
flow, and the dry peptide was dissolved in buffer and analyzed for
peptide content (cell membrane binding). The cell uptake and
membrane binding of peptide and analogues are displayed as the
total amount of peptide in the cell layer. It was tested whether the
recovery of peptide from cell debris was efficient and/or
dependent on acyl chain length. Peptide or analogues were added
to the cell debris pellet after the first centrifugation, taken from
control cell layers with no added peptide, and after following the
subsequent steps for membrane binding, the peptide recovery was
measured. Essentially all added peptide was recovered, and there
was no measurable difference for the different analogues.
The Caco-2 translocation of peptide or mannitol over Caco-2
layers is expressed as the apparent permeability (Papp), given by:
Papp~
dQ
dt
: 1
A:C0
ð6Þ
where
dQ
dt
is the steady-state flux of peptide (pmol/s), A is the
surface area of the cell monolayer (1.12 cm2), and C0 is the initial
sample concentration added to the cell layer [11].
Data analysis
Statistical analysis was carried out using GraphPad Prism,
where unpaired Students t-tests were used for comparison and
significant differences required p,0.05.
Results and Discussion
Characterization of peptide analogues
We synthesized and investigated native GLP-2 and the acylated
analogues shown in fig. 2, where the acyl chain is conjugated to
the E{amino group of a lysine via a b{alanine spacer [8,36].
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The concentration-dependent self-association of GLP-2 and its
analogues was investigated by tryptophan fluorescence (fig. 3).
The acyl chains confer increased hydrophobicity, causing self-
assembly at lower concentrations for the acylated analogues
compared to the native peptide. Furthermore, the self-association
concentration decreased with increasing acyl chain length,
consistent with increasing hydrophobicity.
At physiological ionic strength, the secondary structure of the
c16 acylated analogue was similar to native GLP-2 (investigated by
circular dichroism (CD), see fig. S1). It is worth noting that the
buffer ionic strength is crucial for self-association, as no self-
association was observed with 0 or 10 mM NaCl. This is consistent
with electrostatic screening of the peptides’s multiple negative
charges as a requirement for self-association. The peptide
oligomers of native GLP-2 and its c16-analogue were character-
ized by static and dynamic light scattering (DLS/SLS) and
transmission electron microscopy (TEM), which showed that the
oligomers were spherical and well-defined in size (smaller for the
native peptide than the analogue), and composed of less than 10
monomers (see fig. S2).
Interaction with model lipid membranes
The partitioning of peptides into liposomes was quantified by
tryptophan fluorescence, in order to investigate the effect of
acylation on interactions with lipid membranes. The data
presented in fig. 4 shows that acylation of GLP-2 causes increased
partitioning into POPC membranes, where partitioning of native
GLP-2 is below the measurable limit and is not included in the
graphs. The standard Gibbs free energy of partitioning increases
linearly with acyl chain length for the investigated c8, c12 and c16-
chains, which is consistent with previous reports of acylated glycine
[37]. It is worth noting that the slope of this linear relationship is
lower for the GLP-2 analogues than for the acylated glycine
analogues, as reported by Peitzsch et al. [37]. This indicates that
the dependence of membrane affinity on acyl chain length is
influenced by the peptide or amino acid backbone, and that the
small glycine residue is more sensitive to chain length than the
larger GLP-2 peptide.
It should be noted that the peptides are used at a very low
concentration (2 mM) in order to avoid self-association, and that
the peptide/lipid ratio is quite low. For subsequent cell experi-
ments (and possible therapeutic applications) the peptides are used
at higher concentrations, and the lipid concentration is not well-
defined. Therefore, caution should be exerted when comparing
liposome and cell results, and speculating on in vivo applications.
Receptor activation
The biological activity of the analogues was verified in a
Luciferase assay (sketched in fig. 5), using a cell line stably
expressing the GLP-2 receptor and a luciferase gene, which is
transcribed upon receptor activation.
Figure 2. Schematic representation of native GLP-2 and its acylated analogues. GLP-2 is acylated with c8, c12 or c16-chains (grey) at the
E{amino group of Lys17 (blue) via a b{alanine spacer (green). The lysine residue replaces a leucine at position 17 and the natural lysine at position
30 in GLP-2 is mutated to an arginine (red). The aspartic acid at position 3 is mutated to a glutamic acid (red) to avoid racemization during synthesis.
None of these mutations caused measurable loss-of-function.
doi:10.1371/journal.pone.0109939.g002
Figure 3. Concentration-dependent self-association of GLP-2
and its analogues. Increasing concentration leads to a blue-shift and
increase in tryptophan maximum fluorescence, indicating self-associa-
tion of the peptides. Control experiments with L-Trp, which does not
self-associate, displayed no blue-shift. For the acylated analogues the
self-association concentration decreases with increasing chain length,
consistent with increased hydrophobicity which renders self-association
more favorable. Native GLP-2 is less prone to self-association, and
higher concentrations than the displayed 100 mM are required to reach
full self-association. Data points are mean + SD of 2 separate
experiments, and lines are provided to guide the eye. The sketch
serves as an illustration of self-association.
doi:10.1371/journal.pone.0109939.g003
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Alteration of therapeutic peptides is accompanied by a risk of
reducing potency, and acylation is no exception. However,
through a rational choice of acylation site and type and/or
screening different acylations, it is often possible to limit the
deleterious effects on biological activity [36]. All of of the
investigated acylated GLP-2 analogues display similar function
compared to native GLP-2, suggesting that these acylations did
not negatively impact receptor binding and activation.
The assay is employed to measure picomolar concentrations of
GLP-2 and its analogues after in vitro experiments with Caco-2
cells, using peptide standard curves fitted according to eq. 5. Thus,
the advantage of this cell based reporter assay is its very high
sensitivity.
Interaction with Caco-2 cells
The Caco-2 setup is sketched in fig. 6. The translocation of
peptide over time from the apical (upper) chamber to the
basolateral (lower) chamber was measured, along with the amount
of peptide associated with the cells after an experiment, both in the
aqueous parts of the cells (uptake) and in the lipid membranes.
Peptide translocation. The translocation of GLP-2 and its
analogues is presented in fig. 7, where part A shows the
accumulated amount of peptide in the basolateral compartment
during the 1 hour experiment and part B shows the apparent
permeability (Papp), calculated according to eq. 6.
The translocation depends non-trivially on the acylation chain
length, as the short and medium chains (c8 and c12) increase the
translocation relative to native GLP-2, but the long chain (c16)
decreases it slightly. This indicates an optimum chain length where
the translocation is increased by increased hydrophobicity and
intermediate membrane binding, whereas the long chain causes
too effective membrane insertion and strong binding, which limits
translocation. For the c12 analogue, the increase in translocation
through acylation is roughly a factor 1.5 compared to native GLP-
2.
An alternative explanation for the decreased translocation of
c16 could be increased self-association, which may limit para-
cellular translocation through the concomitant increase in size.
The extent to which the cellular environment affects self-
association is currently unknown, as is the exact degree of peptide
translocation through either the paracellular or transcellular route.
The acyl chain length may have an effect on albumin binding,
and thereby circulation time, which could limit the useful acyl
chain lengths to medium and long chain [8,36], but this is not fully
established [4] and has not been investigated in this study.
Figure 4. Binding to neutral liposomes. Addition of POPC liposomes to 2 mM peptide solutions causes an increase in tryptophan fluorescence,
indicating partitioning of the peptides into the hydrophobic part of the lipid membrane. A) The peptide fluorescence during titration with POPC
liposomes, fitted according to eq. 2 (solid lines), which yields the partitioning coefficients (K) shown in B). For the acylated analogues the partitioning
coefficient increases with increasing chain length, and converting to the standard Gibbs free energy (DG0) according to eq. 3 yields a linear
relationship with the chain length, C). Native GLP-2 partitions very weekly into POPC liposomes, with values below the measurable limit (K,500
M{1), and GLP-2 is therefore not included in the figure. Data points represent mean + SD of 2 separate experiments and stars in B) indicate
significantly different values (p,0.05). The sketch serves as an illustration of membrane-partitioning.
doi:10.1371/journal.pone.0109939.g004
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Cell membrane binding and uptake. The cell membrane
binding and uptake of GLP-2 and its analogues is presented in
fig. 8, where it is evident that both increase with acylation and
increasing chain length. The cell membrane binding qualitatively
resembles the liposome membrane binding presented in fig. 4C,
showing that the chain-length dependence for binding to neutral
model membranes is a valid predictor for cell membrane affinity,
despite the added complexity of the biological environments
compared to a simplified model membrane. It should be noted
that cell studies employ a higher concentration of peptide than
liposome binding studies, which may cause differences in peptide
self-association behavior.
Figure 5. Schematic illustration of the Luciferase receptor activation assay and typical standard curves. A) In order to confirm biological
activity of the analogues and measure picomolar concentrations of the peptides, a cell-line with the GLP-2-receptor and a luciferase reporter gene
was employed. Upon receptor activation by GLP-2 or its analogues, the cells produce luciferase, which can cleave the substrate luciferin to a
luminescent product. B) Representative standard curves of receptor activation (RLU) with increasing peptide concentration, for native GLP-2 and its
analogues. Data points represent mean + SD from 3 determinations, and solid lines are fitted according to eq. 5.
doi:10.1371/journal.pone.0109939.g005
Figure 6. Schematic illustration of the Caco-2 setup. The Caco-2 intestinal model is composed of Caco-2 cells grown in a monolayer on a
semipermeable filter support that separates two solution chambers. The peptide of interest is added to the top chamber (modeling the apical side of
the intestine, i.e. the intestinal lumen), and the translocated peptide is sampled from the lower chamber over time (modeling the basolateral side of
the intestine). Subsequently, the cells are analyzed for peptide content, both in the aqueous parts of the cells (uptake) and in the lipid membranes.
The microscopy image in the insert shows a Caco-2 monolayer on the filter support, after fixing and staining for cell nucleus (blue) and actin (red).
doi:10.1371/journal.pone.0109939.g006
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We speculate that the increase in cell uptake with increasing
acyl chain length is caused by increased cell membrane binding,
where peptide bound to the cell membrane is subsequently taken
up more readily.
The observed cell binding qualitatively supports the hypothesis
that the decrease in cell translocation for long chain acylation is
caused by their increased membrane interactions. The decrease in
translocation for c16-acylation compared to c12-acylation is larger
than expected from the increased membrane binding, however,
this may be explained by the added effect of increased uptake that
could lead to intracellular sequestration.
If the membrane binding is a powerful determinant for cell
translocation, the liposome partitioning coefficient may be used as
a predictor hereof, but this should be investigated in further detail,
using other peptides or acylations.
Absorption enhancers. The two absorption enhancers
EGTA (paracellular) and SDS (transcellular) were employed to
assess the effect of different enhancement mechanisms on the acyl
chain length dependence.
We hypothesize that paracellular enhancers will have little effect
on the acyl chain length dependence, i.e. enhance transport of the
peptide and all its analogues to a similar extent, whereas
transcellular enhancers that fluidize the membrane may have an
increased effect on the long-chain acylated analogue by altering
the membrane affinity and/or dynamics of membrane insertion
and detachment.
A previously performed dose-response experiment was used to
determine the appropriate concentration of absorption enhancers,
that yielded increased mannitol transport and a reversible decrease
in TEER with full recovery after 24 hours, and the results using
the optimal concentrations are presented in fig. 9A and B. The
translocation of GLP-2 and its analogues in the presence of EGTA
or SDS is presented in fig. 9C. For each peptide, the increased
transport in the presence of enhancer was compared to the
transport of the peptide alone as shown in fig. 9D, which
emphasizes the differences between the two types of enhancer.
For EGTA the increase is similar for peptide and analogues, and
the dependence on acyl chain length is retained, whereas for SDS
the increase is greater for the c16-acylation. These results support
the hypothesis that the fluidization of cell membranes caused by
SDS are beneficial for the long chain acylation, possibly due to
altered membrane insertion. This could be verified by investigat-
ing liposome partitioning or cell membrane binding in the
presence of SDS. However, despite the added benefit of SDS for
the c16-acylation, the translocation of the c16 peptide remains
lower than for the c12 peptide, suggesting that the acylation length
is the primary determining factor for optimizing translocation.
EGTA and SDS are employed as representatives of paracellular
and transcellular enhancers, and other enhancers of these types
are expected to elicit similar effects.
In conclusion, EGTA and SDS at the concentrations employed
increase the translocation while retaining the acyl chain length
dependence, with a medium chain length (c12) yielding the highest
translocation.
Figure 7. Translocation of GLP-2 and its analogues across
Caco-2 cell monolayers. A) Accumulated amount of peptide in the
basolateral chamber during the 1 hour experiment. B) Apparent
permeability (Papp) of the peptides, calculated according to eq. 6. Data
points represent mean + SD of 3 separate experiments, each with 4
repeats, and stars indicate significant differences (p,0.05).
doi:10.1371/journal.pone.0109939.g007
Figure 8. Cell membrane binding and uptake. The amount of
peptide bound in the cell membrane A) and the amount of peptide in
the aqueous parts of the cell B) increase with acylation length,
indicating a larger interaction with cells. For the acylated analogues the
membrane binding is roughly linear with chain length, and resembles
the observed binding to model membranes shown in fig. 4C. Data
points represent mean + SD of 3 separate experiments, each with 4
repeats, and stars indicate significantly different values (p,0.05).
doi:10.1371/journal.pone.0109939.g008
Acylated GLP-2 and Intestinal Permeability
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109939
Conclusions and Perspectivation
We have synthesized and investigated a systematic series of
acylated GLP-2 analogues, in order to establish how the
membrane binding correlates to in vitro intestinal permeability.
We find that increasing acyl chain length causes increased self-
association and binding to lipid and cell membranes, whereas
translocation across intestinal cells displays a non-linear depen-
dence on chain length. Short and medium chains improve
translocation compared to the native peptide, but long chain
acylation does not. We explain this correlation by an initial benefit
for translocation for shorter chains through increased interaction
with the cell membrane, which reverts to a hindrance for long
chains, i.e. the analogues get stuck in the cell membrane.
Measurements of liposome binding may be used to predict the
optimal acylation chain length (e.g. the partitioning coefficient of
approximately 1300 M{1 for c12-GLP-2), which can be further
investigated by using other peptides or acylation types.
The translocation of peptide and analogues increases in the
presence of both paracellular and transcellular absorption
enhancers. The acyl chain length dependence persists for the
paracellular enhancer and partially for the transcellular enhancer,
with an increased benefit for the long chain acylation. This can be
explained on the basis of a membrane fluidizing effect of the
transcellular enhancer, which alters the dynamics and strength of
membrane insertion, however, this requires further investigation.
For both enhancers the medium chain acylation (c12) yields the
highest translocation, approximately 1.5 times the native peptide.
The presented results suggest that rational acylation of GLP-2
increases intestinal absorption, and may benefit the oral delivery
route. However, this should be verified in vivo, e.g. by
investigating the intestinal absorption in an animal model
following in situ administration to the intestine. Dosing directly
to the rat intestine circumvents the esophagus and stomach, where
the peptide would most likely require further stabilization to
remain intact, e.g. through encapsulation and/or enteric coating.
In order to assert whether the effect of acylation on GLP-2 is
general and can be used to benefit oral delivery of other
therapeutic peptides, we are currently investigating other acylated
peptides. GLP-2 exerts is therapeutic function locally in the
intestine, which eases oral delivery and limits the challenging
requirement for long circulation times in the blood stream.
However, other therapeutic peptides that function systemically or
at sites apart from the intestine may benefit thrice from acylation,
i.e. on intestinal absorption, enzymatic stability, and circulation
life time.
Supporting Information
Figure S1 Secondary structure of native and acylated
GLP-2. Circular dichroism spectra of GLP-2 and its c16 analogue
in buffers with different ionic strength (0–150 mM NaCl). The
secondary structure of native GLP-2 and its acylated c16 analogue
is different at low ionic strength (as previously reported in [38]),
but similar at physiological ionic strength. It should be noted that
self-association alters the secondary structure, and as described in
the main text, the self-association behavior is affected by acylation.
The employed concentration 150 mM was chosen in order to
compare to [38], and at this concentration the peptides are
expected to be self-associated.
(TIF)
Figure 9. Effect of absorption enhancers on translocation of GLP-2 and its analogues. A) TEER values for Caco-2 cell monolayers after
experiments with absorption enhancers EGTA (paracellular) or SDS (transcellular), and after 24 hour recovery in cell medium. B) Mannitol permeability
in the presence of EGTA or SDS. C) Peptide permeability in the presence of EGTA or SDS. D) Fold increase in peptide permeability with enhancer,
compared to each peptide alone. All data points represent mean+ SD of 2 separate experiments, each with 4 repeats, and stars indicate significant
differences (p,0.05).
doi:10.1371/journal.pone.0109939.g009
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Figure S2 Size of selected peptide oligomers. TEM
(middle) and DLS (bottom) show that the native peptide and its
c16-analogue forms oligomers with radius 2.4 + 0.1 nm and 2.8
+ 0.1 nm, respectively. SLS-measurements show that the native
peptide oligomers are composed of approximately 4 peptide
monomers, whereas the c16 analogue oligomers are larger and
composed of around 7–10 monomers. The top sketch serves as an
illustration of peptide oligomers.
(TIF)
Materials S1 Materials and Methods for Cicular Di-
chroism (CD), Dynamic and Static Light Scattering
(DLS/SLS) and Transmission Electron Microscopy
(TEM).
(PDF)
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1Supporting Information
Materials and Methods
Circular Dichroism, CD UV CD spectra were obtained on a Jasco-J-815 circular dichroism spec-
trophotometer (Jasco, Tokyo, Japan). 150 µM peptide samples in HEPES buffers (10 mM HEPES, 0-150
mM NaCl, pH 7.4) were scanned at room temperature in 0.1 mm cells from 200-260 nm using a bandwidth
of 2 nm, a response time of 2 s, a data pitch of 0.5 nm and a scanning speed of 50 nm/min. The instrument
was calibrated with camphersulfonic acid. A background spectrum of the buffer was subtracted from each
peptide spectrum, and the spectra were converted to molar CD using instrument software.
Dynamic and Static Light Scattering, DLS and SLS Amodified commercial Laser Light Scattering
(LLS) spectrometer (ALV/DLS/SLS-5022F) equipped with a multi−τ digital time correlator (ALV5000)
and a cylindrical 22 mW He-Ne laser (λ0 632.8 nm) was used for static and dynamic light scattering (SLS
and DLS). LLS was performed at angles between 20◦ and 150◦ and the DLS time correlation was analyzed
by ALV Correlator 3.0 software. SLS results were analyzed manually, and the molecular weight of the
peptide oligomers was obtained using the previously reported partial refractive index of 0.186 mL/g (for
proteins in saline buffer with λ0 633 nm) [1].
250 µM peptide samples in HEPES buffer were filtered through 0.22 µM PVDF filters (non-protein
binding Whatman, GE healthcare), while care was taken to avoid dust in the solution and measuring
container.
Transmission Electron Microscopy, TEM TEM imaging was performed on 250 µM peptide samples,
as prepared for LLS measurements. 10 µL of sample was applied onto a carbon covered copper grid for 1
minute, after which excess sample was removed carefully with filter paper. The peptides were stained
with 3% (w/v) phosphotungstic acid (PTA), by applying 10 µL PTA solution to the copper grid for 2
minutes, after which excess solution was removed. The copper grid was rinsed once with a droplet of MQ
water and dried in air for 5 minutes. Samples were imaged at 120 kV in a Technai TEM (FEI).
Figure 1: (Figure S1) Secondary structure of native and acylated GLP-2. Circular dichroism
spectra of GLP-2 and its c16 analogue in buffers with different ionic strength (0-150 mM NaCl). The
secondary structure of native GLP-2 and its acylated c16 analogue is different at low ionic strength
(as previously reported in [2]), but similar at physiological ionic strength. It should be noted that
self-association alters the secondary structure, and as described in the main text, the self-association
behavior is affected by acylation. The employed concentration 150 µM was chosen in order to compare
to [2], and at this concentration the peptides are expected to be self-associated.
2Figure 2: (Figure S2) Size of selected peptide oligomers. TEM (middle) and DLS (bottom) show
that the native peptide and its c16-analogue forms oligomers with radius 2.4 ± 0.1 nm and 2.8 ± 0.1 nm,
respectively. SLS-measurements show that the native peptide oligomers are composed of approximately 4
peptide monomers, whereas the c16 analogue oligomers are larger and composed of around 7-10 monomers.
The top sketch serves as an illustration of peptide oligomers.
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3.1.1 Notes on paper 1 and GLP-2 results
The paper presents results obtained for GLP-2 analogues, but a few additional points deserve
mentioning.
Attaching a hydrophobic moiety to GLP-2 reduced its solubility and ’ease of handling’, so
extra carewas required for verifying peptide concentration in solutions and planning experiments.
Interestingly, the receptor potency did not appear to decrease significantly by acylation. In most
experiments, native GLP-2 was used as reference, however, the acylated analogues contained
several backbonemutations. Thus, GLP-2with D3E andK30R could be a better reference, whereas
L17K was best omitted due to the extra positive charge, which disappears upon acylation. The
GLP-2 backbone (E3, R30, K17) was compared to native GLP-2 with regard to self-association and
liposome partitioning, which yielded similar results, and caco-2 permeability, where permeability
was slightly higher for the backbone, presumably explained by the reduced negative charge.
In the beginning of the project, several complimentary methods were used to characterize
GLP-2 analogues, some of which yielded results not included in the paper. For completeness sake
they are briefly mentioned here, but the methods are not described in detail. The hydrophobicity
of GLP-2 analogues was measured in reverse-phase HPLC, with consistent results for increasing
hydrophobicity with chain length. However, HPLC elution is a very simple model which requires
organic solvents, and we deemed that the liposome partitioning method was more nuanced, well-
controlled and precise (however, also more labor-intensive). Isothermal Titration Calorimetry
(ITC) was briefly attempted formeasuring liposome partitioning, but the quite limitedmembrane-
affinity gave rise to very weak heat-spikes and experiments were discontinued. Regarding the
self-association, NMRstudies yielded similar concentration-dependent results as Trp-fluorescence
and CD and were discontinued. The self-association was initially characterized for native GLP-2
and its c16-analogue using Analytical Ultra Centrifugation (AUC), which roughly supported DLS,
SLS, and TEM studies, i.e. larger oligomers for the acylated analogue than the native peptide.
Native GLP-2 oligomers were not very stable, but were most likely composed of 4 monomers,
whereas c16-acylated GLP-2 oligomers most likely contained 7-8 monomers.
Initially, further in vitro experimentswere plannedwithGLP-2 analogues, but their very limited
interaction with Caco-2 cells motivated us to switch to sCT more rapidly than anticipated. We
found no published reports of Caco-2/GLP-2 studies, but both translocation across and interaction
with Caco-2 cells was very low compared to other peptides, e.g. sCT and insulin. This may be
due to multiple negative charges in GLP-2, whereas sCT is positively charged.
And with these words we turn to the next chapter concerning sCT.
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Chapter 4
Results for sCT
4.1 Paper 2
The following section contains Paper 2, as typeset by the journal, as well as the supplementary
information available online.
Summary The paper investigates two systematic series of acylated sCT analogues, with c8, c12
or c16 acyl chains at the N-terminus or Lys18.
The results demonstrate an unpredicted effect of acylation which largely superseded the an-
ticipated membrane interactions; i.e. acylated sCT acts as its own in vitro intestinal permeation
enhancer. Acylation drastically increases peptide permeability, through reversible cell effect simi-
lar to transcellular permeation enhancers, supported by the observed permeabilization of model
lipid membranes. The effect likely stems from a synergy between the positive peptide charge and
membrane-active acyl moiety, supported by its pH-dependency, whereby the effect increases with
decreasing pH and concomitant charge increase. The extent of permeation enhancing effect is
highly dependent on acylation chain length and position, with highest peptide permeability for
short chain N-terminal acylation or medium/long chain Lys18 acylation, whereas permeability
and cell membrane binding appeared correlated only for some analogues.
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a b s t r a c t
Acylation of peptide drugs with fatty acid chains has proven beneficial for prolonging systemic circula-
tion, as well as increasing enzymatic stability and interactions with lipid cell membranes. Thus, acylation
offers several potential benefits for oral delivery of therapeutic peptides, and we hypothesize that tailor-
ing the acylation may be used to optimize intestinal translocation. This work aims to characterize acy-
lated analogues of the therapeutic peptide salmon calcitonin (sCT), which lowers blood calcium, by
systematically increasing acyl chain length at two positions, in order to elucidate its influence on intesti-
nal cell translocation and membrane interaction.
We find that acylation drastically increases in vitro intestinal peptide flux and confers a transient per-
meability enhancing effect on the cell layer. The analogues permeabilize model lipid membranes, indicat-
ing that the effect is due to a solubilization of the cell membrane, similar to transcellular oral permeation
enhancers. The effect is dependent on pH, with larger effect at lower pH, and is impacted by acylation
chain length and position. Compared to the unacylated peptide backbone, N-terminal acylation with a
short chain provides 6- or 9-fold increase in peptide translocation at pH 7.4 and 5.5, respectively.
Prolonging the chain length appears to hamper translocation, possibly due to self-association or aggrega-
tion, although the long chain acylated analogues remain superior to the unacylated peptide. For K18-
acylation a short chain provides a moderate improvement, whereas medium and long chain analogues
are highly efficient, with a 12-fold increase in permeability compared to the unacylated peptide back-
bone, on par with currently employed oral permeation enhancers. For K18-acylation the medium chain
acylation appears to be optimal, as elongating the chain causes greater binding to the cell membrane
but similar permeability, and we speculate that increasing the chain length further may decrease the per-
meability.
In conclusion, acylated sCT acts as its own in vitro intestinal permeation enhancer, with reversible
effects on Caco-2 cells, indicating that acylation of sCT may represent a promising tool to increase intesti-
nal permeability without adding oral permeation enhancers.
 2015 Elsevier B.V. All rights reserved.
1. Introduction
Acylation of therapeutic peptides with fatty acids is a widely
used peptide alteration strategy in drug delivery, which has found
particular use for prolonging peptide circulation in blood of other-
wise rapidly cleared peptide drugs, e.g. by exploiting the affinity of
serum albumin toward fatty acids [1] and for increasing enzymatic
stability [2–5]. Acylation has been employed for a multitude of
therapeutic peptides [1,3,6,7], including several marketed drugs
(e.g. insulin and Glucagon-like peptide-1). An important drawback
for alteration of therapeutic peptides is the risk of reducing
potency; however, through a rational choice of acylation site and
type and/or screening different acylation positions, it is often pos-
sible to limit the deleterious effects on biological activity [8,9].
The majority of reports regarding acylated peptides have
focused on subcutaneous injection, whereas the potential for oral
administration remains an emerging field. Acylation may benefit
several of the challenges in oral delivery, e.g. the highly metabolic
environment in the stomach and intestine [10], and the limited
absorption of large, hydrophillic peptide drugs through the intesti-
nal epithelial barrier [11]. A widely used method for predicting
http://dx.doi.org/10.1016/j.ejpb.2015.09.001
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in vivo oral absorption is in vitro quantification of translocation
across monolayers of the human colon cancer cell line (Caco-2),
which has been shown to correlate well with oral bioavailability
[12,13]. In a few cases, acylation has been shown to increase
intestinal permeability of peptide drugs [6,8,14]; however, detailed
investigations of systematic acyl variations are lacking. Such inves-
tigations will benefit rational design of new peptide drugs, as
investigations of peptide interactions with model lipid membranes
[15–17] can elucidate its influence on cellular membrane translo-
cation potentially leading to higher oral bioavailability.
Calcitonin (CT) is a single-chain 32 amino acid peptide hor-
mone, with an N-terminal disulphide bridge between positions 1
and 7, and a C-terminal amidated proline. It is produced in the thy-
roid gland and secreted in response to excess calcium in serum
[18], and its primary biological function is the inhibition of
osteoclast-mediated bone resorption. Calcitonin is employed in
the treatment of bone-related disorders such as osteoporosis,
osteoarthritis, Paget’s disease, and hypercalcemia [19,20]. Whereas
human calcitonin (hCT) is physically and chemically unstable [21],
salmon calcitonin (sCT) is more stable, potent [22] and has a longer
in vivo half-life [20,23]. Consequently, the therapeutic use is
mainly based on sCT.
Administration of sCT is currently limited to either parenteral or
intranasal routes; however, several examples of oral delivery exist
in the literature and, recently, several clinical trials have been com-
pleted [20,24]. Most of these reports deal with native sCT in com-
bination with oral permeation enhancers or enzyme inhibitors
[20,23,24], which is challenging due to the requirement for suffi-
ciently high additive concentration to allow for intact peptide per-
meation. Other approaches include advanced delivery systems
[25–28] and a few examples of modifying the peptide itself
[6,29–31]. 2K PEGylation at Lys18 was shown to increase in vivo
efficacy but not in vitro permeability, so the improvement was
ascribed primarily to increased enzymatic stability [31]. Dual acy-
lation with long chains at the sulphide bridge in a reversible or per-
manent manner was shown to increase oral bioavailability but the
in vitro permeability was not investigated [6,29,30].
A previous study of acylated analogues of Glucagon-like
peptide-2 (GLP-2), a negatively charged peptide hormone [32],
revealed a non-trivial relationship between translocation ability
and acyl chain length, which correlated with the level of pep-
tide–membrane interactions.
In the present study we wish to investigate this effect in more
detail, and have, similar to the GLP-2 analogues, synthesized and
characterized a series of acylated sCT analogues where the system-
atically increasing acyl chains have been placed at two positions on
the positively charged backbone. This allows an investigation into
the effects of the acyl chain length, backbone charge and acylation
placement on membrane interaction and in vitro intestinal perme-
ability and, when compared to acylated GLP-2, enables elucidation
of potential general trends of peptide acylations on membrane
translocation properties.
2. Materials and methods
2.1. Materials
Resin and natural amino acids were purchased from Nov-
abiochem (Germany). c8, c12 and c16 carboxylic acids, Fmoc-
beta-Alanine and native sCT were provided by Novo Nordisk A/S.
Palmitoyloleoylglycerophosphocholine (POPC) was purchased
from Avanti Polar Lipids (USA). HEPES, Ovalbumin (OVA, from
chicken egg white) and other standard chemicals were purchased
from Sigma–Aldrich (Denmark).
Dulbecco’s Modified Eagle Medium (DMEM), L-glutamine and
penicillin/streptomycin were purchased from Lonza (Switzerland).
Hank’s Balanced Salt Solution (HBSS), foetal bovine serum (FBS),
nonessential amino acid and other standard cell culture products
were purchased from Gibco (Denmark). Radioactively labelled
[3H]mannitol, scintillation fluid (Microscint-40), luciferase sub-
strate (SteadyLitePlus) and 96-well plates for luciferase assay (Cul-
turPlate, black) were purchased from PerkinElmer (USA). 12 well
Transwell plates for Caco-2 cell monolayers (polycarbonate,
12 mm, pore size 0.4 lM) were purchased from Corning Costar
Corp. (USA). hCT-R BHK cells (Hollex-1, ZymoGenetics, US patent
5622839) were provided by Novo Nordisk and Caco-2 cells (HTB-
37) were purchased from ATCC.
2.2. Peptide synthesis
The peptides were synthesized by automated Fmoc based SPPS,
using a Rink Amide AM resin in a 0.25 mmol scale on a Prelude
peptide synthesizer (Protein Technologies), using standard proto-
cols (coupling with 6 eq. amino acid or fatty acid, diisopropylcar-
bodiimide (DIC) and ethyl 2-cyano-2-(hydroxyimino)acetate
(Trade name Oxyma Pure) in N-Methyl-2-pyrrolidone (NMP) for
60 min at r.t.; deprotection with 20% piperidine in NMP for
2  10 min). Acetamidomethyl (Acm) was used as protecting
groups for Cys. Formation of the disulphide bridge was performed
by dissolving the peptides in H2O (1 mg/1 ml), adjusting pH to 5.5
with acetic acid (AcOH) and oxidizing with a solution of 5% I2/
AcOH at room temperature for approximately 2 h. For N-e-lysine
acylated peptides the 4-Methyltrityl (Mtt) protecting group was
used. Mtt was removed with neat hexafluoro-2-propanol (HFIP,
3  15 min) followed by washings with dichloromethane (DCM)
and the acylation performed on a Prelude peptide synthesizer,
using the same conditions as described above. The peptides were
cleaved from the resin and deprotected using Trifluoroacetic acid
(TFA)/H2O/Thioanisole (TIS) 92.5:2.5:5 v/v for 3 h, followed by pre-
cipitation with diethylether. The peptide was dissolved in a suit-
able solvent (e.g. 95:5 H2O:MeCN) and purified by preparative
RP-HPLC on an XBridge c18 column (Waters) using MeCN/H2O/
TFA. The fractions were analyzed by UPLC, LCMS, and chemilumi-
nescent nitrogen detection [33], and the appropriate fractions were
pooled and portioned for lyophilization.
2.3. hCT receptor activation
The receptor potency of modified sCT analogues was assessed
using a hCT-R transfected BHK cell line, similar to previously
described for GLP-2 [32].
Briefly, hCT-R cells were cultured in DMEM with 10% FBS and
1% penicillin/streptomycin, and the assay was performed in
DMEM without phenol red, containing 10 mM HEPES, 1% gluta-
max, 0.1% OVA and 1% penicillin/streptomycin. Prior to experi-
ments, cells were plated in 384-well plates (CulturPlate) at
1  105 cells/ml, centrifuged for 20 s at 1500 rpm, and incubated
overnight (at 37 C and 5% CO2). After wash with assay medium,
cells were incubated with peptide analogues for 3 h, prepared
by 7-fold dilutions in the concentration range 0.1 pM–10 nM
(and pure buffer as 10 fM point). Cells were then incubated with
luciferase substrate for 30 min at room temperature while pro-
tected from light, and after a brief shake the luminescence
was measured in a topcounter (Packard Topcount). Relative
Luminescence Units (RLU) depend on peptide concentration as
shown in Eq. (1):
RLU ¼ Aþ B A
1þ 10ððlog EC50xÞCÞ
ð1Þ
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where x is log(concentration) of the peptide in M, and A, B, C and
EC50 are fitting parameters [35]. Curves were fitted in GraphPad
Prism.
2.4. Caco-2 cells and translocation experiments
Caco-2 cells (passage 40–65) were cultured routinely [12] in
DMEM with 10% (v/v) FBS, 1% (v/v) nonessential amino acids,
100 U penicillin, 0.1 mg/mL streptomycin and 2 mM L-glutamine.
The Caco-2 cells were seeded at a density of 105 cells/well on 12
well Transwell plates (polycarbonate, 12 mm, pore size 0.4 lM)
and grown for 14–16 days in DMEM with media change every sec-
ond day. The cell layer was previously confirmed to consist of a sin-
gle monolayer of cells by immunohistochemistry and fluorescence
microscopy (data in [32]). Per standard nomenclature [12] the
upper compartment above the cell layer is designated the apical
side, and the lower compartment below the cell layer is designated
the basolateral side.
The barrier property and integrity of cell monolayers during
growth and before/after experiments was verified by the transep-
ithelial electrical resistance (TEER), measured using a Millicell
ERS-2 epithelial volt-ohm meter (Millipore, USA). The widely used
translocation marker mannitol (radioactively labelled) was
included in all test solutions as another control of the cell layer
tightness and integrity [12]. Test solutions were prepared freshly
in either HBSS/HEPES buffer (pH 7.4) or HBSS/MES buffer (pH
5.5) (buffers containing 0.1% (w/v) OVA and 20 mM HEPES or
MES), and were treated very gently to avoid physical instability.
Although more stable than hCT, native sCT can form amyloid fibrils
in solution [34], and preliminary tests indicated that the acylated
analogues were less stable in HBSS buffer than in sCT. The stability
in HBSS buffer increased with decreasing pH, presumably through
increased charge and inter-peptide repulsion. Investigating the
peptide at lower pH is furthermore interesting from an oral drug
delivery perspective, as the pH is slightly acidic in the upper gas-
trointestinal tract, i.e. the duodenum and proximal jejunum
[35,36].
Before transport experiments, DMEM medium was changed to
HBSS/HEPES buffer (0.4 mL apical side and 1 mL basolateral) and
left to equilibrate for 60 min. Buffer was replaced apically by
0.4 mL test solution at time zero, and the plates were incubated
at 37 C and 5% CO2 with gentle shaking. Test solutions contained
100 lM peptide and 0.8 lCi/mL [3H]mannitol. Basolateral samples
of 200 lL were taken every 15 min for 1 h, and replaced by buffer.
The apical test solutions and basolateral samples were analyzed for
peptide content with commercial ELISA kits (see next paragraph)
and for [3H]mannitol content in a scintillation counter (Packard
TopCount), after mixing 1:1 with scintillation fluid.
After experiments, the cells were washed twice with buffer and
replenished with medium for 24 h recovery, or washed thrice with
ice cold buffer and frozen at 80 C for cell membrane binding and
uptake analysis. Membrane binding and uptake were performed as
previously described [32]. Briefly, the frozen cells were scraped off
filter inserts, resuspended in cold buffer and centrifuged. The
supernatant was analyzed for peptide content (cell uptake), and
the pellet was resuspended in buffer, vortexed thoroughly, and
centrifuged after addition of ethanol and thorough vortexing. The
supernatant solvent was evaporated under nitrogen-flow, and the
dry peptide was dissolved in buffer and analyzed for peptide con-
tent (cell membrane binding). The cell uptake and membrane bind-
ing of peptide and analogues are displayed as the total amount of
peptide in the cell layer as percentage of apically added amount
(40.000 pmol).
The Caco-2 translocation of peptide or [3H]mannitol over Caco-
2 layers is expressed as the apparent permeability (Papp), given by
Papp ¼ dQdt
1
A  C0 ð2Þ
where dQ/dt is the steady-state flux across the cell layer (pmol/s), A
is the surface area (1.12 cm2), and C0 is the initial sample concentra-
tion [12].
2.5. sCT concentration measurements
Apical and basolateral samples from Caco-2 experiments were
analyzed using commercial sCT EIA kits, as recommended by the
manufacturer. sCT samples and standards were diluted in HBSS
buffer as used for Caco-2 experiments, and for each analogue stan-
dards were included on the same plate as samples. Standards were
prepared for each analogue from sCT test solutions by 10-fold dilu-
tions in the concentration range 1 nM–10 lM, and were fitted to
Eq. (3) using GraphPad Prism:
Abs ð450 nmÞ ¼ Aþ B A
1þ 10ððlog EC50xÞCÞ
ð3Þ
where x is log(concentration) of peptide in M, and A, B, C and EC50
are fitting parameters [35].
2.6. Liposome calcein release
A possible membrane-permeabilizing effect of the acylated pep-
tide analogues was studied using POPC liposomes encapsulating
the water-soluble fluorophore calcein. POPC lipid films were pre-
pared by evaporation from chloroform:methanol (9:1 v/v) using
a gentle nitrogen flow. The residual organic solvent was evapo-
rated in vacuum overnight and the lipid films were rehydrated to
25 mM in HEPES/calcein buffer (20 mM HEPES, 75 mM calcein,
pH 7.4) at room temperature with frequent vigorous agitation for
1 h. The multilamellar lipid suspensions were subjected to 10
cycles of freeze–thawing (isopropanol/dry-ice and 40 C water
bath) and extruded to 100 nm liposomes by passing it 21 times
through a 100 nm polycarbonate filter in a manual extruder
(Avanti Polar Lipids) [37]. The liposome hydrodynamic size after
extrusion was measured in a ZetaPALS Zeta Potential Analyzer
(Brookhaven Instruments Corporation), after dilution to 50 lM in
sterile filtered HEPES buffer. In all experiments the liposome diam-
eter was 130 ± 5 nm with PDI 0.1.
Liposomes were separated from unencapsulated calcein by size-
exclusion chromatography on a Sepharose CL-4B column (GE
Healthcare, Sweden), with HEPES buffer as eluent (20 mM HEPES,
150 mM NaCl, pH 7.4). The liposomes eluted first, and were col-
lected by an automatic fraction collector. The lipid concentration
after extrusion and column purification were measured in tripli-
cate with ICP-MS, as the amount of atomic phosphor compared
to phosphor standard curves, and with Ga as internal standard.
Roughly 80% lipid is lost during extrusion and column purification,
so the expected concentration is around 5 mM, and a typical mea-
sured concentration was 6.7 ± 0.3 mM.
The peptide-induced leakage of encapsulated calcein from POPC
liposomes was measured in a Victor plate reader (PerkinElmer)
with black 96-well microplates, where peptide was mixed with
the appropriate buffer to a total volume of 90 lL, and at time zero
10 lL liposome suspension was added to all wells. The plate was
incubated at 37 C while the calcein fluorescence (It) was measured
regularly (Ex/Em at 485/535 nm), and after 1 h 10 lL 1% Triton X-
100 was added to each well to cause total leakage (I1). Buffer was
used as a negative control and initial fluorescence (I0), and the cal-
cein release was calculated according to
Release ð%Þ ¼ It  I0
I1  I0  100% ð4Þ
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2.7. Data analysis
Statistical analysis was carried out using Prism-6 (GraphPad,
USA). Results are presented as the mean ± standard deviation of
the mean (SDOM). Unpaired Student’s t-tests were used for com-
parison, and a significant difference was considered if p < 0.05.
3. Results and discussion
3.1. Peptide analogues
sCT and its acylated analogues are shown in Fig. 1, where the
acyl chain is conjugated to a primary amine at either the N-
terminus or the lysine in position 18. The peptide backbone (BB)
differs from native sCT in the Y22?W mutation, introduced to
allow for fluorescence measurements. The potency of sCT is highly
dependent on the C-terminus [19], whereas the role of the N-
terminal cysteine bridge and the central a-helix motif is somewhat
unclear [38]. Since reports have described biological activity of sCT
di-acylated at the cysteines or PEGylated at K18 [6,31], we placed
the acylation at the N-terminus or K18, and deemed that the
Y22?W mutation would have limited effect due to the conserva-
tive character of the alteration and proximity to K18.
3.2. Receptor activation
The biological activity of the analogues was verified via Lucifer-
ase expression in an hCT receptor transfected cell line, and the rel-
ative potency values are shown in Fig. 1 (examples of response
curves are shown in supplementary information, Fig. S1).
All analogues were active toward the hCT receptor, although the
receptor activation was affected by the Y22?W mutation and by
acylation. The effect of acylation depends on its position, as the
K18-analogues were more potent than the N-terminal analogues,
and especially for K18-analogues the potency appeared to increase
with acylation chain length.
The potency reduction observed for the peptide backbone and
peptide analogues may be due to an altered peptide secondary
structure, which preliminary structure investigations suggests for
BB and c8-N (see supplementary information, Fig. S2).
3.3. Effect of acylation on interaction with Caco-2 cells
Addition of the acylated analogues to Caco-2 cell monolayers
elicited a somewhat unexpected response, as the cell layer integ-
rity was transiently affected, and the analogue permeability was
drastically increased compared to the peptide backbone (see
Fig. 2) and native sCT (similar to BB, data not shown). The perme-
ability of the widely used transport marker mannitol [12] was
increased for the c8-analogue in a similar manner as the peptide
itself, which together with the reversible TEER-decrease and a
moderate release of LDH from the cells (data not shown) appears
suggestive of an intestinal permeation enhancer effect [39,40].
The enhancer-like effectwas evenmore pronounced at lower pH,
indicatingasynergybetweentheacylationandpositivechargeof the
peptide,which increasesat lowerpH.The theoretical chargesof c8-N
atpH5.5and7.4areroughly+3and+2, respectively, calculatedbased
on the amino acid sequence. Initial studies showed an even higher
effectatpH4.5(datanotshown),butat thispHtheTEERwasnotcom-
pletely reversible after 24 h in freshmedium.
The pH-effect could also be due to pH-dependent structural
changes of the acylated peptide, in particular when interacting
with the membrane, as both pH- and charge-dependent interac-
tions with lipid membranes are widely reported for antimicrobial
peptides [41,42] and fusogenic peptides [43].
The accumulated amount of peptide in the basolateral compart-
ment throughout the experiment is calculated as % of amount
added apically (see supplementary information, Fig. S3), and after
a 1 h experiment the values are roughly 0.05% and 0.5% for BB
and c8-N, respectively, at pH 5.5. The dependence on acylation
and pH is very similar to the permeability data shown in Fig. 3B,
thus displaying an acylation-induced improvement in peptide
translocation on par with currently employed oral translocation
enhancers [44].
To further investigate the effect of acylation and pH, the amount
of peptide bound in the Caco-2 cell membrane or aqueous lumen
was measured after the permeation experiment (see Fig. 4).
The cell membrane binding was increased drastically by acyla-
tion, whereas the cell uptake was increased moderately. Interest-
ingly, the pH-effect was reversed by acylation, as the peptide
backbone displays largest membrane binding and uptake at low
pH where the positive charge is largest, whereas the c8-analogue
displayed less binding and uptake at low pH. Thus, at lower pH
Fig. 1. Schematic representation of the analogues. sCT (with positive and negative amino acids highlighted) is acylated with c8, c12 or c16-chains (green) at either the N-
terminus or Lys18 (blue). Tyr22 is changed to Trp (yellow) to allow for fluorescence measurements, and the unacylated peptide backbone (BB) with W22 is used for
comparison.
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the acylated peptide translocates more efficiently across Caco-2
cell monolayers and less is retained in the cell layer.
3.4. Effect of acylation on interaction with model lipid membranes
To further investigate the effect of acylated sCT on Caco-2 cells
and resemblance to permeation enhancers, we utilized model lipid
membranes in the form of liposomes, encapsulating the
water-soluble fluorophore calcein. If the effect that the acylated
analogue exerts on Caco-2 cell monolayers is a detergent-like per-
meabilization of the membrane, it is expected to cause fluorophore
leakage from liposomes. The results are shown in Fig. 5, where it is
evident that the acylation induces a strong membrane-
permeabilization, in a pH- and concentration dependent manner.
The pH-dependency correlates well with Caco-2 permeability
(Fig. 3), indicating that the enhancer-like effect on Caco-2 cells is
due to permeabilization of the cell membrane.
The peptide backbone and native sCT (data not shown) caused
only negligible leakage within the 1 h experiment, although there
are reports in the literature of native sCT forming pores in model
membranes [45]. However, this was only observed for very specific
lipid mixtures, and not for PC liposomes around neutral pH [45].
For c8-N the leakage was measured in a range of concentrations,
in order to investigate the effect of different peptide/lipid ratios
(as lipid concentration was kept constant). The leakage after
15 min increased with concentration of c8-N, ranging from very
limited leakage at 5 or 10 lM, to very rapid leakage at 100 lM.
The pH-dependency was retained at all concentrations, and subse-
quent experiments were performed at 50 and 100 lM. In calcein
release experiments the peptide/lipid ratio is approximately 0.15
for 100 lM peptide, as used in Caco-2 experiments, but for cell
experiments the lipid concentrations are less well-defined. Thus,
it may also be interesting to vary the lipid concentration, while
keeping peptide concentration constant at 100 lM.
Triton X-100 was used to cause total leakage, and two previ-
ously investigated permeation enhancers [32] with different
enhancing mechanism were included for validation purposes.
Fig. 2. In vitro receptor activation of hCT receptor by sCT analogues. IC50 potency
relative to native sCT, presented as mean ± SDOM ofP2 separate experiments, each
in duplicate. All analogues activate the receptor, although the potency is reduced
relative to native sCT. The potency is lowest for N-terminal acylated analogues,
whereas K18-acylation has less effect.
Fig. 3. Effect of acylation on sCT permeation across Caco-2 monolayers, investigated for sCT backbone (BB) and c8-N analogue at pH 5.5 or 7.4. (A) TEER values for Caco-2 cell
monolayers after experiments and after 24 h recovery in cell medium. (B) Peptide and (C) mannitol permeability during the experiment. The acylation causes a reversible
TEER-decrease and large increase in peptide and mannitol permeability. The effect is enhanced at lower pH, where the peptide is more positively charged, indicating a
synergistic effect of acylation and charge. For the peptide backbone, native sCT (data not shown) or buffer alone there is no pH-dependence, and the permeability is consistent
with previously reported values for native sCT [23,31]. All data points represent mean ± SDOM of P2 separate experiments, each with 4 repeats.
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Ethylene glycol-bis(b-aminoethyl ether)-N, N, N, N-tetraacetic acid
(EGTA) is a paracellular enhancer which increases transport
between the cells by opening of the tight junctions [46], and
sodium dodecyl sulphate (SDS) is a transcellular enhancer which
increases transport through the cells at low concentrations, pre-
dominantly by fluidizing the cell membrane [47]. Thus, EGTA is
not expected to cause leakage, whereas SDS is. The two enhancers
were tested at the concentrations used in previous Caco-2 experi-
ments (13 mM and 0.6 mM, respectively), which caused a reversi-
ble TEER-decrease and approximately 4-fold increased
permeability of mannitol and GLP-2 [32]. EGTA caused no liposome
leakage, whereas SDS caused moderate leakage (slow compared to
c8-N), with approximately 30% after 15 min (see supplementary,
Fig. S4). These results indicate that the liposome system is a useful
tool for understanding interactions with Caco-2 cell monolayers,
despite its simplicity.
From the leakage of encapsulated calcein, it is difficult to say
whether the liposomes are still intact, i.e. whether or not the pep-
tides create a form of pores in the membrane or if they destroy the
liposomes in a detergent-like micellization. Liposomes incubated
with either 100 lM BB or c8-N for 15 min appeared intact as no
change was observed by DLS measurements (data not shown) sug-
gestive of the former, whereas the positive control Triton X-100
caused disappearance of liposomes, suggestive of the latter.
3.5. Dependence of Caco-2 permeability on acylation position and
chain length
The different combinations of acylation chain length and place-
ment on the sCT backbone were compared at pH 5.5, and as shown
in Fig. 6, all acylated analogues affected Caco-2 cells in a similar
fashion to the N-terminal c8-analogue, where some even displayed
larger increases in peptide translocation. The large, transient TEER-
effect of the acylated analogues correlated well with the perme-
ability of peptide and mannitol, and was highly dependent on acy-
Fig. 4. Effect of acylation on sCT interaction with Caco-2 monolayers, investigated
for sCT backbone and c8-N analogue at pH 5.5 or 7.4. (A) Peptide amount bound in
the Caco-2 cell membranes and (B) inside the cells after 1 h permeation experiment,
presented as a percentage of apically added peptide. Acylation increased both cell
membrane binding and uptake, and the effect of pH appears to be reversed by
acylation, where the peptide backbone displayed increased binding and uptake at
low pH, where the peptide has the largest positive charge. All data points represent
mean ± SDOM of 2 separate experiments, each with 4 repeats.
Fig. 5. Permeabilization of model lipid membranes for the acylated c8-analogue, as evidenced by release of encapsulated calcein from POPC liposomes. (A) Example of release
curves for 100 lM sCT backbone and its N-terminal acylated c8 analogue at pH 5.5, (B) release after 15 min at pH 5.5 and 7.4 (for 100 lM) and (C) concentration-dependence
for c8-N. Acylation of sCT backbone confers a strong membrane interaction, causing rapid permeabilization of liposomes. For c8-N the effect is pH- and concentration-
dependent, with larger (or more rapid) release at lower pH and/or higher concentration (although 5 and 10 lM are similar). All data points represent mean ± SD of 2 separate
experiments, each with 2 repeats.
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lation chain length and position. For N-terminal acylation, the
shorter chain(s) gave rise to the highest permeability, whereas
moving the acylation to K18 reversed this, although with compara-
ble permeability for c12- and c16-K. Compared to the unacylated
peptide backbone, all acylation chain lengths at both positions
gave rise to an increased peptide translocation, particularly for
c8-N (roughly 9-fold increase at pH 5.5) and c12-K/c16-K (roughly
12-fold). This acylation-induced improvement is on the same scale
as currently employed oral permeation enhancers [44], suggesting
that acylation of sCT could reduce or eliminate the need for these
in oral formulations.
For the K18-acylated analogues the amount of peptide bound in
the cell membrane increased with increasing chain length, which is
similar to what has been observed previously for GLP-2 analogues
[32]. Surprisingly, for the N-terminal acylated analogues the chain-
length dependence was reversed, indicative of a competitive self-
association or aggregation. Preliminary studies suggest that N-
terminal acylation increases peptide self-association at conditions
similar to Caco-2 experiments, as evidenced by altered Trp-
fluorescence (method described in [32], data not shown). However,
the decreased cell-membrane binding for longer chain acylations
indicates that the self-association may not be entirely reversible,
and could limit the interaction with and permeation across Caco-
2 monolayers. For K18-acylated analogues, increasing the acyl
chain length from c8 to c12 increased permeability. However,
increasing chain length further to c16 did not increase the perme-
ability in comparison with c12, which in combination with the
increased cell-membrane binding, could indicate that an acylation
chain length around c12 is optimal for K18-acylation, whereas N-
terminal acylation is optimal with a chain length around c8.
For sCT, acylation drastically increases Caco-2 interaction and
translocation, in particular for short and medium chains, but for
longer chains the cell membrane binding (and possibly self-
association) becomes somewhat limiting for translocation. We
have previously observed an optimum for c12-acylation of GLP-2,
where increased chain length caused decreased permeability
[32]. However, the GLP-2 analogues did not exhibit an effect on
Caco-2 cell layers as observed for sCT in the present study, and
the benefit of GLP-2 acylation was quite modest compared to the
current results.
3.6. Dependence of membrane interaction on acylation position and
chain length
We further investigated the liposome permeabilization, and
found that the acylated analogues caused leakage of calcein
(Fig. 7), consistent with cell membrane permeabilization as a cause
of enhanced Caco-2 translocation. The permeabilization potency of
the different analogues qualitatively correlated reasonably well
with their Caco-2 permeability, and the subtle differences may
be ascribed to the simplicity of the model system, e.g. different
affinities of the analogues to the POPC membrane compared to
the cell membrane with its complex mixture of lipids and mem-
brane proteins.
For selected analogues, the liposomes were investigated by DLS
after incubation, and for 100 lM c16-K the liposomes appeared
intact right after mixing, but absent after 15 min. For c16-K the
leakage was very rapid (almost instantaneous), which correlates
well with a micellization of the liposomes as opposed to leakage
Fig. 6. Interaction of sCT backbone and acylated analogues with Caco-2 monolayers, investigated for c8-, c12- or c16-acylations at the N-terminal or Lys18. (A) TEER values
for Caco-2 cell monolayers after experiments and after 24 h recovery in cell medium. (B) Peptide and (C) mannitol permeability during the experiment. (D) Cell membrane
bound peptide after the experiment. All acylated analogues caused a reversible decrease in TEER, increased permeability of peptide and mannitol, as well as increased cell
membrane binding (and uptake, data not shown). TEER-decrease and permeability are quite well correlated, and show a marked dependence on both acylation chain length
and position. For N-terminal acylation, the longer chains display lower permeability, whereas for K18-analogues the dependence is reversed, with c12- and c16-K showing
comparable permeability. The amount of peptide bound in the cell membrane shows a similar trend, although with a higher value for c16-K than c12-K. All data points
represent mean ± SDOM of P2 separate experiments, each with 4 repeats.
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through pores. As described previously, leakage caused by c8-N
was not accompanied by destruction of liposomes after 15 min.
4. Conclusions
In the present work a series of systematically acylated sCT ana-
logues were investigated, in order to establish how in vitro intesti-
nal permeability is affected by acylation of different lengths in
different positions. We find that peptide acylation results in a per-
meation enhancing effect in an in vitro intestinal model and that
acylated sCT exhibits a cell penetrating peptide like effect on cellu-
lar membranes. The acylation-induced permeability enhancing
effect on the cell layer was found to be transient, as the cellular
barrier fully recovered after peptide exposure. The analogues per-
meabilized model lipid membranes, indicating that the effect is
due to a detergent-like solubilization of the cell membrane, similar
to certain oral permeation enhancers.
The permeability enhancing effect of the peptides was highest
at reduced pH, and was further dependent on acylation chain
length and position. For N-terminal acylation the short c8-
acylation provided the most pronounced effect, whereas the longer
chain acylations may be hampered by self-association or aggrega-
tion. For K18-acylation the short chain provided a moderate
improvement, whereas the c12 and c16 analogues were highly effi-
cient, with a 12-fold increase in cell translocation compared to the
unacylated peptide backbone. For K18-acylation an optimum acyla-
tion length appears to exist around c12, as the c16 chain caused
greater binding to the cell membrane but similar permeability,
and we speculate that increasing the chain length further may
decrease the permeability as previously observed for GLP-2 ana-
logues [32].
Acylated sCT acts as its own permeation enhancer, with effects
on Caco-2 cells that are rapid, reversible and on par with currently
employed oral permeation enhancers; thus, acylation of sCT could
represent a promising tool to increase its intestinal permeability
without simultaneous administration of absorption enhancers.
Although the receptor activation potency is moderately reduced,
acylation is expected to confer increased enzymatic stability and
prolonged blood circulation, and the presented results suggest that
acylation of sCT increases intestinal absorption, which might
improve delivery by the oral route.
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Supplementary Information  
 
 
Figure S1. In vitro receptor activation of human calcitonin receptor (hCT-R) by salmon calcitonin (sCT) 
analogues, presented as mean ± SDOM of duplicates, with sigmoidal fitted curves.  
 
 
Figure S2. Circular dichroism spectra of 100 µM native sCT, peptide backbone (BB) and c8-N 
analogue in the physiological HBSS/HEPES buffer (pH 7.4) used for cell studies (although without 
OVA). The Y22->W mutation and/or acylation appears to alter the secondary structure, e.g. by 
decreasing the α-helix content, which may explain the receptor potency reduction observed in fig. S1. 
Preliminary measurements further suggests a buffer- and pH-dependency of c8-N structure, with a 
CD-response resembling BB in either a more simple HEPES/NaCl buffer (pH 7.4, 150 mM NaCl) or in 
HBSS buffer at pH 5.5 (data not shown). 
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Interaction with Caco-2 cells  
 
Figure S3. Accumulated amounts of peptide during Caco-2 permeability experiment, presented as % 
in basolateral (BL) compartment of added apical (AP) amount. All data points represent 
mean ± SDOM of 2 or 3 separate experiments, each with 4 repeats. 
The time-resolved accumulation is not completely linear for c8-N, and the calculation 
of Papp (eq. (2) in Materials and Methods) assumes linearity between 2 consecutive 
time points, but the error is minimal (and would diminish with closer sampling time 
points). The increasing rate of accumulation throughout the experiment indicates 
that the effect exerted by c8-N on the cell layer continues and increases through the 
experiment, which is reasonable considering that the majority of peptide remains 
above the cell layer.  
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Calcein release    
 
Figure S4. Permeabilization of model lipid membranes as evidenced by release of encapsulated 
calcein from POPC liposomes. The acylated c8-analogue is compared to a transcellular enhancer (SDS) 
and paracellular enhancer (EGTA), at the concentrations where they transiently decrease TEER and 
increase Caco-2 permeability approximately 4-fold [1]. The transcellular detergent-like enhancer SDS 
causes moderate leakage after 15 minutes, whereas the paracellular enhancer EGTA does not cause 
leakage, consistent with their respective mechanism of action. 
All data points represent mean ± SDOM of 2 separate experiments, each with 2 repeats. 
 
[1] S. Trier, L. Linderoth, S. Bjerregaard, T.L. Andresen, U.L. Rahbek, Acylation of Glucagon-like peptide-
2: interaction with lipid membranes and in vitro intestinal permeability., PLoS One. 9 (2014) e109939.  
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4.1.1 Notes on paper 2
The figure caption of fig. 4 contains a small error, as the cell bound peptide is expressed as pmol
instead of as % of AP amount as stated.
Caco-2 experiments also featuredmeasurements of Lactate Dehydrogenase (LDH) release after
experimentswith sCT analogues, which is indicative of cell stress or damage. Thesemeasurements
were very consistent with liposome permeabilization and reversible TEER decreases, and were
not included in the paper.
Peptide modifications and potency Conjugating the acylation to a primary amine reduces the
peptides positive charge (most pronounced for K-analogues and at higher pH), which may in
itself alter the peptide. This could be compensated by adding a cationic amino acid in the peptide
backbone, however, it was not attempted due to the risk of perturbing the peptide structure and/or
function in an unpredictable manner.
As described in paper 1, GLP-2 contains a tryptophan in position 25, which was used in
fluorescence spectroscopy studies of peptide self-association and membrane partitioning. sCT
does not contain a tryptophan, so we altered the tyrosine at pos. 22, but the combination of a
point mutation and acylation appeared to affect the peptide in a synergistic manner (particularly
the physical stability, as described later), and furthermore the fluorescence studies turned out not
to be entirely feasible (described in the next section).
The receptor potency of all analogues (fig. 2 in paper 2) was affected to a surprising degree,
particularly BB, where the Y22W point mutation reduced potency by 50 %. Acylation decreased it
further, particularly N-terminal acylation, somewhat in contrast to reported sCT analogues with
dual long-chain acylations at both cysteines (pos 1 and 7) and reasonable potency [96]. Interest-
ingly, the potency appeared to increase slightly with increasing chain length for both acylation
positions. For this group of analogues the separate effect of acylation can not be distinguished,
but in section 4.3.1 we describe a group of acylated analogues without the backbone mutation.
The receptor potency was measured quite late in the project, and as sCT was partially used as
a model peptide it was not a ’show-stopper’, but there were other issues with the analogues.
Failed fluorescence spectroscopy As briefly mentioned in paper 1, peptide self-assocation and
liposome partitioning elicit similar changes in Trp fluorescence, and therefore liposome partition-
ingmeasuremens require peptide concentrations below the self-association threshold. Unacylated
GLP-2 or sCT do not readily self-associate, whereas acylation increases self-association, and al-
though employing low peptide concentrations did not pose problems for GLP-2 analogues, it
caused difficulties for sCT analogues. Trp measurements for pure peptide solutions in quartz
cuvettes showed a gradual and substantial decrease in fluorescence when stirring was initiated,
plateauing after roughly 30 minutes. We later found a very similar fluorescence profile reported
in [75], explained by adsorption of cationic peptide to the walls of the quartz cuvette and to
the stirring bar. The adsorption may be aggravated by acylation [78], but was not observed for
acylated GLP-2 analogues in the current setup. Adsorption may possibly be avoided by using
higher peptide concentrations, using containers designed to limit binding (e.g. Protein LoBind
tubes) or coating the inner surfaces with inert polymers or proteins [53]. However, fluorescence
experiments are very restrictive regarding peptide concentration, and to our knowledge there
is no LoBind alternative to the quartz cuvette. Surface coating with an inert protein is in fact
employed in all other experiments, as OVA is included in buffers, but here it would interfere with
Trp fluorescence. Polymer coating (e.g. PEI as in [75]) is labor-intensive and requires validation
in the present experimental setup. For the record, liposome partitioning experiment are already
quite time-consuming.
Furthermore, since Caco-2 studies indicated amore profound effect onmembranes than simple
partitioning, we focused instead on investigating themembrane-destabilization effect described in
paper 2 (calcein release), where it was possible to use higher peptide concentrations and include
OVA.
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Liposome partitioning was initially an important part of the thesis scope, and as mentioned
in paper 1, we aimed at using the partitioning coefficient as a predictor of Caco-2 permeability.
However, the enhancer-effect on Caco-2 cells might render this idea moot.
The concentration dependent self-association of sCT analogues was intended to be estimated
using Trp fluorescence (as for GLP-2 analogues in paper 1), mostly as a prerequisite for liposome
partitioning studies. However, apart from peptide surface adsorption at low concentrations,
measurements at high concentrations were marred by the physical instability described in the
next section. Although, an interesting result was obtained for BB and c8-N. As briefly introduced
in paper 1, the fluorescence spectrum for Trp is red-shifted in a polar environment, e.g. for
free L-Trp in solution, and blue-shifts in a more hydrophobic environment, e.g. in oligomers
of acylated GLP-2 analogues. However, c8-N exhibited the opposite behavior, with red-shifted
signal (similar to BB) at high concentration and blue-shifted at lower concentration. This may
be explained if the Trp residue is situated in a hydrophobic environment (’protected’ by the acyl
chain?) in the monomeric peptide. If one then assumes self-association in a micelle-like oligomer
centered around the acylated N-termini, then the Trp residue, which is situated at pos. 22, in a
somewhat hydrophilic region of the peptide, may be pushed out towards water. This is extremely
speculative, and based on quite preliminary results, but it illustrates the potential use of Trp
fluorescence for more advanced purposes, as it has been used to follow conformational changes
in larger proteins [83].
Solution stability ’Traditional’ sample preparation for Caco-2 experiments or Trp fluorescence
studies did not play well with some sCT analogues, specifically, prolonged heating to 37 ◦C and
shaking or magnet stirring in the physiological HBSS buffer caused solutions to become turbid
and/or gel-like. This behavior may be indicative of peptide fibrillation, which is investigated
in paper 3. Initial attempts with different buffers indicated that the issue persisted in other
physiological buffers, such as PBS and FASSIF (simulated intestinal fluid), also when preparing
stock solutions in DMSO. Non-physiological buffers with e.g. low salt concentration or very
low pH were highly beneficial, but can not be used in caco-2 experiments. Instead, moderate
improvements were achieved by very careful handling of samples (i.e. no shaking!), preparing
stock solutions in MQ and diluting in the relevant buffer immediately before experiments. This
enabled the experiments presented in paper 2, but further improvements were attempted, as
presented in paper 3.
(Incidently, lowering pH to 5.5, which was tolerated by caco-2 cells, revealed the interesting
pH dependency presented in paper 2.)
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4.2 Paper 3 (draft)
The following section contains a manuscript draft for Paper 3, which concerns the acylated sCT
analogues introduced in paper 2. The investigation is not a part of the thesis scope, and as such
was a bit of a detour project, but it is included here as it represents an interesting perspective on
acylation.
Summary The manuscript draft investigates sCT analogues with c8, c12 or c16 acyl chains at the
N-terminus or Lys18.
The results demonstrate that prolonged heating and/or solution storage of certain acylated
sCT analogues cause aggregation in physiological buffer solutions, potentially forming fibril-like
structures. Lys18 acylation appears superior to N-terminal acylation, most clearly exemplified
by the short chain c8-analogues, however, no systematic dependence on acylation chain length is
apparent. For all analogues, self-association is efficiently inhibited by addition of DM-β-CD, how-
ever, the separate permeability enhancing effects of acylated analogues andDM-β-CD are reduced
in the mixtures. Thus, acylation of sCT for oral delivery purposes may not be indiscriminately
applicable, and requires rational choices of acylation details and/or additives.
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Abstract 
Acylation of the therapeutic peptide salmon calcitonin (sCT) increases its enzymatic 
stability, and was recently shown to confer intestinal permeability enhancement to 
the peptide when acylated with various chain lengths at the N-terminus or K18. 
However, certain acylations appeared to cause aggregation of sCT, and this work 
aims to characterize this solution behavior. Furthermore, the effect of adding 
dimethyl-β-cyclodextrin (DM-β-CD) to monomerize peptide analogues is 
investigated, in terms of solution behavior and in vitro permeability in Caco-2 cell 
monolayers. 
We find that N-terminally acylated analogues aggregate into fibril-like structures 
upon prolonged heating in physiological buffers, whereas moving the acylation to 
Lys18 decreases or delays aggregation. Short c8-chain analogues display time-
dependent binding profiles to Thioflavin T, where the lag-time is extended roughly 
2-fold for Lys18 vs. N-terminal acylation, whereas longer chain analogues display less 
well-defined profiles. Addition of DM-β-CD strongly inhibits aggregation for all 
analogues, however, the intestinal permeability enhancing effect of both acylated 
analogues and DM-β-CD appears hampered in the mixture. The permeability is 
efficiently increased by addition of DM-β-CD to the unacylated peptide backbone, 
whereas it is only slightly increased for c8-K and reduced for N-terminal analogues.  
In conclusion, acylation of sCT can increase its intestinal permeability, but also its 
propensity to fibrillate in physiological buffers, with a marked dependence on 
acylation chain length and position. Addition of DM-β-CD abolishes aggregation, 
however, this combination may not be optimal for intestinal translocation. Thus, 
acylation of sCT for oral delivery purposes is not indiscriminately applicable, and 
requires rational choices of acylation details and/or additives. 
Introduction 
The 32 amino acid peptide hormone calcitonin, which lowers blood calcium and is 
employed in the treatment of bone-related disorders such as osteoporosis and 
hypercalcemia,  has been described extensively elsewhere [1–4]. Whereas human 
calcitonin (hCT) is physically and chemically unstable[5], salmon calcitonin is more 
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stable, potent [6] and has a longer in vivo half-life [4,7]. Consequently, the therapeutic 
use is mainly based on sCT, through either parenteral or intranasal routes. Literature 
reports and clinical trials attempting oral delivery of sCT has mostly employed native 
sCT in combination with oral permeation enhancers [4,7,8], although there are a few 
examples of advanced delivery systems [9–11] and modifying the peptide itself [2,12–
16]. Acylation of therapeutic peptides with fatty acids is beneficial for prolonging 
circulation [17], increasing enzymatic stability [18–21], and may moderately increase 
oral bioavailability of peptide drugs [12,22,23]. Intestinal absorption is often assessed 
in vitro in the caco-2 model [24,25], and we recently described how acylation of sCT 
elicited a drastic increase in caco-2 monolayer translocation, due to an oral enhancer-
like permeabilization of the cell membranes [2]. 
However, although sCT is more stable than hCT, fibrillation occurs upon ageing or 
otherwise challenging solutions [26], and acylation appeared to affect the solution 
behavior. Some acylated analogues showed signs of gel-formation upon ageing, 
agitation or prolonged incubation at 37°C in the physiological HBSS buffer used for 
Caco-2 experiments, although they were quite stable in MQ and low salt buffers. This 
prompted a more detailed study of the solution behavior of sCT analogues. We 
further attempt to limit self-association by addition of DM-β-CD to peptide solutions, 
as similar β-cyclodextrins have been reported to monomerize peptides [27–29], likely 
through binding of hydrophobic peptide side chains in the hydrophobic core of β-
CD. Furthermore, cyclodextrins have been employed as absorption enhancers for 
nasal [30] or oral peptide delivery [31,32], acting through binding of the peptides or 
depletion of cholesterol from epithelial cell membranes [29,30,33,34], thus lowering 
their barrier function. We investigate the effect of combining acylated sCT analogues 
with DM-β-CD on in vitro intestinal peptide permeability. 
Materials and Methods 
Peptide synthesis 
The peptide synthesis has been described previously [2]. Briefly, peptides were 
synthesized by automated Fmoc based SPPS, using Rink Amide AM resin on a 
Prelude peptide synthesizer (Protein Technologies), employing standard protocols 
(coupling with 6 eq. amino acid or fatty acid, DIC and Oxyma Pure in NMP for 60 
min at r.t.; deprotection with 20% piperidine in NMP for 2 x 10 min). Cys was 
protected with acetamidomethyl (Acm), and the disulfide bridge was formed by 
dissolving peptides in MQ, adjusting pH to 5.5 with acetic acid and oxidizing with a 
solution of 5% I2/AcOH at room temperature for approximately 2h. Primary amines 
were protected with 4-methyltrityl, and deprotected in neat HFIP, followed by 
washings with DCM. Peptides were cleaved from the resin and deprotected using 
TFA/H2O/TIS for 3 hours, followed by precipitation with diethylether. Peptides were 
 3 
 
dissolved in H2O/MeCN and purified by preparative RP-HPLC. The fractions were 
analyzed by UPLC, LCMS, and chemiluminescent nitrogen detection [35] and the 
appropriate fractions were pooled and portioned for lyophilization. The peptide 
concentration of each analogue stock solution in MQ was verified with 
chemiluminescent nitrogen detection [35]. The cysteine bridge was verified by 
measuring peptide mass in LCMS following reduction with DTT. 
 
Thioflavin T (ThT) assay 
100 µM peptide samples were mixed with 1 µM ThT in 96 well microtiter plate 
(Packard OptiPlate-96, white) and incubated at 37 °C, while ThT fluorescence was 
measured (Ex 444 nm/ Em 485 nm) in a Fluoroskan Ascent FL fluorescence plate 
reader (Thermo Labsystems). 
 
Transmission Electron Microscopy (TEM) 
100 µM peptide samples were placed on Formvar-coated copper grids (1 min 
residence time, then removed with filter paper) and stained with a 2 % (w/v) uranyl 
acetate solution (1 min, then removed). Samples were examined with a FEI Morgagni 
268 electron microscope operating at 80 kV. Samples were prepared in HBSS/MES 
buffer, similar to Caco-2 experiments (see below), apart from the absence of 
ovalbumin (OVA), which was verified in ThT assay to be inconsequential for self-
association. 
 
Caco-2 cells 
The growth of and experimental setup for Caco-2 cell monolayers has been described 
previously [2,16]. Briefly, Caco-2 cells (HTB-37, ATCC, passage 40–65) were cultured 
routinely [24], seeded at 105 cells/well on 12 well Transwell plates and grown for 14–
16 days in DMEM with media change every second day. The barrier property and 
integrity of cell monolayers during growth and before/after experiments was verified 
by the transepithelial electrical resistance (TEER), measured using a Milicell ERS-2 
epithelial volt-ohm meter (Millipore, USA), and 0.8 μCi/mL [3H]mannitol was 
included in all test solutions as a translocation marker [24]. Test solutions were 
prepared freshly with 0-100mM DM-β-CD in HBSS/HEPES buffer (0.1% OVA (w/v) 
and 20 mM HEPES, pH 7.4), and were treated very gently.  
Transport experiments were performed in HBSS/HEPES buffer, with test solutions 
added apically after 60 min. equilibration with buffer, while incubated with gentle 
shaking. Basolateral samples were collected every 15 minutes for 1 hour and 
analyzed along with apical test solutions, for peptide content using commercial 
ELISA kits (see next paragraph) and for [3H]mannitol content in a scintillation 
counter (Packard TopCount), after mixing with scintillation fluid (Microscint-40). 
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After experiments, cells were washed twice with buffer and replenished with 
medium for 24 hour recovery. The Caco-2 translocation of peptide or [3H]mannitol 
over Caco-2 layers is expressed as the apparent permeability (Papp), given by: 
Eq. (1):   𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡
 
1
𝐴 ∙ 𝐶0
 
where dQ/dt is the steady-state flux across the cell layer (pmol/s), A is the surface 
area (1.12 cm2), and C0 is the initial sample concentration [24]. 
 
sCT concentration measurements 
Apical and basolateral samples from Caco-2 experiments were analyzed using 
commercial sCT EIA kits, as recommended by the manufacturer (Phoenix 
Pharmaceuticals). sCT standards were prepared for each analogue from sCT test 
solutions, and were fitted to eq. 2 using GraphPad Prism. 
Eq. (2):  𝐴𝑏𝑠(450𝑛𝑚) = 𝐴 +
𝐵−𝐴
1+10((𝑙𝑜𝑔𝐸𝐶50−𝑥) ∙ 𝐶)
 
where x is log(concentration), and A, B, C and EC50 are fitting parameters [36]. 
 
Data analysis 
Statistical analysis was carried out using GraphPad Prism, where unpaired Students 
t-tests were used for comparison, and a significant difference was considered if p < 
0.05.  
 
Results and Discussion 
Peptide analogues  
Acyl chains were conjugated to a primary amine in sCT at either the N-terminus or 
at K18, and the peptide backbone (BB) differs from native sCT in a Y22W mutation, 
initally introduced to allow for fluorescence measurements. Despite the mutation’s 
conservative character and its vicinity to previously described major alterations not 
causing loss-of-function [12,15], the potency of BB towards the hCT receptor was 
found to be reduced roughly 50% compared to native sCT [2]. Acylation caused 
further reduction, particularly for N-terminal acylations, although all analogues 
displayed activity towards the receptor.  
 
Solution behaviour of sCT analogues in physiological buffer 
The fluorophore ThT is widely used to probe fibrillation due to its propensity to bind 
cross-β structures in (amyloid) fibrils [37], where the resulting excitation and 
emission shifts enables fast and sensitive screening for fibril formation. Freshly 
prepared peptide solutions gave rise to quite varied time profiles (fig. 1). 
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Figure 1 ThT fluorescence intensity measured over time, for incubation of sCT 
analogues and a control peptide at 37 °C. A gradual increase in fluorescence intensity 
as observed for c8-analogues indicates fibrillation, whereas the constantly low value 
for BB (similar to buffer) indicates no fibrillation during the time course of the 
experiment. Data points represent mean ± SDOM of 3 separate experiments. 
During the time course of the experiment, BB (and native sCT, data not shown) 
displayed a constant low ThT signal similar to buffer, indicating no fibrillation. For 
c8-analogues the gradual increase in fluorescence indicates fibrillation during the 
experiment, with a longer lag-phase for c8-K than for c8-N. For the longer chain 
acylations the data is less clear, with a low and constant signal (c12- and c16-N), high 
and constant (c16-K) or a slight increase over time (c12-K). False-negative signals for 
fibrils and ThT fluorescence have been reported, as well as similar profiles to those 
observed for c16-analogues [27,38], which was ascribed to fibril subtypes which did 
not bind ThT and conformational changes in fibrils causing changes in ThT 
fluorescence, respectively. However, the signals could also be due to non-fibril self-
association, so the previously investigated peptide analogue GLP2-c16 [16] was 
included as a control (fig. 1). The c16-acylated analogue of Glucagon-like peptide-2 
(GLP-2) was previously observed to form well-defined oligomers in saline buffers at 
physiological pH [16], and fibrillation was not observed on intermediate time scales. 
As evident from fig. 1, the ThT fluorescence profile of the peptide control is similar 
to the c16-sCT analogues, although with a higher signal than for c16-N. This indicates 
that the ThT-signals observed for the long chain acylations could be caused by self-
association or other modes of aggregation than fibrillation.  
In order to investigate the self-assemblies in more detail, peptide solutions were 
visualized using TEM, where an initial positive control using an aged c8-N solution 
(several days old) showed widespread elongated structures. TEM images for selected 
samples are presented in fig. 2. 
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Figure 2 TEM images of peptide analogues, with 44kx (left) or 180kx magnification 
(right). TEM visualization was repeated 2-3 times with similar results. 
 7 
 
In fig. 2, c8-N displayed elongated structures, slightly entangled networks, and 
longitudinal twisting at high magnification. c12-N and c16-N appeared as untwisted, 
shorter fibers, whereas c12-K and c16-K displayed very short rods. For BB and c8-K, 
no structures were visible in TEM, however, room temperature incubation of the c8-
K solution for 3 hours caused development of some visible structures.  
 
The acylation was initially placed at the N-terminus, but the analogues’ aggregation 
propensity spurred an alternative placement at K18. Peptide fibrils have been 
reported to consist of parallel or anti-parallel alignment of peptides, perpendicular 
to the fiber axis [39], and the N-terminal acylation might increase parallel alignment 
of sCT analogues. Acylation at K18 may alleviate this, and ThT and TEM results show 
some reduction in aggregation through moving the acylation, in particular for c8-
analogues. However, previously reported results [2] show a non-trivial relationship 
between acylation chain length or position and intestinal permeability, where the 
short c8 chain is optimal for N-terminal acylation and the medium or long chain is 
optimal for K18-acylation (superior to c8-N). 
 
Addition of DM-β-CD 
For c8-analogues mixed with DM-β-CD, the ThT fluorescence intensity increase was 
delayed or abolished altogether (fig. 3), indicating inhibition of self-association at the 
employed concentrations. For c12- and c16-analogues DM-β-CD caused a lowering 
of ThT fluorescence signals to time-independent values, and for c12-K thus abolished 
the slight signal-increase over time, however, the values remained higher than 
buffer. In preliminary experiments DM-β-CD was employed at 10, 50 or 100 mM with 
similar impact on ThT fluorescence intensity, but the lowest concentration was 
chosen for further experiments based on a preliminary Caco-2 screening of 
cyclodextrin toxicity (see next section). The lower concentration limit for inhibition 
of aggregation was not investigated. 
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Figure 3 ThT fluorescence intensity measured over time, for incubation of sCT 
analogues +/- DM-β-cyclodextrin at 37 °C. Data points represent mean ± SDOM of 2-3 
separate experiments. 
 
The effect of cyclodextrin was investigated with TEM, where self-association was 
drastically reduced for all analogues, and essentially no structures were visible in the 
presence of DM-β-CD. Furthermore, preliminary DLS investigations confirmed the 
presence of large structures in the solutions of acylated analogues (not for BB), which 
in most cases disappeared in the presence of cyclodextrin, consistent with TEM 
images. 
 
 
Interaction with Caco-2 cells   
The translocation of sCT analogues through Caco-2 monolayers was previously 
found to cause enhanced translocation through permeation enhancer-like effects on 
the cells, which depended non-trivially on acylation chain length and position [2]. 
The peptide samples were treated gently to avoid fibrillation, and for c8-analogues 
the lag time preceding an increase in ThT fluorescence did not indicate significant 
fibrillation during the 1 h Caco-2 experiment. For c8-N the use of aged solutions 
(positive control for fibrillation) reduced the translocation and enhancer-effect on the 
cells, indicating a detrimental effect of aggregation into larger structures. 
Translocation of the large peptide structures is presumably negligible, and 
dissociation may be either irreversible or slower than the time-scale of the 1 h cell 
experiment, thus limiting the amount of peptide monomer free to interact with the 
cells. For longer chain acylations, K18 analogues displayed far superior translocation, 
enhancer-effect and binding to the cell membrane compared to N-terminal analogues 
[2]. This may indicate that K18 analogues aggregate less or in a more reversible 
manner, which is partially supported by TEM visualization (fig. 2).   
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If the Caco-2 interaction of longer chain N-terminal analogues is in fact impaired by 
aggregation, then monomerization by DM-β-CD should improve Caco-2 interaction, 
and ease the handling of samples for future applications.  
 
 
Figure 4. Effect of DM-β-CD on the interaction of sCT analogues with Caco-2 
monolayers, investigated for BB and N-terminal or K18-acylated analogues. A) TEER 
values for Caco-2 cell monolayers after experiments and after 24-hour recovery in cell 
medium. B) Peptide and C) mannitol permeability during the experiment. All data 
points represent mean ± SD of 2 separate experiments, each with 4 repeats. 
 
However, Caco-2 translocation in the presence of DM-β-CD (fig. 4) indicates an 
interesting effect. Cyclodextrin addition to BB provides an efficient permeability 
enhancement, which is not observed for the acylated analogues, and for N-terminal 
analogues the acylation-induced enhancement is in fact less efficient in the presence 
of DM-β-CD. For c8-K, cyclodextrin addition appears to be slightly beneficial, but the 
enhancement is very limited compared to the effect for BB, or the acylation-induced 
enhancement.  
Cylodextrin alone enhances mannitol permeability enhancement and decreases 
TEER, which indicates an unspecific effect on the cell layer, e.g. through cholesterol 
depletion. For the BB/DM-β-CD-mixture, TEER values do not recover entirely after 
24 h in fresh medium, and preliminary experiments with higher DM-β-CD 
concentrations (50 and 100 mM), either alone or in combination with c8-N, showed 
very large decreases in TEER with no recovery after 24 h. Full recovery after exposure 
to the BB/ DM-β-CD-combination could presumably be obtained by lowering the 
 10 
 
cyclodextrin concentration, however, the unacylated peptide was not the focus of 
this work.  
The ability of DM-β-CD to limit aggregation of acylated sCT analogues may explain 
the somewhat detrimental effects on caco-2 translocation. The ability of acylated sCT 
analogues to act as their own permeability enhancer are speculated to be due to a 
synergy between the hydrophobic acyl chain and the positively charged peptide 
backbone, causing efficient insertion into the caco-2 cell membrane and a disruptive 
effect similar to transcellular oral permeation enhancers [2]. However, if the acyl 
chain binds in the hydrophobic core of DM-β-CD with a high affinity, then the 
insertion into caco-2 cells may be hindered. Furthermore, if the permeation enhancer 
effect previously observed for similar β-CDs [31,34] is partially due to extraction of 
cholesterol from cell membranes, this could be hampered by too tight binding to 
acylated sCT analogues. However, the high molar excess of DM-β-CD to peptide 
(100:1) should lower the possible importance of ‘scavenging’ by sCT analogues.  
In fig. 4, addition of cyclodextrin affects the caco-2 permeability of the two c8-
analogues differently, as it is decreased for c8-N (particularly mannitol permeability) 
and it is slightly increased for c8-K. This difference may be caused by different 
binding affinity of the two analogues to DM-β-CD. Cyclodextrin addition to c12-N 
and c16-N caused very limited effects on the cell layer tightness and mannitol 
translocation, which could be due to even tighter binding, and the expected 
improvement due to cyclodextrin-mediated inhibition of aggregation is not 
observed.  
Conclusions 
Depending on acylation chain length and position, certain acylated sCT analogues 
aggregate in physiological buffer solutions, potentially forming fibril-like structures. 
Placement of the acylation at Lys18 appears to cause less aggregation compared to the 
N-terminal, most clearly exemplified by the short chain c8-analogues. These 
analogues display well-defined fibrillation time profiles during heating, with a lag-
time for c8-K roughly twice as long as for c8-N. All N-terminal analogues appear as 
elongated structures in TEM, with c8-N displaying longitudinal twisting. K18 
analogues are less well-defined, with c8-K initially displaying no visible structures 
(similar to the unacylated peptide backbone), whereas c12-K and c16-K display short 
rods that are not well-defined. For all analogues, self-association is efficiently 
inhibited by addition of DM-β-CD, likely through monomerization of peptides via 
binding in the hydrophobic cavity. However, binding may hamper the interaction of 
both acylated analogues and DM-β-CD with Caco-2 cells, as their respective 
permeability enhancing effects are reduced in the mixtures. Whereas DM-β-CD is an 
efficient enhancer for the unacylated peptide backbone, it confers only a slight 
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improvement to c8-K, and all N-terminal analogues display reduced permeability 
when combined with DM-β-CD. The impairment of permeability enhancing may be 
reduced by varying peptide to cyclodextrin ratio, or using different cyclodextrins 
with lower affinity for the acylated peptides, but we speculate that this will also 
diminish the self-association inhibition. 
Acylation of sCT can increase its intestinal permeability, however, the risk of reduced 
solution stability demands rational choices or optimization of acylation details for 
oral delivery purposes. 
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68 CHAPTER 4. RESULTS FOR SCT
4.2.1 Notes on paper 3
Asmentioned earlier, the Trp backbonemutation in sCT reduced its potency, whereas the solution
stability of BB appears quite similar to sCT. No aggregation/fibrillationwas observed for BB in the
performed experiments (similar to sCT), including ThTmeasurements with prolonged incubation
(20 h, data not shown).
As a brief addition, preliminary experiment showed that the pH-dependency of c8-Ndiscussed
in paper 2 was retained in the mixture with DM-β-CD, with higher permeability at pH 5.5 than
7.4. The enhancer-effect of DM-β-CD alone was pH-independent in this pH range, so the effect
may be due to unbound peptide, or possibly pH-dependent binding affinity of cyclodextrin and
c8-N.
The solution stability of sCT analogues was tentatively investigated in FaSSIF buffer, with no
apparent improvement.
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4.3 Additional results
The following results have not yet been published, however, we intend to collate parts of it in a
manuscript.
4.3.1 A new family of sCT analogues
The surprisingly profound impact of the Trp backbone mutation and the failed fluorescence ex-
periments motivated us to investigate acylated sCT analogues with the native backbone. Initially,
the c8-K Y22 analogue showed very promising results, and motivated synthesis and investigation
of the longer chain analogues. However, the synthesis was delayed substantially, and the longer
chain analogues were not characterized as thoroughly as intended. Furthermore, several exper-
iments were postponed to include these analogues, but they did not fulfill our expectations. In
the following section the results will not be presented in chronological order, but as a compari-
son of the various analogues, and include both old and new results for the previously described
analogues.
Receptor potency of K18-acylated analogues The in vitro receptor activation of sCT analogues
with the native Tyr22 is shown in fig. 4.1, along with previously described Trp22 analogues for
comparison. The c8-analogue appears to benefit somewhat from removing the backbonemutation,
whereas the longer chain analogues appear independent of the mutation.
Figure 4.1: In vitro receptor activation. IC50 potency of K18-acylated sCT analogues relative to
native sCT, with native Tyr22 (labeled Y22) or with Trp22 point mutation. Values are presented as
mean ±SDOM of 3 separate experiments, each in duplicate.
Solution stability of K18-acylated analogues The solution stability of the new K18-acylated sCT
analogues with native Tyr22 is presented in fig. 4.2, along with older analogues for comparison.
For c8-analogues, ThT-fluorescence increase is substantially delayed for c8-K Y22 compared to
c8-K (and c8-N), indicating delayed fibrillation by reverting to the native Tyr22. However, the
results are less clear for longer chain acylations, as c12- and c16-K Y22 display similar profiles but
higher values than their W22-mutated counterparts. All long chain analogues were previously
observed to display unclear ThT fluorescence profiles, possibly due to self-association.
Caco-2 interaction of K18-acylated analogues The permeability through caco-2 monolayers and
cell binding of the K18-acylated sCT analogues with native Tyr22 is presented in fig. 4.3, along
with old analogues for comparison. As previously alluded to, c8-K Y22 displays a very high
permeability, whereas for c12- and c16-K Y22 it is surprisingly low. For c16-K Y22, the increased
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Figure 4.2: Solution stability of sCT analogues. ThT fluorescence intensity measured over time
at 37 ◦C. sCT analogues with Trp backbonemutation or native Tyr (Y22), and short chain acylation
(A) or longer chains (B) at N-terminus or K18.
cell membrane binding, uptake and mannitol permeability could indicate a too great membrane
affinity of the peptide, where the permeabilizing effect allows translocation of mannitol but the
peptide itself is stuck. However, for c12-KY22 all values are very low, and the long chain analogues
with W22 display both higher permeability and higher cell-association.
For K18-analogues, long chain analogues appear optimal for translocation only in combination
with the W22 mutation, whereas a short chain acylation is far superior when using the native
backbone. Apart from the differences in solution stability, we currently have no explanation for
these profound effects of the backbone mutation, which limits any conclusion on the systematic
effects of acylation chain length, as observed for GLP-2 analogues.
Specifically for c8-K Y22, the high peptide permeability is not accompanied by a substantial
increase in mannitol permeability, indicating a more peptide-specific enhancer effect for this
peptide analogue. This is supported by a limited liposome permeabilization and TEER-decrease,
in contrast to previous observations for other acylated analogues.
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Figure 4.3: Caco-2 interaction of sCT analogues. Permeability of peptide (A) and mannitol
(B), along with cell membrane binding (C) and uptake (D), investigated for native sCT, back-
bone (BB) with Y->W22 mutation and selected N-terminal or K18-acylated analogues. All data
points represent mean ± SD of at least 2 separate experiments, each with 4 repeats. TEER-values
were transiently reduced for acylated analogues (as previously shown), to varying degrees very
consistent with their respective enhancing effect, and therefore values are not included here.
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4.3.2 A closer look at cell interactions and enhancing effects
To further investigate the enhancing effect of selected sCT analogues, we employed fluorescence
microscopy, either through immunocytochemistry for caco-2 monolayers used in experiments or
live-cell imaging for caco-2 cell monolayers grown on microscope slides. We originally planned
to attach a fluorophore to selected peptide analogues, but this carries a risk of altering the peptide
properties due to the charge/hydrophobicity/size of most fluorophore moities, particularly for
small peptides as sCT. We opted instead for antibody-mediated fluorescence staining of peptide
analogues and/or addition of FITC Dextran 4 kDa (FD4), which is similar to sCT in size and
widely used as a model compound in caco-2 enhancer studies.
For FD4, we initially investigated the permeability and cell association in combination with
peptide analogues (see fig. 4.4).
Figure 4.4: Enhancer effect of sCT analogues. Permeability (A) andmembrane binding (B) of FD4
in combination with selected sCT analogues. The cell uptake for FD4 is very similar to membrane
binding results, and therefore not shown here. All data points represent mean ± SD of 2 separate
experiments, each with 4 repeats.
FD4-permeability is enhanced by c8-N, c12-K and c16-K, consistent with a non-specific mem-
brane permeabilization effect as previously discussed. For c8-K Y22 the very limited enhancement
is similar to mannitol-results and consistent with a more peptide-specific enhancement. The cell
membrane binding and uptake of FD4 is almost unaltered by K18-analogues, and independent
of acylation chain length (in contrast to the peptide itself). Interestingly, FD4 cell association
is greatly enhanced by c8-N, possibly indicating an interaction between c8-N and FD4 causing
peptide-mediated cell anchoring.
Immunocytochemistry (See description of staining procedure in experimental section 4.3.4.)
Confocal laser scanning microscopes (CLSM) allow imaging thin section of the fixed cell layer
in side-view or cross-section, as shown for an untreated caco-2 monolayer in fig. 4.5.
After permeability experiments, the distribution of sCT analogueswithin the caco-2monolayer
can be visualized, along with possible morphological changes to the cell layer. As shown in 4.6,
the unacylated backbone displays insignificant cell-association, and the cell morphology is very
similar or identical to control, whereas acylated analogues c8-N and c16-K are present in the
cell layer, which also appears slightly altered. Both analogues appear to have ’stunted’ the cells
somewhat, and caused slight alterations in the actin structure. However, these effects are far
more subtle than other permeation enhancers, which feature disruption of tight junction protein
complexes causing paracellular channel opening and/or profound actin reorganization [5, 18, 63,
98, 104] (or actual holes in the cell layer), see fig. B.1 in appendix B.
c8-N appears to be bound to the apical part of the cells as large assemblies, possibly on both
sides of the actin wall (it is not entirely clear in images, but videos scanning the entire cell layer
are more informative). The cell distribution of c16-K is somewhat different, as it appears more
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Figure 4.5: Appearence of untreated caco-2 monolayers. Fluorescence microscopy images of a
caco-2monolayers following permeability experiments with control (buffer), fixed in formalin and
stained for filamentous actin (red) and nucleus (blue). A cross-section in the middle of the cell
monolayer (bottom left) and side-view (top) show the tightly adhering and columnar endothelial
cell morphology, and a cross-section zoom (right) at the top of the cell-layer shows the actin-rich
protruding microvilli.
evenly distributed, mostly in the cell cytosol and the cytosolic side of the cell membrane. These
observations are fairly consistent with the quantification of cell association in fig. 4.3, where cell
membrane binding is similar for c8-N and c16-K, but cell uptake (in the aqueous cell lumen)
is much greater for c16-K. However, it should be noted that ’membrane bound’ comprises all
membrane components in the cell (following lysis), i.e. also various cytosolic compartments.
Generally, these quantifications of cell association are far less well-defined than the liposome
membrane partitioning measured for GLP-2 analogues, and interpretation should be performed
with caution.
Regarding microscopy images, it should be noted that the fluorescence staining is performed
with a primary antibody for sCT, which binds less efficiently to the altered analogues, similarly to
the previously described issues for ELISA quantification. Thus, the acylated analogues (particu-
larly long-chain) did not stain too well. Generally, fluorophore signals are merely qualitative (not
quantitative!) and images have been optimized for presentation purposes. The poor staining for
acylated analogues could possibly be compensated by increasing antibody concentration based
on ELISA binding efficiency, but due to lack of time this was not attempted.
Fig. 4.7 shows caco-2 monolayers exposed to native sCT and its short- or long-chain K18-
acylated analogues. sCT displays some cell association, almost entirely at the apical microvilli.
The acylated analogues appear in the cytosol of some cells only, and not as widespread as c16-K,
consistent with the measured cell association in fig. 4.3.
In a somewhat experimental attempt, FD4 distribution in cell layers was visualized directly,
which simplifies the staining procedure substantially. In most cases the fluorescence signal was
quite weak, but the three examples shown in fig. 4.8 appear consistent with the peptide distribu-
tion. For c8-N, the FD4-signal is in fact more clear than the peptide staining, and the quite distinct
cell association is nicely visualized. The relative FD4-signals for the three acylated analogues
(which is not marred by differences in antibody affinity) are very consistent with the measured
cell-association presented in fig. 4.4.
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Figure 4.6: Caco-2 cell interaction of W22 sCT analogues. Microscopy images of caco-2 cell
monolayers following permeability experiments with selected sCT analogues, in side-view (top)
or cross-section in the middle of the cell layer (bottom). Cells are fixed and stained for nucleus
(blue), filamentous actin (red) and sCT (green).
Figure 4.7: Caco-2 cell interaction of Y22 sCT analogues. Microscopy images of caco-2 cell
monolayers following permeability experiments with selected sCT analogues, in side-view (top)
or cross-section (bottom). Cells are fixed and stained for nucleus (blue), filamentous actin (red)
and sCT (green).
Following caco-2 experiments, TEER was routinely measured after 24h recovery in medium,
where the pronounced TEER-decreases caused by acylated sCT analogues were shown to be
reversible. Imaging of the cell layers after 24h recovery was very consistent with this. For most
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Figure 4.8: Caco-2 cell interaction of FD4 and sCT analogues. Microscopy images of caco-2 cell
monolayers following permeability experiments with FD4 and selected sCT analogues, in side-
view (top) or cross-section (bottom). Cells are fixed and stained for nucleus (blue) and filamentous
actin (red), and FD4 fluorescence is depicted in green.
Figure 4.9: Prolonged effects of c8-N and FD4. Microscopy image (side-view) of a caco-2 cell
monolayer exposed to FD4 and c8-N, after 24h recovery in medium. Cells are fixed and stained
for nucleus (blue) and filamentous actin (red), and FD4 fluorescence is depicted in green.
of the investigated analogues cell layers were identical to controls, with no FD4 present (not
attempted with peptide-staining). However, for c8-N an interesting feature is shown in fig. 4.9.
The cell layer appeared normal and devoid of FD4, but many small lumps of cell debris and FD4
were ’clinging’ to the apical side of the cell layer, again indicating a specific c8-N/FD4 association
not observed for the other analogues.
Live-cell imaging (See description of experimental setup in section 4.3.4.)
Immunocytochemistry imaging is somewhat limited by its ’snapshot’ character, yielding little
dynamic information, and besides being time consuming it features numerouswashing stepswith
a risk of losing cell-bound peptides or fluorophores. Therefore we attempted live-cell imaging
for the two most ’cell-active’ analogues, c8-N and c16-K, which previously has yielded interesting
results for absorption enhancers (see e.g. fig. B.2 in appendix B).
Fig. 4.10 shows caco-2 cell monolayers after 15 minute exposure to FD4 (control) or together
with c16-K. In the control, no FD4 enters the cell layer for (at least) 1h, whereas inclusion of c16-K
causes a rapid decrease in cell barrier integrity.
After 15minutes, FD4 appears visible both inside some cells and between the nuclei of adjacent
cells which could indicate both paracellular and transcellular translocation. However, due to the
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Figure 4.10: Live-cell imaging with FD4 ±c16-K. Microscopy images of caco-2 cell monolayers
following exposure to FD4 and c16-K, in side-view (top) or cross-section (bottom). Cells are stained
for nucleus (blue) and FD4 fluorescence is depicted in green.
lack of actin staining, the cell boundaries are not easily distinguishable. Interestingly, FD4 also
appears to enter some cell nuclei, which is not widely observed in fixed cells. It should be noted
that the cell monolayer may grow slightly differently on glass slides compared to Transwell filters,
and when adding peptides and fluorophores apically they cannot ’escape’ into the BL chamber
and may accumulate to a higher degree in the cell layer.
Furthermore, the staining procedure is different, and it is worth noting that the nuclear stain
appear quite different from previous immunocytochemistry images, which is due to differences
in the two stains. The ToPro-3 stain for fixed cells (cell-impermeant, requires permeabilization
before staining) binds dsDNA, thus has a high selectively for nuclear over cytoplasmic staining,
whereas the live-cell stain SYTO 61 (cell-permeant) stains all nucleic acids.
Experiments with the small fluorophore carboxyfluorescein yield similar results for control
and c16-K, possibly with more accumulation in cells and nuclei for c16-K.
Figure 4.11: Live-cell imaging with FD4 and c8-N.Microscopy image of a caco-2 cell monolayer
following exposure to FD4 and c8-N, in side-view. Cells are stained for nucleus (blue) and FD4
fluorescence is depicted in green.
Fig. 4.11 shows a caco-2 cell monolayer exposed to FD4 and c8-N, and although not the most
clear image, FD4 appears to attach to the apical (top) part of the cell layer and is only weakly
visible in the cell cytosol / at the cell junctions. The apical association appears reminiscent of
c8-N- and FD4-behavior in figs. 4.6 and 4.8.
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4.3.3 Preliminary conclusions on enhancing effects
Asmentioned in section 4.3.1 and shown in fig. 4.3, the caco-2 permeability of different analogues
families does not appear entirely systematic, and may involve very specific features for each
analogue. If we look at the three most permeable analogues, c8-N, c8-K Y22 and c16-K, the
cell-interaction and enhancing effects are profoundly different.
c16-K displays highmembrane binding (consistentwith its chain length) and very high uptake,
and it facilitates very high permeability of mannitol and FD4 (the highest of all analogues).
However, c16-K does not cause FD4 binding to cells, indicating a non-specific enhancing effect
(i.e. c16-K ’opens the door’ but does not interact with FD4). In liposome permeabilization
studies c16-K has the greatest effect on liposomes, possibly destroying them altogether, which
is consistent with a strong membrane binding and fluidizing effect, allowing translocation of
other compounds. Microscopy results for c16-K indicate a mix of transcellular and paracellular
translocation, both for the peptide itself and FD4. Although mannitol and FD4 permeability is
often used as an indicator for paracellular translocation, this distinction is not entirely clear and
several permeability enhancers may involve a mix of both pathways [11, 76]. Extensive membrane
permeabilization as observed for c16-K will likely also open paracellular junctions, e.g. through
dislodging membrane-bound junction proteins or actin reorganization.
c8-N displays high membrane binding (higher than expected for its chain length) and low
cell uptake, and it facilitates high permeability of mannitol and FD4. Uniquely for this analogue,
c8-N also increases membrane binding of FD4, as clearly evident from both measured values
and microscopy images. Both the peptide and FD4 appear to adhere to the apical side of the
cell layer in big clusters, possibly on both sides of the cell membrane. However, this complex
behavior is not easily translated to a translocation mechanism. The membrane-permeabilization
observed in liposomes indicate a transcellular component, although not as pronounced as for
c16-K. The stability of peptide and FD4 clusters on the outside of cells through repeated washing
steps (before fixing cells) and 24h recovery in medium, indicates either very slow dissociation
kinetics or irreversible assemblies. One may speculate if the fibrillation tendencies of c8-N has a
role to play in this behavior.
c8-K Y22 displays the highest caco-2 permeability, but very limited cell membrane binding
and uptake. Furthermore, it leaves mannitol/FD4 permeability almost unaffected, and causes
limited TEER decrease and liposome permeabilization (similar to c8-K). This indicates a quite
peptide-specific translocation enhancement which is unabated by cell binding and/or peptide
aggregation. The ’selfish’ enhancement characteristics may be quite advantageous in a crowded
gut environment.
4.3.4 Experimental details for additional methods
Caco-2 permeability studies with FD4 were carried out similar to peptide experiments, using 540
µM FD4. Samples were analyzed for FD4 content in a fluorescence plate reader (MD Spectramax
Gemini) with Ex/Em 490/525 nm, based on standard curves prepared from test solutions.
Immunocytochemistry The cell layer was fixed in formaldehyde and stained for nucleus, actin
and sCT analogues.
After transport experiments, filter inserts were washed twice with PBS buffer for 5 minutes,
and the cells were fixed with 4 % formalin in PBS buffer for 10 minutes (1 mL basolateral and 0.5
mL apical). The filters were washed twice with PBS buffer, cut from the filter inserts and placed
in a 48-well plate with 0.3 mL block buffer pr. well (PBS w. 3 % Goat serum, 1 % BSA and 0.05 %
Tween20).
The filters were protected from light and incubated sequentially with 0.3 mL of the relevant
antibody or stain (primary monoclonal mouse anti-sCT antibody overnight at 4 ◦C (2 µg/mL in
block buffer); secondary goat anti-mouse antibody labeledwith Alexa Flour 488 for 60minutes (10
µg/mL in block buffer); Texas Red-X phalloidin for 30 minutes (66 nM in PBS w. 1 % (w/v) BSA);
ToPro-3 for 5 minutes (200 nM in PBS buffer) or block buffer for negative controls), separated
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by washing with PBS buffer (twice with 0.5 mL for 5 minutes). The filters were mounted on
microscope slides (objective glass) with the cell layer facing up and covered by a cover slide,
using fast drying fluorescence mounting medium (Dako). The cell layers were visualized in a
confocal fluorescence microscope (CLSM, Leica SP5), using a fluid immersion objective (water:
63x magnification or oil: 100x magnification).
Live-cell imaging Caco-2 cells were seeded on 8-well chambered cover slips (Ibidi) at a density
of 6.25·103 cells/well (250 µL of 2.5·104 cells/mL) and grown for 14 days in DMEM with media
change every second day (every day in the last few days). The cell morphologywas verified before
experiments by staining the nucleus with SYTO 61 (Molecular Probes, ThermoFisher) (500 nM
in HBBS buffer for 60 minutes), adding a water-soluble fluorophore (Carboxyfluorescein or FD4)
above the cell layer, and visualizing the cells by CLSM. For fluorophore permeation experiments, a
fluorophore/peptide mixture was added (50 µL fluorophore + 150 µL fluorophore/peptide, final
concentrations 540 µM and 100 µM), and the cell layer was visualized over time. The microscope
stage is encased in a box with 5 % CO2 and 37 ◦C to allow prolonged live-cell imaging, and laser
power was limited to avoid cell damage.
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Chapter 5
Microfluidic Caco-2 setup
(collaboration)
Hsih-Yin Tan, who is currently a Post.Doc at DTU Nanotech, developed a microfluidic setup for
growth and permeability studies of caco-2 cells in her PhD project, and in the final phase I aided
in evaluating the setup for permeability studies compared to the standard Transwell setup. We
tested the permeability of mannitol and FD4 (as otherwise described in this thesis) and human
insulin (similar to GLP-2 and sCT studies), alone or with addition of the permeability enhancer
Tetradecyl maltoside (TDM). We showed comparable permeability values in the two setups, with
increased permeability of all three compounds upon TDM addition, although the microfluidic
setup displayed a large variability within the 8 chambers on each chip. The results are described
in the paper draft in appendix C, along with the development of the microfluidic device and
characterization of cells layers.
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Chapter 6
Conclusions and future perspectives
6.1 Conclusions
Partial conclusions were presented at the end of papers 1, 2 and 3 (draft), and at the end of
chapter 4. However, for completeness’ sake, the following sections will briefly summarize the
main conclusions of this thesis.
6.1.1 GLP-2
For GLP-2, we found that increasing acyl chain length caused increased self-association and
binding to lipid and cell membranes, whereas translocation across intestinal cells displayed a non-
linear dependence on chain length. Short and medium chains improved translocation compared
to the native peptide, whereas long chain acylation displayed no improvement in translocation.
This indicates an initial translocation benefit for shorter chains through increased interaction with
the cell membrane, which reverts to a hindrance for long chains, i.e. the analogues get stuck in
the cell membrane. This interpretation is supported by the effects of co-administered para- and
transcellular enhancers, which increased translocation irrespective of acyl chain length for the
former, whereas the latter displayed increased synergy with the long chain acylation, however,
with the c12-acylation remaining optimal.
The results demonstrate that rational acylation of GLP-2 can increase its intestinal absorption,
alone or in combination with permeation enhancers, and are consistent with the initial project
hypothesis. We speculate that the absolute quantification of liposome binding (partitioning co-
efficient 1300 M−1 for c12-GLP-2) may be used to predict the optimal acylation chain length for
other acylation types or peptides.
6.1.2 sCT
For sCT, we discovered an unpredicted effect of acylation which largely superseded the antici-
pated membrane interactions; i.e. acylated sCT acted as its own in vitro intestinal permeation
enhancer. Acylation drastically increased peptide permeability, through reversible cell effect sim-
ilar to transcellular permeation enhancers, supported by the observed permeabilization of model
lipid membranes. The effect likely stems from a synergy between the positive peptide charge and
membrane-active acyl moiety, supported by its pH-dependency, whereby the effect increasedwith
decreasing pH and concomitant charge increase. The extent of permeation enhancing effect was
highly dependent on acylation chain length and position, with highest peptide permeability for
short chain N-terminal acylation or medium/long chain Lys18 acylation. Permeability and cell
membrane binding did not immediately appear correlated for the N-terminal analogues, whereas
increasing membrane binding with increasing chain length for Lys18 analogues may have hin-
dered translocation slightly for the longest chain (and we speculate that further prolonging the
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chain may prove problematic).
The experimentswere complicated by another unforeseen effect of sCT acylation, i.e. decreased
solution stability. Prolonged heating and/or solution storage of certain acylated sCT analogues
caused aggregation in physiological buffer solutions, potentially forming fibril-like structures.
Lys18 acylation appeared superior to N-terminal acylation, most clearly exemplified by the short
chain c8-analogues, however, no systematic dependence on acylation chain length was apparent.
For all analogues, self-association was efficiently inhibited by addition of DM-β-CD, however, the
separate permeability enhancing effects of acylated analogues and DM-β-CD were reduced in the
mixtures, and the additive was not investigated further. Thus, acylation of sCT for oral delivery
purposes may not be indiscriminately applicable, and requires rational choices of acylation details
and/or additives.
The surprisingly profound impact of the Trp backbone mutation motivated a new family of
Lys18 sCT analogues with the native backbone, however, only the short chain analogue was
superior regarding receptor potency, solution stability and cell permeation.
The most cell-permeable analogues were investigated further, which unveiled quite distinct
permeation enhancer effects. c16-K exhibited high membrane binding and permeabilization, and
non-specific enhancing effect onmodel compounds, likely through amix of para- and transcellular
pathways. c8-N exhibited high membrane binding, apparently through a clustering at the outer
cell membrane, and uniquely it could anchor themodel compound FD4 quite stably, although also
facilitating efficient translocation of FD4. c8-KY22 exhibited the highest peptide permeabilitywith
very limited membrane binding, and in fact showed very limited unspecific permeation enhancer
effects, i.e. c8-K Y22 translocated quite efficiently and selectively.
6.1.3 Overall
The enhancer-effects observed for sCT analogues was a game-changer, which altered the scope
considerably, and the initial aim of using two model peptides to distinguish subtle effects of
the backbone and the acyl chains, became somewhat complicated. Whereas membrane-binding
appeared to affect acylated GLP-2 cell permeability as hypothesized, the effects for sCT were
not merely controlled by membrane-binding, although it may remain important for the enhancer
effect. For K18 sCT analogues, the very pronounced membrane binding and cell uptake for the
long chain acylation may in fact hinder translocation.
The liposome partitioning coefficient, which may be a useful metric for predicting in vitro per-
meability of acylated analogues, could not be determined for sCT analogues due to experimental
difficulties, but themembrane permeabilizing effect would likely have complicatedmeasurements
(although the peptide concentration is far lower in partitioning studies than in cell studies).
As a brief note, the peptide receptor potency following acylation was quite different for the
two peptides, with GLP-2 analogues retaining their potency, whereas sCT analogues displayed
markedly reduced potency, depending on acylation position and length.
Lessons learned For GLP-2, the study setup worked quite well, but for sCT the number of
analogues got a little out of hand, and in the end we did not entirely understand the differences.
Thus, one lesson is that modifications should be more well-founded, with fewer analogues at a
time, i.e. an even more circular setup.
6.2 Future perspectives
The interesting results obtained prompt a multitude of questions, and many future studies can be
envisioned.
The enzyme stability and albumin binding of acylated analogues would be interesting to
investigate, as both are expected to increase compared to the native peptides.
The mechanism of membrane insertion for both peptide groups would be very interesting
to investigate further, e.g. through differential scanning calorimetry (DSC), circular dichroism
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or other structural techniques, although the membrane permeabilizing effect for sCT analogues
could cause problems. Molecular dynamics simulationsmight also provide additional insight into
the interaction between peptides andmembranes, but would have to be correlated to experimental
results, e.g. partitioning coefficients for GLP-2 analogues.
The employed POPC liposomes are a very simple model system, and could be optimized to
better mimic the cell membranes by addition of negatively charged lipids or cholesterol. Further-
more, the calcein-release study might be adjusted to employ FD4, in order to better model the cell
membrane permeability studies.
For in vitro studies, numerous studies could provide interesting insight, e.g. the effect of
mucus on the cell membrane binding and permeability, which may be different for the two
oppositely charged peptides and their analogues. The translocation in both directions across
the cell layer (AP->BL or BL->AP) should be similar for passive permeation, as expected for the
studied compounds. Including FaSSIF/FeSSIF buffer could be interesting to study the effects of
bile salts and lipids, that would likely interfere with the membrane binding of acylated analogues.
It would be interesting to study a few of the analogues (primarily sCT analogues) ex vivo in Uss-
ing chambers, to investigate whether the effects persist in permeation across tissue. Furthermore,
an in vivo investigation of the pharmacokinetics and therapeutic effect of native sCT compared to
one or two of the most potent analogues would be highly valuable to validate the results obtained
in these model systems.
Lastly, several new acylated analogues could provide interesting results, e.g. more medium-
chain analogues with smaller increments in chain length. For GLP-2, c12-acylation was superior
to c8- and c16-acylation, and thus c9-, c10-, c11-, c13-, c14-, and c15-acylation might improve
permeability further. Similarly for sCT, smaller chain length variations ’in the vicinity’ of the
most potent analogues would be interesting (e.g. c13-, c14-, c15-, and c17-acylations for K18
W22-analogues, c7-, c9-, c10-acylations for N-terminal and K18 Y22-analogues). Furthermore, the
reduced receptor potency of sCT analogues prompts an investigation into amore optimal acylation
position, with the most ambitious version being a full scan of acylations at all backbone positions.
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Appendix A
Kyte-Doolittle plots [55] displaying the hydrophobic/hydrophilic character of the two employed
peptides GLP-2 and sCT (native sequences).
Figure A.1: Kyte-Doolittle plots for GLP-2 and sCT. Kyte-Doolittle plots display the distribution
of polar and apolar residues along a protein or peptide sequence and can predict hydrophilic or
hydrophobic regions. Regions with values above 0 are hydrophobic in character. Plots shown
here have a window size of 7 which refers to the number of amino acids examined at a time to
determine a point of hydrophobic character and is appropriate for finding hydrophilic regions that
are likely exposed on the surface. (Note the different scale for the two graphs.) Figures created
from http://web.expasy.org/cgi-bin/protscale/protscale.pl?1
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Appendix B
Unpublished results for caco-2 absorption enhancers Tetradecyl maltoside (TDM) and Lauryol
carnitine (LC) were previously investigated for their permeability enhancement of mannitol and
human insulin, and for their effects on caco-2 cell monolayers. Microscopy images following
immunocytochemistry are shown in fig. B.1, and for live cells in fig. B.2.
The employed concentrations of TDM and LC caused caco-2 permeability enhancement of
mannitol and insulin, and reversible TEER decreases.
Figure B.1: Caco-2 cell interaction of TDM and LC.Microscopy images of caco-2 cell monolayers
following permeability experiments with human insulin and TDM or LC, where cells are fixed
and stained for nucleus (blue), filamentous actin (red), and insulin (green).
For TDM, holes where apparent in the cell layer, with small amounts of insulin visible at the
edges. (Incidently, previous experiments with higher TDM concentrations caused even larger
holes.) Interestingly, the cell layers recovered completely after 24 h in medium, both regarding
TEER values and visible appearence. However, cell layer holes (although reversible) are likely not
ideal, and may not correctly represent the in vivo absorption mechanism for TDM. Other studies
have demonstrated both paracellular and transcellular components of TDM enhancement [76].
For LC, widespread actin reorganization is observed, with insulin mostly visible at the para-
cellular cell junctions. In the higher magnification image (bottom), the actin cell boundaries may
have disbanded, as previously observed for paracellular enhancers [5]. However, as for TDM the
cell layer recovers completely after 24 h in medium.
For live caco-2 monolayers addition of TDM and LC causes appearence of fluorescence be-
tween adjacent cells, indicative of paracellular permeability enhancement, which is slightly more
pronounced for the smaller fluorophore CF.
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Figure B.2: Live-cell imaging with TDM and LC. Microscopy images of caco-2 cell monolayers
following exposure to Carboxyfluorescein (CF) or Oregon Green dextran (10 kDa) and TDM or
LC, in side-view or cross-section. Cells are stained for nucleus (blue) and fluorescence is depicted
in green.
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Appendix C
The following manuscript draft was prepared in collaboration with Hsih-Yin Tan and concerns
the development of a microfluidic setup for culturing and studying caco-2 cells. The manuscript
and its supplementary information will shortly be submitted to PNAS, and is typeset according
to the journal guidelines.
The manuscript was primarily written by Hsih-Yin Tan, where my contribution consists of fig.
6, partially fig. 5, and experimental details for Transwell permeability experiments.
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This paper presents the design and fabrication of a multi-layer and
multi-chamber microchip system using thiol-ene ‘click chemistry’
aimed for drug transport studies across tissue barrier models. The
tissue barrier model employed to test the device was based on
Caco-2 intestinal model and mannitol, dextrane and insulin were
used as drug molecules (in the presence or absence of membrane
permeability enhancers) to investigate transport in the microﬂu-
idic barrier system in comparison to the conventional Transwell
system. The developed fabrication process allows for rapid pro-
totyping of multi-layer microﬂuidic chips using different thiol-
ene polymer mixtures. We incorporated porous Teﬂon support
membranes to accommodate cell growth by masked sandwiching
thiol-ene-based ﬂuid layers. Electrodes for TEER measurements
were incorporated using low melting soldering wires melted into
channels as in combinationwith platinumwires.We demonstrated
that the thiol-ene-based microchip material including the elec-
trodes does not induce adverse effects on the cells. The Caco-
2 cells cultured on the thiol-ene microchip differentiated and
showed signs of producing mucus within 9 - 10 days of cell culture,
indicating theformation of a robust barrier at a much faster rate
than in conventional Transwell models. The presented microdevice
for cell culture is useful for carrying out real-time studies of cellular
barriers under optical monitoring, and enables transport studies of
drugs, chemicals, and pathogens. The system may have additional
uses in toxicological assessments.
thiol-ene microchip j Caco-2 cell culture j membrane barrier studies j
drug permeability
Manuscript Text
Introduction
Covering the inner walls of the intestines is a single layer of
epithelial cells that forms a rate limiting barrier to the absorption
of drugs. Numerous experimental models have been developed
for the prediction of intestinal permeability - including in situ
isolated perfused intestinal systems (1–4). However, the use of
animal models is time consuming, labour intensive and costly.
Furthermore, animal models also raise ethical issues and are
often not able to accurately predict the results in humans (5).
Culturing and differentiation of epithelial cells derived from
the intestine can provide relevant in vitro models for prediction
of drug absorption in humans (6, 7). Caco-2 cells constitute a
gold standard of intestinal model when cultured under specific
conditions, i.e., grown on Transwell permeable filter supports, the
cells will form a monolayer (8). They will further spontaneously
differentiate and proliferate, thus exhibiting many features of
the small intestinal villus epithelium (9, 10). Some of the most
prominent features of Caco-2 cells cultured in this way are the
formation of brush border microvilli (10) on the upper side of the
cells, development of intercellular tight junctions (11), and the
presence of various metabolic enzymes present in the intestinal
epithelium (10, 12). Due to the formation of a tight monolayer
of Caco-2 cells, this provides a physical and biochemical barrier
to the passage of ions and small molecules through the Caco-2
cell layer. Therefore, it is one of the most well-established human
intestinal epithelial cell lines and has been extensively used as an
in vitro intestinal model for pharmaceutical studies, e.g., ADME-
Tox (adsorption, distribution, metabolism, excretion, and toxicol-
ogy) studies. About three weeks are required for Caco-2 cells to
fully differentiate and form confluent and tight monolayers in
Transwell inserts (8). However, this in vitro model does not allow
to recreate the presence of continuous fluid flow nor the presence
of fluid shear stresses on the epithelial cells as can be found in
their natural environment. It has been postulated that the fluid
shear stress in the intestinal tract varies depending on the exact
location and fluid shear stresses from 1 to 5 dyn/cm2 have been
reported (13).
By using micro total analysis system technology, various
functional microfluidic systems can be developed to provide
integrated microenvironments for cell maintenance, continuous
perfusion and real-time monitoring of cells. Several groups have
reported on the design and fabrication of polydimethylsiloxane
(PDMS) based microdevices for Caco-2 cell culture (14–18).
Kim et al. have reported that with the combination of peristaltic
motion and fluid flow in the microfluidic device, the Caco-2 cells
displayed intestinal villi with physiological growth up to several
hundreds of microns in height, as well as increased expression
of intestine-specific functions, including mucus production (17).
However, the reported microfluidic devices are only capable of
culturing one set of Caco-2 monolayers for analysis at any one
time. In biological cell analysis studies or drug transport studies
across Caco-2 monolayers, or other model tissue barriers, it is
highly desirable to investigate different conditions in the same
Signiﬁcance
Transwell culture system is the gold standard in vitromodel for
assessing and predicting permeability and absorption of oral
drugs in pharmaceutical industry. However, this platform can-
not support any form of luminal ﬂow conditions on the cells to
more closely mimick in vivo conditions. Relevance of this study
lies in engineering an eight chamber multi-layer microchip to
support long-term studies of tissue barriers by using the Caco-
2 cell intestinal model. We demonstrate the feasibility of using
the in vitro intestinal model culture in the thiol-ene-based
microchip for transport studies by using three different test
compounds. Such a platform paves the way towards advanced
in vitro intestinal model for high throughput screening of
drugs, chemicals, pathogens as well as toxicological studies.
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Fig. 1. Schematic illustration of the thiol-ene based microﬂuidic chip for
intestinal transport studies. (A) Cross-sectional view of human intestinal
microvilli. (B) Microarchitecture of one microchamber on the thiol-ene mi-
croﬂuidic chip consisting of upper and lower cell culture chambers separated
by an ECM coated Teﬂon membrane. (C) Presence of membrane enhancer
causing compounds to be transported across Caco-2 monolayer
Fig. 2. (A) Schematic process of fabricating the thiol-ene coated membrane.
(B) Exploded view of the high throughput multi-layer thiol-ene microchip for
cell culture (Dimension of microchip: 76 mm x 52 mm x 2.7 mm). Thickness
of the modiﬁed membrane is 0.3 mm. The membrane is coated with a thiol-
ene mixture on both sides to ensure good bonding between the chip layers.
Fluids were pumped in the upper and lower layers. (C) SEM images of Teﬂon
membrane (Top view). Surface morphology was changed signiﬁcantly after
coating a layer of thiol-ene. The surface of the membrane has become very
smooth after coating and curing a layer of thiol-ene (as indicated by red
arrow). (D) Expanded view of Teﬂon membrane that was masked off and
rinsed with methanol, thus maintaining its porous structure in these areas.
experimental system in a high throughput manner (19). Scaling
up the number of cell culture microchambers on the microfluidic
chip provides the possibilityfor analyzing more than one sam-
ple in parallel under controlled conditions, therefore allowing
for controlled parameter comparisons. Although PDMS is an
excellent material choice for fabricating microfluidic devices for
cell culture, it may pose some challenges in studies that involve
chemicals and drugs (20). Furthermore, PDMS has a tendency
to absorb small hydrophobic molecules and this may compromise
accurate measurements of drug efficacy and toxicity (21–23).
To pursue the goal of developing an alternative in vitromodel
of the human intestines for high throughput transport studies
(Fig. 1), we have explored the use of thiol-ene chemistry and
a novel membrane system for cell support within a microfluidic
system to develop a multi-chamber microchip. The developed
microchip contains eight micro-chambers, thus allowing parallel
culturing of Caco-2 cells or other tissue models. The design of
eight channels allows for significant controls during drug trans-
port studies and allowed us to employ the previously reported
microfluidic flow system developed by some of the authors (24).
To quantitatively evaluate the integrity of the Caco-2 monolayer,
two pairs of electrodes were embedded in the microchambers
on the microchip to acquire trans-epithelial electrical resistance
(TEER). To further assess the rate-limiting barrier of the Caco-2
monolayers cultured in the microfluidic device, transport studies
using three different test compounds were examined (mannitol,
dextrane and insulin). Mannitol and dextrane were used as model
drugs. Insulin was used due to the interest in oral delivery of this
drug in the pharmaceutical industry to provide a proof of concept
of the Caco-2 monolayers cultured in the thiol-ene microchip for
drug permeability studies. Insulin is usually administered by the
subcutaneous route (25, 26); however, orally delivered insulin is
attracting considerable attention due to the improved compliance
this would provide for diabetic patients (25). Oral delivery of
insulin has major limitations, due to the degradation of insulin
by proteolytic enzymes in the gastrointestinal tract and poor
intestinal barrier permeability due to its molecular weight (26).
To increase the oral bioavailability, various strategies have been
made to investigate to facilitate the absorption and transporta-
tion of insulin. One of the more successful methods is to co-
administer membrane permeability enhancers (27–31) (Fig. 1c)
together with the drug. For this reason, we chose to investigate
the use of permeability enhancers for aiding insulin transport
to further demonstrate the usability of microfluidic-based tissue
barrier platforms for investigating drug transport.
Results and discussion
Development of thiol-ene-based microchip for Caco-2 cell cul-
ture. We designed and developed a thiol-ene based microchip
that consists of eight cell culture micro-chambers where each cell
culture chamber has two compartments (to become the apical
and basal side of the cell layer, respectively) (Fig. 1). Thiol-
ene was chosen since thiol-ene polymers have been reported to
show low affinity to absorb molecules, have low volume shrinkage
(32, 33), and are biocompatible for use in cell culture (34). The
thiol-ene-based microchip has an external dimension of 76 mm
x 52 mm x 2.7 mm and consists of three layers. The top and
bottom layers of the microchip were fabricated via the method
reported by Lafleur et. al. (35) using a two-step UV exposure
(36, 37) (SI Text Fabrication of microfluidic device). The middle
layer was a porous Teflon membrane (BGCM 00010; Millipore,
Denmark) (0.4 μm in pore size; 40 μm in thickness). This porous
Teflon membrane was suitable for cell culturing and it became
transparent to visible light when wetted (Fig. S2), thus allowing
real-time and fluorescence microscopic monitoring of the Caco-2
cells cultured on it. The bonding of the thiol-ene top and bottom
fluidic layers with the Teflon membrane required a dedicated
modification of themembrane. The porous Teflonmembrane was
coated with a thiol-ene mixture and exposed to UV radiation
with a plastic mask that protected the part of the membrane to
be used for cell cultures. Methanol was used to rinse the entire
membrane to remove any traces of uncured thiol-ene. The end
result was a thiol-ene modified membrane with regions, which
were not coated with thiol-ene and thus allowed the porous Teflon
membrane to be used for cell culturing. When examined with a
scanning electron microscope (SEM), a smooth surface was ob-
served in regions where the porous Teflon membrane was coated
with thiol-ene and exposed to UV light. In regions that were
masked and rinsed with methanol, the porous structure of the
Teflonmembrane was preserved (Fig. 2D). This procedure clearly
demonstrated that thiol-ene ‘click’ chemistry can be exploited to
functionalise and pattern the membrane surface (36, 37). In our
pressure burst studies of the microfluidic chip, the multi-layer
microchip could withstand burst pressures of more than 6 bars (SI
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Fig. 3. Caco-2 cells cultured in microﬂuidic system (A-F and H). Caco-2 cells cultured in Transwell system (G and I). Phase contrast images of the Caco-2 cells
cultured in the microchambers on the thiol-ene microchip over 10 days. (A) Day 1; (B) Day 2; (C) Day 5; (D) Day 8. Cells multiply and differentiate over the days
of culture. Folds in the monolayer of Caco-2 cells start appearing from day 4 of cell culture. The folds in the Caco-2 monolayers are more prominent from day
5 onwards (indicated by red arrows). Dark ‘patches’ also start appearing on the Caco-2 monolayers from day 7 onwards. They become more prominent from
day 8 of cell culture (indicated by white arrow). (E) Immunoﬂuorescence image showing the distribution of the tight junction protein, occludin (green) at day
3. (F) Immunostaining of tight junctions (green) and nuclei (magenta). (G) Caco-2 cells cultured in Transwell stained for nucleus and tight junctions (Nuclei in
red and tight junctions in green) (Day 21). (H) Vertical cross-section view of the Caco-2 monolayer (nuclei in magenta, tight junctions in green). The Caco-2
cells are ≈ 40 μm – 50 μm in height on day 3 of cell culture in the thiol-ene microﬂuidic chip. (I) Vertical confocal image of Caco-2 cells in Transwell (Nuclei
in red and tight junctions in green). Immunoﬂuorescence staining of nucleus and mucus on Caco-2 cells cultured in: (J) Thiol-ene microchip on day 10 of cell
culture (nucleus in red, mucoprotein 2 (MUC-2) in green). The ﬂuorescent images of the cells demonstrate that the cells have polarised into columnar cells of
about 100 μm in height and formed villious-like structures. (K) Cells in the Transwell inserts were stained for nucleus and mucoprotein 2 at day 21. Only the
nuclei could be ﬂuorescently imaged but not MUC-2. Height of cells were about 25 -30 μm at day 21. (L) Differentiation of Caco-2 cells cultured in Transwell
inserts and thiol-ene microchip as indicated by the activity of the brush border enzyme aminopeptidase. (n = 3, mean ± SD). Magniﬁcation 10 x. (Scale bar =
50 μm)
Table ST1). The presented method of fabricating the microfluidic
chip is rapid and can easily be carried out at room temperature
and in standard laboratory environments, therefore eliminating
the need for costly or specialized cleanroom facilities.
Caco-2 cell culture in microfluidic system. To investigate the
feasibility of culturing Caco-2 cells in the microchambers of the
thiol-ene microfluidic chip, Caco-2 cells were seeded into the mi-
crochamber at a density of 8.5 x 106 cells/ml. Cell culture medium
was perfused through the upper and lower fluidic layers at a
flow rate of 3 μl/min for 9 – 10 days. Caco-2 cells were observed
to adhere onto the extracellular matrix (ECM) coated Teflon
membrane (SI Text Cell culture in microfluidic system) within 30
min after cell seeding. During the phase of active growth, it was
observed that once the flow of cell culture media was started (first
24 hrs of cell culture), the Caco-2 cells spread out (38). Yet, in
some regions on the ECM coated Teflon membrane, they had the
affinity to grow as clusters. However, over the days of cell culture,
with the constant supply of cell culture medium, the Caco-2 cells
were observed to multiply and differentiate. By day 2 (Fig. 3B),
distinct polygonal shapes with clear, sharp boundaries between
the Caco-2 cells were observed in all the microchambers. The
shape and morphology of the Caco-2 cells in the microfluidic
device was similar to the cells cultured in a microplate (results
not shown). Confluent monolayers of Caco-2 cells were observed
in the microfluidic device typically around day 3-5 of cell cul-
ture. Folds started appearing in the monolayers around day 5 (a
suggestion of villous formation) and it became more challenging
to observe the cells through an optical microscope (Fig. 3C).
From day 7 onwards, the appearance of ‘dark’ patches (Fig. 3D)
were observed on the cells. As the cell culture period progressed,
these ‘dark’ patches increased in area, or more ‘dark’ patches
started appearing on the Caco-2 monolayers. However, these
‘dark’ patches were not observed when the cells were cultured at
a flow rate of 0.5 μl/min (results not shown). It is suspected that
these dark patches are the result of mucus produced by the Caco-
2 monolayers under shear stress from the flow.
Caco-2 cell morphological studies. The establishment of api-
cal tight junctions determines the integrity of the human intestinal
epithelial cell monolayer (8). To visualise and validate the pres-
ence of apical tight junctions in the Caco-2 cells cultured in the
microfluidic device, immunofluorescence staining using antibod-
ies directed at the tight-junction protein, occludin, was carried out
(SI Text Morphological studies of Caco-2 cells in microfluidic and
Transwell cultures).
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Fig. 4. (A) TEER measurements of Caco-2 cells cultured in thiol-ene microchip
and Transwell inserts for the same cell concentration of 2.55 x 105 cells/cm2.
(Here, number ofmeasurements per data point n = 12 formicroﬂuidic device;
and n = 5 for Transwell inserts). (B) Effect of test compounds alone or with
TDM on Caco-2 TEER in the Transwell or microﬂuidic system, immediately
after the experiment or following 24 h recovery in medium.
Fig. 5. Permeability of (A) mannitol, (B) FD4 and (C) insulin, alone or
with TDM, across Caco-2 monolayers grown in the Transwell or microﬂuidic
system. Data points represent mean ± SD (n = 4 for all Transwell inserts), (n
= 4 for each of the experiments carried out with the microﬂuidic device)
The immunofluorescence images confirmed the formation of
confluent Caco-2 monolayers, expressing tight junctions (Fig. 3E-
F). Analysis of the vertical sections of the confocal images of the
Caco-2 cells (Fig. 3H) revealed that the tight-junction proteins
were situated between neighbouring cells at the apical side of
the Caco-2 cells (Fig. 3F and 3H). Images of the cells cultured
in the Transwell inserts at day 21 appeared cuboidal with heights
of 14 – 20 μm (Fig. 3I). However, the Caco-2 cells cultured in
the thiol-ene microfluidic device (three days of cell culture) were
observed to appear columnar in shapewith heights of≈ 40 – 50 μm
(Fig 3H). Our data is consistent with a previous report (17). The
Caco-2 cells cultured in the microfluidic device is about the same
columnar size and shape (40-50μm) as reported in healthy human
intestinal epithelial cells (39). It is believed that the presence of
continuous perfusion of cell culture medium in the microfluidic
device may be responsible for stimulating the Caco-2 cells to
polarise into columnar cells that were almost 2 fold taller than
the cells from Transwell inserts.
In our microfluidic device, over the days of cell culture in
the microfluidic device, from microscopic phase contrast images,
there were observable regions of ‘dark’ patches (Fig. 3D). These
‘dark’ patches started appearing from day 7 of cell culture, but
became more prominent from day 8 onwards. We observed that
these dark patches were absent when the cells were cultured
at a low flow rate of 0.5 μl/min (results not shown). To further
investigate the nature or origin of these ‘dark’ patches, the Caco-2
monolayers were stained for themuco-protein,Mucin-2 (Mucin-2
is commonly found in human intestines) on day 10 of cell culture.
Our immunofluorescence staining directed towards the protein
Mucin-2 showed positive stains at the apical surfaces of the villous
Caco-2 monolayers (Fig. 3J). This is surprising as in an earlier
study (17, 40) the authors claimed the production of mucus on
the Caco-2 cells cultured in a microfluidic device was due to fluid
flow and cyclic peristaltic motions. However, the Caco-2 cells
cultured in the thiol-ene microfluidic device were only exposed
to low fluidic stresses (≈ 0.008 dyn/cm2). It was also reported
the gastrointestinal tract has a tendency to protect itself from
mechanical and other stresses by producing and secreting a layer
of lubricating mucus onto epithelial surfaces (41). Therefore, we
hypothesise the exposure to low fluidic shear stresses (≈ 0.008
dyn/cm2) may have resulted in the Caco-2 cells exhibiting some
protective function by producing mucus on the apical side of the
cells. To further confirm our observation, we also performed the
same staining procedure on cells cultured in the Transwell inserts.
Past studies have reported that Caco-2 cells do not producemucus
when cultured in static culture conditions (19). As expected the
images of our Transwell cultures did not show the presence of
Mucin-2 on the Caco-2 monolayers (Fig. 3K).
From the fluorescent images (Fig. 3J), it can also be observed
that the Caco-2 cells cultured in the microfluidic device form
folds and are capable of growing up to a height of ≈ 100 μm
when they are cultured for a longer term (day 9 – 10). These
results are consistent with an earlier study which showed fluid
flow can encourage the formation of villous structures in the
Caco-2 monolayers (17, 40).
Differentiation of Caco-2 cells. Another characteristic of dif-
ferentiated Caco-2 cells is the high level expression of brush
border enzymes that are commonly found in small intestinal ep-
ithelial cells (10, 12). To evaluate the differentiation of the Caco-2
cells that were cultured in our thiol-ene microchip, we measured
the level of aminopeptidase activity by using the substrate L-
alanine-4-nitroaniline hydrochloride (L-A4N). The aminopepti-
dase experiments were also carried out in the static Transwell
inserts. The Transwell studies were carried out on day 5 and 21
of cell culture. In the microfluidic device, the aminopeptidase
studies were carried out on day 5 of cell culture. Our analysis of
data from the Transwell cultures showed that the aminopeptidase
activity increased by more than 5-fold between Caco-2 cells cul-
tured for 5 days and 21 days, respectively. These data are con-
sistent with earlier findings (12, 17). Interestingly, analysis of the
samples collected fromourmicrofluidic device, with only 5 days of
cell culture, showed that the aminopeptidase activity was 4 times
higher than the aminopeptidase activity in the Transwell inserts
at day 21 (Fig. 3L). Our results are comparable to earlier findings
(14, 17). These results clearly confirmed that cells cultured in
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the presence of continuous flow (as in the microfluidic device)
required a shorter time to polarise and differentiate.
Trans-epithelial electrical resistance (TEER)measurements.
Trans-epithelial electrical resistance (TEER) is a widely used
technique for quantifying the integrity of the tight junctions
present between cells that govern the solute transport across the
paracellular space of epithelial monolayers (10). To ensure as
much as possible an equal potential drop over the entire mem-
brane (42), the electrodes were embedded directly above and
below the membrane in our microfluidic device. The electrodes
embedded in the thiol-ene microfluidic chip were produced in-
house using a low-melting indium alloy (InBiSn) (SI Fabrication
of microfluidic device) for the bottom electrodes and platinum
wires for the top electrodes. TEERmeasurements were obtained
by coupling the electrodes to a multi-meter (Keithley, USA)
that supplied DC signals (constant current = 10 μA). TEER
measurements of the Caco-2 monolayer cultured in the thiol-ene
microchip were taken fromday 3 onwards of cell culture andmon-
itored over the remaining days of the experiments. Importantly,
the TEERmeasurements of the Caco-2 cells cultured in the thiol-
ene microchip showed a significant increase over the days of
cell culture (Fig. 4A). TEER values for the microfluidic system
reached a maximum of about 1400 Ω∙cm2 and the high values
could be maintained from day 7-9. The standard deviation (SD)
of the TEER values from the microfluidic device is much larger
compared to the SD of the data from the Transwell inserts. This
is attributed to the difference in electrode designs. Furthermore,
the positions of the electrodes on the microfluidic device may
vary slightly from microchamber to microchamber, and this may
contribute to differences in measured resistances (43).
Effect of membrane permeability enhancer on TEER values.
To validate the accuracy of the TEER values acquired from
the electrodes on the microfluidic chip, a membrane enhancer,
tetradecyl-β-D-maltoside (TDM), was introduced to the Caco-2
monolayers for two hours. TDM, is a compound that interacts
with lipid cell membrane to permeabilise it, therefore increas-
ing the transcellular pathway (28, 30, 44). It also modifies the
tight junctions between adjacent cells, hence causing a drop in
the TEER values. Consequently, this also causes an increase
in the paracellular transport of compounds across the Caco-2
monolayer (28, 30, 44). The concentration of TDM used in this
study is within the range that was reported previously (29). The
concentration of TDM used in this study would disrupt the in-
tegrity of the Caco-2 monolayer while allowing it to recover when
subjected to 24 hours of recovery with cell culture medium (Fig.
4B). Therefore, one will expect the TEER values to drop after
exposing the Caco-2 monolayers to TDM, and then an increase
of TEER values after 24 hours recovery period in cell culture
medium. Interestingly, with the introduction of TDM to theCaco-
2 monolayers cultured in the microfluidic device, the TEER data
acquired in the absence and presence of membrane permeability
enhancers showed distinct differences. It could be clearly seen
that in the presence of TDM, the TEER values measured in the
microfluidic device dropped to 20.6 % of their initial values (Fig.
4B). When the Caco-2 monolayers were subsequently subjected
to 24 hours of continuous perfusion with cell culture medium,
the TEER values recovered to 90 % of the initial values (Fig.
4B). This significant drop in TEER values with the introduction
of TDM and an increase in the TEER values during the 24
hour recovery in cell culture medium was consistent with the
data acquired from the static Transwell cultures (Fig. 4B). The
TEER results recorded from the microfluidic device were also
an indication that the electrodes fabricated on the microfluidic
device were sensitive to detect dynamic changes in the integrity
of the Caco-2 monolayers.
Permeability studies of FITC–dextran (FD-4), mannitol and
insulin in the presence or absence of membrane permeability
enhancer. Paracellular transport of compounds across the Caco-
2 monolayers is governed by the presence of the tight junctions
between adjacent cells. To assess if the Caco-2 monolayers cul-
tured in the thiol-enemicrochip exhibit a rate-limiting barrier, the
behavior of three different test compounds (mannitol, fluorescein
isothiocyanate (FITC)-labeled-dextran (FD 4) and insulin) was
studied.
Permeability studies were carried out on day 9 or day 10 of
cell culture. We measured the permeabilities (Papp) for mannitol,
FD-4 and insulin to be 3.94 x 10-6 cm/s, 2 x 10-7 cm/s and 9.43 x
10-7 cm/s, respectively, in the microfluidic chip. The Papp values of
similar compounds in the static Transwell cultures were slightly
lower as compared to the microfluidic device (Fig. 5). To further
investigate whether the permeability of different test compounds
is affected by the introduction of TDM,we next exposed theCaco-
2 monolayers in both the microfluidic device and the Transwell
inserts to mixtures of test compounds with TDM. In both sys-
tems, the Papp values for all three compounds greatly increased
(Fig. 5) in the presence of TDM. In the microfluidic device, the
Papp values for mannitol, FD-4 and insulin were 12.42 x 10-6 cm/s,
14.29 x 10-7 cm/s and 11.02 x 10-7 cm/s respectively (Fig. 5). While
the Papp values of the similar test compounds from the static
Transwell cultures were 13.9 x 10-6 cm/s, 19.72 x 10-7 cm/s and
9.43 x 10-7 cm/s. The permeability results clearly demonstrated
that the addition of T M effectively permeabilised the Caco-
2 monolayers in both systems and allowed substantial transport
of compounds across the Caco-2 monolayers. Additionally, the
Papp values of the test compounds in the presence of TDM
were comparable between the static Transwell cultures and the
microfluidic system. Therefore, the Caco-2 monolayers cultured
in the microfluidic device could be an interesting alternative in
vitro model of the human intestines for drug transport studies.
Conclusion
A thiol-ene basedmulti-chamber andmulti-layermicrofluidic
chip was engineered to provide a controlled platform to sustain
long-term Caco-2 cell cultures under fluidic flow for transport
studies. Characterization of the microfluidic chip revealed that
the functionality of the porous Teflon membrane (sandwiched
between the top and bottom fluidic layers) could be changed by
coating and curing it with a thiol-ene mixture, followed by ECM
coating of the porous region of the Teflon. Thus, bonding the
Teflon membrane between two cured thiol-ene layers within a
fluidic system formed a microchip that could support long time
cell culture. The experiments with the Caco-2 cells cultured in
the thiol-ene microfluidic chip revealed, the growth and differ-
entiation of the Caco-2 cell cultures accelerated under fluidic
conditions. Furthermore, under continuous flow conditions, the
Caco-2 cells cultured in the microchip developed villous morpho-
genesis, exhibited increased differentiation and formed a tight
barrier, closely mimicking the human intestine. We showed that
this intestinal model was adequate for transport studies.
In summary, this work has shown that Caco-2 cells cultured
in a microengineered thiol-ene microfluidic chip may serve as a
promising alternative in vitro platform for pharmaceutical, toxico-
logical, and cell-cell communication studies, among others. With
eight chambers fabricated on the same microchip, it allows for
parallel studies to be carried out on the same microfluidic chip
under basically identical conditions.
Materials and methods
Fabrication of thiol-ene microﬂuidic chip. Pentaerythritol tetrakis-(3-
mercaptopropionate) (4 thiol moieties), tri-allyl-tri-azine (3 ene moieties)
and trimethylopropane tris-(2-mercaptopropionate) (3 thiol moieties) used
for fabricating the ﬂuidic layers in the thiol-ene microﬂuidic chips were all
purchased from Sigma Aldrich, Denmark. The commercially available Teﬂon
membrane that was modiﬁed and sandwiched between the thiol-ene layers
was purchased from Milipore, Germany. Methanol (Sigma, Denmark) was
used for removal of uncured thiol-ene on the modiﬁed Teﬂon membrane.
The microelectrodes embedded in the thiol-ene microchips were fabricated
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by inserting pieces of low-melting temperature indium alloy (InBiSn, In 51 %
Bi 32.5 % Sn 16.5 % by weight) (Indium Corp., Utica, NY) for the bottom
ﬂuidic layer and platinum wire (Advent, UK). The detailed fabrication of
the microﬂuidic device is reported in the SI Text Fabrication of microﬂuidic
device.
Cell culture. Human Caco-2 intestinal epithelial cells used in the experi-
ments were obtained from American Type Culture Collection ((ATCC), HTB-
37, Germany). The passages of the Caco-2 cell line used in the microﬂuidics
studies ranged from the 40th to 50th passages, and for the Transwell studies,
passages in the range of 40th to 65th were used. The Caco-2 cells were
cultured routinely in Dubelco’s Modiﬁed Eagle Medium (DMEM; Sigma, Den-
mark). The culture medium is supplemented with 10 % (v/v) heat-inactivated
fetal bovine serum (FBS; Sigma, Denmark), 1% (v/v) nonessential amino acids
(NEAA; Gibco, Denmark) and 1% (v/v) penicillin-streptomycin (P/S; Gibco,
Denmark).
Cell staining for morphological studies. To visualize the cytoskele-
ton and morphology of the cultured Caco-2 cell monolayers in the mi-
crochip, the Caco-2 monolayers were ﬁrst ﬁxed in 4% paraformaldehyde
and permeabilied with 0.1% (v/v) Triton-X-100 (Sigma, Denmark). F-actin,
tight junctions and mucin were stained using Rhodamine-Phallodin (RP;
(Invitrogen, USA), anti-occludin antibodies (Z0-1-1A12 mouse monoclonal
antibody-Alexa Fluor® 488, Life Technologies, USA) and anti-mucin 2 an-
tibodies (mouse monoclonal antibody; Abcam, Denmark) respectively. 7-
Aminoactinomycin D (7-AAD; Invitrogen, USA) was used to stain the nucleus.
The cells were imaged with a laser scanning confocal microscope (Carl Zeiss
Axio Observer, Germany).
Preparation of compounds for permeability studies. The compounds
used in the permeability studies, [3H]-mannitol (PerkinElmer; USA), ﬂuores-
cein isothiocyanate (FITCH)-labeled dextran (FD4; 4kDa; Sigma, Denmark),
insulin (Novo Nordisk, Denmark) and tetradecyl-β-D-Maltoside (TDM; Sigma,
Denmark) were all prepared using buffer+ as the diluent. Buffer+ was pre-
pared by mixing Hank’s Buffered Saline solution (HBSS; Gibco, Denmark),
0.1% (wt/v) OVA (ovalbumin; from chicken egg white, Sigma, Denmark) and
10 mM HEPES (HEPES; Sigma, Denmark) at pH 7.4. The different compounds
were prepared in various concentrations: 0.8 μCi/ml [3H]-mannitol, 100 μM
insulin (peptide/drug) or 540 μM FD4, and 0 or 400 μM TDM.
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Fabrication of microfluidic device. Two sets of molds were required to fabricate the fluidic layers of the 
thiol-ene microchip. The first mold was fabricated on polymethylmethacrylate (PMMA). The design of this 
mold was the exact replica of the thiol-ene microchip design. A second mold made from PDMS was the inverse 
design of the PMMA mold. The designs of the top and bottom layers of the microchip were first drawn with 
an engineering software, Autocad (Ver 18.1). To fabricate the first master molds, the drawings were converted 
to codes by EZ-CAM (ver 15.0, Germany) and micromilled (Mini-Mill/3, Minitech Machinery Corporation, 
GA, USA) onto 5 mm PMMA blocks. The second molds were fabricated by mixing poly dimethylsiloxane 
(PDMS; DowCorning, Germany) in the ratio of 1:10 (curing agent: pre-polymer), degassed under vacuum and 
poured onto the PMMA master mold. The liquid PDMS was cured in the oven at 70 °C for more than 20 hrs. 
Once the PDMS molds were cured, they were de-molded from PMMA molds, bearing the replicated design of 
the microchip layers. 
    Two different mixtures of thiol-ene were prepared for the microchip fabrication. The top and bottom layers, 
containing the fluidic microchannels and chambers were fabricated with a mixture of pentaerythritol tetrakis-
(3-mercaptopropionate) (tetra-thiol moieties; Sigma, Denmark) (and 1,3,5 trilallyl-1,3,5-triazine-
2,4,6(1H,3H,5H)-trione (tri-allyl moieties; Sigma, Denmark) in stoichiometric ratios. The different 
components were mixed, poured onto the PDMS molds and exposed to UV (for 40 s on both sides (Dymax 
5000-EC Series UV curing flood lamp, Dymax Corp., Torrington, CT, USA, ∼40 mW cm−2 at 365 nm) (Fig 
S1A).  
    To fabricate the thiol-ene coated Teflon membrane, a commercially available Teflon membrane (Millipore, 
Denmark) (0.4 μm in pore size; 40 μm in thickness) was modified to enable better bonding of the membrane 
to the thiol-ene parts containing the fluidic manifolds. A thiol-ene mixture consisting of trimethylopropane 
tris-(2-mercaptopropionate) (tri-thiol moieties; Sigma, Denmark) and the tri-allyl component as above, in 
stoichiometric ratios, was prepared and used to coat the membrane. The coated membrane was exposed to UV 
radiation for 25 s through a plastic mask (Infinite Graphics, Singapore) that protected the cell culture regions 
(Step 2 in Fig S1B). Thereafter, methanol (Sigma, Denmark) was used to rinse the entire membrane to remove 
any uncured thiol-ene (Step 3 in Fig. S1B). Before bonding the layers, holes for the inlets, outlets and electrode 
ports were drilled through the partial cured thiol-ene layers. Next, the layers (thiol-ene coated membrane and 
thiol-ene fluidic manifolds) were aligned onto each other. Slight pressure was applied with a roller over the 
layers to ensure good contact between the surfaces. To finalise the bonding, the combined layers were exposed 
to UV radiation for an additional minute on each side (Final step in Fig S1).   
The completed microchip would have two sets of electrodes (top and bottom) embedded into selected 
chambers for measurement of the trans-epithelial electrical resistance (TEER). The bottom electrodes were 
fabricated using an Indium alloy (InBiSn (In 51 % Bi 32.5 % Sn 16.5 % by weight); Indium Corp, Utica, NY). 
Top electrodes were fabricated using Platinum wire (Pt, Advent, UK) (diameter 0.5 mm). To fabricate the 
bottom electrodes, the assembled microfluidic chip was first placed onto a hot plate set at 80 °C for 10 min. 
Pieces of the InBiSn metal, with length of 5 mm, were inserted into the electrode ports (connecting to the lower 
fluidic layer) on the thiol-ene microchip. Slight pressure was applied manually to push the melted metal into 
the electrode groove. Once the electrodes were formed, electric wires of diameter 0.4 mm were inserted to the 
liquid metal to act as connecting wires to the multimeter (Keithley, USA). To fabricate the top electrodes, 
pieces of Pt wires (diameter of 0.5 mm, length of 5 mm) were forced fit into the electrode ports drilled through 
the top fluidic layer. Two connecting Cu wires were soldered to the Pt wires. To fix the electrodes in position, 
UV-epoxy (NOA81; Norland, USA) was applied at the junctions between connecting wires and thiol-ene chip. 
The entire chip was exposed to UV light for 30 s. The entire procedure of embedding the electrodes on the 
microchip could be carried out in ambient environment, eliminating the use of expensive, sophisticated 
instruments in environment-controlled cleanroom. 
 
Pressure burst studies of thiol-ene microchip layers. The burst pressure test of the different thiol-ene 
microfluidic chips were carried out at two different temperatures, namely room temperature (25°C) and 
incubator temperature (37 °C). The bond strength between the layers were investigated at 37 °C, which was 
the required temperature for cell culture of Caco2 cells. Therefore, this will also be the temperature that the 
microfluidic chip would be subjected to for long periods. For the studies carried out at 37 °C, the microchip 
was first placed into an oven set at 37 °C, then transferred to a hotplate set at 37°C during the burst pressure 
tests. The system and method reported by Silkane et. al. (1) was used to carry out the burst pressure studies. 
The microchannels were first filled with diluted red food colour dye. Red dye was used to allow better visual 
observations during the pressure experiments. When testing the top layer, the inlets and outlets of the bottom 
layer and the outlet of the top layer were sealed with a layer of cured thiol-ene. These ports were sealed to 
prevent any leakage of pressure during the studies. The same procedure was carried out when testing the 
bottom fluidic layer. The instrument for the pressure test, as well as the chip filled with dye are shown in Fig. 
S2. Next, the microchip was connected to a mechanical clamp, where a pressure sensor was mounted onto a 
polycarbonate block. Via a tube, the system was connected to two 10 ml syringes. Pressure in the microchip 
was increased, by using the clamp to compress the air in the syringes. The entire system for the burst pressure 
test is shown schematically in Fig. S2a. The output of the pressure sensor was measured with an in-house 
written Labview program (National Instruments, Austin, TX, USA). 
 
Cell culture in Transwell inserts and microfluidic chip 
Transwell system. Control studies were carried out using static cultures of Caco-2 cells in 12 well Transwell 
plates (Corning , Sigma, Denmark). The inserts in the well plate each had a porous polycarbonate membrane 
(1.1 cm2, 0.4 μm pores). In the Transwell studies, the Caco-2 cells harvested with trypsin/ETDA solution 
(0.05 %; Sigma, Denmark) were seeded on the top surface of the porous Transwell membrane at a density of 1 
x 105 cells/well. The Caco-2 cells were grown for 14–16 days in Dulbecco’s Modified Essential Medium 
(DMEM; Sigma, Denmark) supplemented with 10 % (v/v) heat-inactivated fetal bovine serum (FBS; Sigma, 
Denmark), 1% (v/v) nonessential amino acids (NEAA; Gibco, Denmark) and 1% (v/v) penicillin-streptomycin 
(P/S; Gibco, Denmark). The medium was changed every second day of cell culture.  
 
Microfluidic system. After the microchip was fabricated, it was assembled onto the platform with 
MAINSTREAM components (2). The Teflon tubings (inner diameter = 0.2 mm; Bola, Denmark) 
microcomponents and microchip were sterilised by perfusing 70 % ethanol throughout the entire system at a 
flow rate of 5μl/min for 2 hours. Following that, sterile water was flushed into the entire system for an 
additional 2 hours at a flow rate of 5μl/min. It was crucial to ensure good microenvironment in the cell culture 
chamber and good cell attachment during cell seeding in the microchip. To achieve this, extra cellular matrix 
mixtures (ECM) known to have the ability in improving the cellular microenvironment (3–5), was used to coat 
the Teflon membrane. An ECM mixture: 300 μg/ml matrigel (Corning, United Kingdom) and 50 μg/ml 
collagen (BD Bioscience, Denmark) and serum-free DMEM was flowed into the microchip to coat the porous 
membrane. The ECM mixture was flowed into the microchip for 2 hours at a flow rate of 5μl/min in an 
incubator. After the incubation, the microchip device was perfused with cell culture medium overnight in an 
incubator (37°C, 5 % CO2). Following that, the harvested Caco-2 cells from the trypsin/EDTA solution was 
seeded into the microfluidic chip. 
    For cell seeding in the microfluidic microchip, the harvested Caco-2 cells was diluted with DMEM 
containing 60 % (v/v) FBS solution. The re-suspended cell mixture was syringed into the ‘cell loading’ 
reservoirs that were assembled onto the microfluidic platform. The peristaltic micropump on the microfluidic 
platform was activated at a very high flow rate (flow rate ≈ 65 μl/min) to draw the cell suspension into the cell 
culture chambers. The microchambers were seeded with Caco-2 cells at a concentration of 2.5 x 105 cells/cm2. 
A normal optical microscope was utilized to observe the distribution of the cells in the chambers. Caco-2 cells 
attached onto the ECM-coated Teflon membrane within 30 minutes. Next, the entire system with the microchip 
was placed in the incubator (37°C, 5% CO2). After 2 hours, the peristaltic micropump was activated to perfuse 
culture medium through the upper microchannels and microchambers at a constant flow rate of 0.5 μl/min. 
Cell culture medium was flowed only in the upper layer on day 1 of cell culture. This was to ensure the Caco-
2 cells establish an intact monolayer. From the second day of cell culture onwards, the micropump that was 
perfusing through the lower microchannels and microchambers was also activated. Flow rate was set at 3 
μl/min for both top and bottom channels. Over the 9 - 10 days of cell culture, phase contrast images of the cells 
in four different positions of each of the microchambers were taken and compared. 
 
 
Trans epithelial barrier measurements (TEER) 
Transwell set-up. To acquire the TEER measurements (Ω) from the Transwell inserts, a Millicell ERS-2 
(Millipore, USA) coupled to a pair of chopstick Silver/SilverChloride (Ag/AgCl) electrodes was used. TEER 
values (Ω∙cm2) were determined by subtracting the baseline measurements recorded in absence of cells, then 
multiply the cell culture area (cm2) (eq. 1). 
 
Microfluidic device. TEER measurements (Ω) of the Caco-2 cells cultured in the microfluidic device were 
obtained by coupling the connecting wires of the electrodes to a multimeter (Keithley, USA) using alligator 
clips. Similar to the Transwell studies, the final TEER values were determined by subtracting the baseline 
measurements recorded in the absence of cells, then multiply the cell culture area of the porous Teflon 
membrane (area 0.1 cm2). 
 
TEER measurements. The final TEER values (Ω∙cm2) from the microfluidic device were determined by 
subtracting the baseline measurement in the absence of cells (Rbaseline) from the read out (R1) and multiplying 
with the area of cell culture (Ao) as shown in equation 1. 
 
Eq (1):    (R1-Rbaseline) x Ao = TEER 
 
Morphological studies of Caco-2 cells cultured in microfluidic system and Transwell cultures. Phase 
contrast images of the Caco-2 monolayers were obtained using an inverted microscope (Carl Zeiss, Germany). 
Images were analysed with the imaging software (AxioVision 4.8.2, Carl Zeiss, Germany). Fluorescent 
confocal images of the monolayer morphology were obtained using a confocal microscope (Carl Zeiss, 
Germany). The procedure for cell staining and the dyes used were the same for both Transwell cultures and 
microfluidic device. PBS was used to rinse the cells between each processing step. The Caco-2 cells were fixed 
with 4% (vol/vol) paraformaldehyde for 30 min, following by permeabilisation with 0.1 % Triton X-100 for 
30 min. After which, a blocking buffer (1% bovine serum albumin (BSA; Sigma, Denmark), 0.1% Tween-20 
(Sigma, Denmark) in phosphate buffer saline (PBS; Sigma, Denmark)) was introduced to the cells for 1 hr. To 
visualize tight junctions, immunofluorescence staining was performed using mouse anti-ZO-1 (Z0-1; Life 
Technologies, Denmark) diluted in the blocking buffer 1:100, and introduced into the cells and left static 
overnight in the fridge at 4°C. Immunofluorescence staining was also carried out to stain the mucoprotein, 
mucin-2. Primary mouse monoclonal antibody (ab11197; AbCam, Denmark) prepared in blocking buffer 
(1:100), was introduced to the cells. The samples were protected from light and left static overnight in the 
fridge at 4°C. After which, the cells was rinsed with blocking buffer followed by introducing the secondary 
antibody (AlexaFluor 488 goat anti-mouse; Life technologies, Denmark) prepared in blocking buffer (1:200) 
and left static in room temperature for 2 hrs. Staining of the nucleus and actin were carried out by diluting 7-
aminoactinomycin D (AAD; Invitrogen, Denmark) (32 μM) and rhodamin phallodin (RP; Life Technologies, 
Denmark)) to 1:100 in PBS and incubated with the cells for 1 hr. Lastly, mounting media (Vectashield; VWR, 
Denmark) was added to the cells to protect the fluorescent dyes. For the Transwell cultures, the membranes 
were removed from the inserts and mounted onto glass slides before microscopic imaging. Staining of cells in 
the microfluidic device, were performed in situ within the microchannels by flowing the different reagents into 
the microchannels and microchambers via MAINSTREAM platform. Fluorescent imaging of the stained Caco-
2 cells on the thiol-ene microchip was performed through the thiol-ene layer on an upright microscope (ZEISS 
Axioscope; Carl Zeiss, Germany). The recorded images of the cells were analysed with an imaging process 
software AxioVision SE64 Rel4.8.  
 
Aminopeptidase studies to determine differentiated Caco-2 cells. L-alanine-4-nitroaniline hydrochloride 
(L-4AN; Sigma, Denmark) was prepared by dissolving the L-A4N substrate in DMEM without phenol red 
(DMEM-PR, Gibco, Denmark) to a concentration of 1.5 mM. In the Transwell studies, the Caco-2 cells were 
first rinsed with DMEM-PR in both the apical and basolateral sides for 3 times. 500 μl of L-A4N substrate 
solution was added to the apical side of the cells and 1500 μl of DMEM-PR was added to the basal lateral side 
of the cells and incubated at 37 °C. Sample aliquots of 100 μl was removed from the apical side at 30 min 
intervals and transferred to a 96-well microplate. Studies were carried out for a 2 hr period. Analysis of the 
sample aliquots were carried out with a microplate reader (Victor 3V; Perkin Elmer). DMEM-PR was set as the 
reference. The test was calibrated with a series of dilutions of 4-nitroanilide in DMEM-PR. One unit is defined 
as the hydrolysis of 1.0 μmol of 4-nitroanilide per minute. All of the reagents preparation and experimental 
studies were conducted under the protection of light. The aminopeptidase experiments in the Transwell 
cultures were carried out on cell culture day 5 and 21. 
    In the microfluidic device, the aminopeptidase studies were carried out on day 5 of cell culture. DMEM-PR 
was first perfused to both the top and bottom fluidic channels for 45 min at a flow rate of 3 μl/min. Next, 1.5 
mM of L-A4N solution was flowed into the upper microchannels and microchambers of the thiol-ene 
microchip at a flow rate of 3 μl/min. Sample aliquots of 120 μl were removed from the outlets of the upper 
microchannels at every 30 min and transferred to a 96-well microplate. Similar to the Transwell studies, the 
sample aliquots from the microfluidic system were analysed for the cleaved product, 4-nitroanalide with the 
microplate reader. 
 
Permeability studies of fluorescein isothiocyanate–dextran (FD-4), mannitol and insulin in the presence 
or absence of membrane enhancer. In the Transwell studies, before carrying out the transport experiments, 
DMEM was changed to buffer+ (see Materials and methods for preparation of buffer+). 400 μl of buffer+ was 
added to the apical side and 1 ml to the basolateral prior to equilibrate the Transwell plate for 60 minutes. 
Buffer+ was replaced apically by 400 μl test solution at time zero, and the Transwell plates were incubated at 
37°C and 5% CO2 with gentle shaking. The gentle shaking is to ensure there was little unstirred diffusion 
layers of fluid in the basolateral region. Basolateral samples were collected every 15 minutes for 1 hour and 
analyzed along with apical test solutions, for [3H]-mannitol content in a scintillation counter (Packard 
TopCount; PerkinElmer), after mixing with scintillation fluid (Microscint-40; PerkinElmer), along with a 
peptide and FD4 content. We chose to use the peptide, insulin, as a proof-of-concept demonstration in using 
the Caco-2 monolayers cultured in the thiol-ene microchip for drug permeability studies. After experiments, 
cells were washed twice with buffer+ and replenished with medium for 24 hour recovery. In the microfluidic 
set-up, similar to the Transwell studies, before the start of experiment, the DMEM was replaced with buffer+. 
Buffer+ was flowed into the system for 1 hr. Subsequently, the buffer was changed to the test solutions in the 
top fluidic layer. Flow rate was set at 3 μl/min (in both the upper and lower layers). In the waste collection 
reservoirs, 200 μl of buffer was added to each of the waste reservoirs. This would enable sample aliquots of 
100 μl collected at every 15 min intervals. During calculation of the permeability of the compounds across the 
cell monolayers, dilution of the sample aliquots were factored. Preparation of the test solutions can be found 
in Materials and methods segment. 
 
Data analysis of permeability results. The Caco-2 translocation of peptide or [3H]mannitol over Caco-2 
layers is expressed as the apparent permeability (Papp), given by: 
Eq. (E1):   𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡
 
1
𝐴 ∙ 𝐶0
 
Where dQ/dt is the steady-state flux across the cell layer (pmol/s), A is the surface area (1.12 cm2 for 
Transwell, 0.1 cm2 for microfluidic), and C0 is the initial sample concentration (6) . 
The basolateral samples were analyzed for insulin content using commercial insulin enzyme immunoassay kit 
(EIA, Phoneix Pharmaceuticals, Germany).  Standards were prepared from test solutions, and were fitted to 
eq. 2 using Prism-6 (GraphPad). 
Eq. (E2):  𝐴𝑏𝑠(450𝑛𝑚) = 𝐴 +
𝐵−𝐴
1+10((𝑙𝑜𝑔𝐸𝐶50−𝑥) ∙ 𝐶)
 
where x is log(concentration) of peptide in M, and A, B, C and EC50 are fitting parameters (7). 
 
Basolateral samples were analyzed for FD4 content in a fluorescence plate reader (MD Spectramax Gemini, 
USA) with excitation/emission of 490/525 nm, based on standard curves prepared from test solutions. 
Statistical analysis was carried out using the softwares, Origin (OriginPro, Ver 9.1) and Prism (GraphyPad, 
Ver 6), where unpaired Students t-tests were used for comparison, and a significant difference was considered 
if p < 0.05. Results are presented as the mean ± standard deviation of the mean (SD). 
 
 
 
 
SI figures 
 
Figure S1. Schematic process of fabricating the thiol-ene microchip. (A) The upper and lower fluidic layer; 
(B) The thiol-ene coated Teflon membrane. (C) Final assembled system with microfluidic chip for cell culture. 
Microchambers on the microchip are embedded with the electrodes for acquiring TEER measurements. 
 
 
Figure S2. Porous Teflon membrane modified with a layer of cured thiol-ene mixture. Black arrow indicating 
the region on porous membrane that was protected by a plastic mask during UV-exposure. When dry, the 
region appeared white and opaque. (b) Two chambers were wetted with DI water, as indicated by red arrows. 
Teflon membrane becomes transparent in visible light. (Scale bar = 5 mm) 
 
 
 
(C) 
Thiol-ene microfluidic chip 
(A) (B) 
 
Figure S3. Burst pressure study for thiol-ene microchip. (a) Schematic view of the pressure system (1). The 
thiol-ene microchip was clamped between the PC holders. The pressure sensor on the top of the PC holder will 
measure the pressure of the set-up. The syringes are compressed to provide the pressure into the microchip. 
(b) Microfluidic chip filled with red dye. The inlet and outlet ports for the bottom fluidic layer and outlet for 
the top layer were sealed with cured thiol-ene. The inlet port of the top fluidic layer is clamped between the 
mechanical device.  
 
Sample Maximum pressure (Bars) Temperature 
3T3E + 3T3E 2.0 ± 0.66  
25 °C 
4T3E + 4T3E Layers could not be bonded 
4T3E + 3T3E > 6.0 
3T3E + 3T3E < 0.3  
37 °C 
4T3E + 4T3E Layers could not be bonded 
4T3E + 3T3E > 6.0 
Table ST1. Tabulated data of the maximum pressure the different thiol-ene mixtures used for fabricating the 
microchips could withstand in different temperature conditions. All thiol-ene mixtures were prepared in 
stoichiometric ratios. Where 4T = tetra-thiol, 3T = tri-thiol and 3E = tri-allyl. (n = 6) 
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